

CITATION REPORT

List of articles citing

Comprehensive molecular characterization of gastric adenocarcinoma

DOI: 10.1038/nature13480

Nature, 2014, 513, 202-9.

Source: <https://exaly.com/paper-pdf/59308840/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|------|--|----|-----------|
| 2212 | Correction to "Three-dimensional pulse-width modulation technique in three-level power inverters for three-phase four-wired system". 2001 , 16, 888-888 | | |
| 2211 | Deadlock-free scheduling method using genetic algorithm and timed S/sup 3/PR nets. 2004 , | | 1 |
| 2210 | Epstein-Barr virus and nasopharyngeal carcinoma. 2014 , 33, 581-90 | | 129 |
| 2209 | Endoscopic gastric cancer screening and surveillance in high-risk groups. 2014 , 47, 497-503 | | 44 |
| 2208 | Oncogenic induction of cellular high CpG methylation by Epstein-Barr virus in malignant epithelial cells. 2014 , 33, 604-8 | | 17 |
| 2207 | Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. 2014 , 14, 115 | | 31 |
| 2206 | Anti-angiogenic therapies for advanced esophago-gastric cancer. 2014 , 35, 253-62 | | 10 |
| 2205 | Hypoxia-inducible lncRNA-AK058003 promotes gastric cancer metastasis by targeting Eynuclein. 2014 , 16, 1094-106 | | 78 |
| 2204 | Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. 2014 , 5, 252 | | 31 |
| 2203 | Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice. 2014 , 28, 1043-53 | | 32 |
| 2202 | Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. 2014 , 5, 5477 | | 130 |
| 2201 | Implementation of gastric cancer screening - the global experience. 2014 , 28, 1093-106 | | 38 |
| 2200 | Pan-cancer patterns of DNA methylation. 2014 , 6, 66 | | 107 |
| 2199 | Genetics: New molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas. 2014 , 11, 577 | | 1 |
| 2198 | RNF43 is frequently mutated in colorectal and endometrial cancers. 2014 , 46, 1264-6 | | 287 |
| 2197 | Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas. 2014 , 11, 499 | | 32 |
| 2196 | Genetics of gastric cancer. 2014 , 11, 664-74 | | 274 |

| | | |
|------|---|-----|
| 2195 | TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. 2014 , 33, 469-70 | 26 |
| 2194 | Seom guidelines for the treatment of gastric cancer 2015. 2015 , 17, 996-1004 | 18 |
| 2193 | MEK and PI3K inhibition in solid tumors: rationale and evidence to date. 2015 , 7, 170-80 | 84 |
| 2192 | Clinicopathological characterisation of small (2 cm or less) proximal and distal gastric carcinomas in a Chinese population. 2015 , 47, 526-32 | 23 |
| 2191 | Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. 2015 , 4, 1079-90 | 52 |
| 2190 | The role of Epstein-Barr virus in epithelial malignancies. 2015 , 235, 323-33 | 206 |
| 2189 | Pathogenesis of Gastric Cancer. 2015 , 20 Suppl 1, 30-5 | 32 |
| 2188 | Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. 2015 , 106, 951-8 | 44 |
| 2187 | Tumors of the Stomach. 2015 , 1121-1140 | |
| 2186 | Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. 2015 , 89, 305-10 | 4 |
| 2185 | Whole genome and transcriptome sequencing of matched primary and peritoneal metastatic gastric carcinoma. 2015 , 5, 13750 | 51 |
| 2184 | Slow Progression of Poorly Differentiated Gastric Carcinoma Associated with Epstein-Barr Virus Infection: 12-year Follow-up. 2015 , 54, 1505-8 | |
| 2183 | Molecular biomarkers in gastric cancer. 2015 , 13, e19-29 | 26 |
| 2182 | High-Throughput miRNA Sequencing Reveals a Field Effect in Gastric Cancer and Suggests an Epigenetic Network Mechanism. 2015 , 9, 111-7 | 29 |
| 2181 | Organtypische Slice-Kulturen aus humanen Geweben. 2015 , 21, 388-391 | |
| 2180 | Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. 2015 , 16 Suppl 8, S5 | 22 |
| 2179 | Genetic and epigenetic alterations of netrin-1 receptors in gastric cancer with chromosomal instability. 2015 , 7, 73 | 6 |
| 2178 | Overexpression of Ras-GTPase-activating protein SH3 domain-binding protein 1 correlates with poor prognosis in gastric cancer patients. 2015 , 67, 677-88 | 32 |

| | | |
|------|---|-----|
| 2177 | Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. 2015 , 8, 189-205 | 6 |
| 2176 | The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers. 2015 , 15, 950 | 27 |
| 2175 | Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study. 2015 , 13, 304 | 15 |
| 2174 | Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing. 2015 , 10, 169 | 12 |
| 2173 | CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. 2015 , 16, 160 | 132 |
| 2172 | Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer. 2015 , 112, 585-91 | 22 |
| 2171 | Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?. 2015 , 20, 1448-56 | 2 |
| 2170 | High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples. 2015 , 237, 123-32 | 99 |
| 2169 | D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy. 2015 , 94, e951 | 28 |
| 2168 | Hepatic resection for gastric cancer liver metastases: A systematic review and meta-analysis. 2015 , 111, 1021-7 | 26 |
| 2167 | NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. 2015 , 137, 678-85 | 63 |
| 2166 | Good distant outcome of treatment of a patient with advanced gastric cancer. 2015 , 1, 52-55 | |
| 2165 | Current Status on Stem Cells and Cancers of the Gastric Epithelium. 2015 , 16, 19153-69 | 31 |
| 2164 | The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis. 2015 , 8, 2427-33 | 46 |
| 2163 | Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. 2015 , 21, 7343-8 | 62 |
| 2162 | Chemotherapy beyond second-line in advanced gastric cancer. 2015 , 21, 8811-6 | 15 |
| 2161 | Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. 2015 , 8, 1149-56 | 5 |
| 2160 | Role of DFNA5 in hearing loss and cancer - a comment on Rakusic et al. 2015 , 8, 2613-5 | 2 |

| | | |
|------|---|------|
| 2159 | Computational characterisation of cancer molecular profiles derived using next generation sequencing. 2015 , 19, A78-91 | 4 |
| 2158 | Current Trends in Studies of Epstein-Barr Virus (EBV) Associated Gastric Carcinoma. 2015 , 45, 262 | 1 |
| 2157 | Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. 2015 , 6, 24750-79 | 92 |
| 2156 | Enhanced plasmonic effects in Ag decorated amorphous TiO ₂ nanotube arrays. 2015 , | |
| 2155 | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. 2015 , 3, 149-181 | 19 |
| 2154 | Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets. 2015 , 4, 1798-814 | 14 |
| 2153 | Loss of ARID1A Expression in Gastric Cancer: Correlation with Mismatch Repair Deficiency and Clinicopathologic Features. 2015 , 15, 201-8 | 15 |
| 2152 | Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. 2015 , 56, 1177-85 | 42 |
| 2151 | Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. 2015 , 10, e0118829 | 15 |
| 2150 | Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer. 2015 , 10, e0125834 | 25 |
| 2149 | The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. 2015 , 19, A68-77 | 1337 |
| 2148 | Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. 2015 , 10, e0142433 | 7 |
| 2147 | A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. 2015 , 11, e1004518 | 79 |
| 2146 | Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer. 2015 , 10, e0132327 | 31 |
| 2145 | Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies. 2015 , 10, e0136058 | 27 |
| 2144 | Noncoding Genomics in Gastric Cancer and the Gastric Precancerous Cascade: Pathogenesis and Biomarkers. 2015 , 2015, 503762 | 18 |
| 2143 | Comparative Transcriptomes and EVO-DEVO Studies Depending on Next Generation Sequencing. 2015 , 2015, 896176 | 3 |
| 2142 | HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach. 2015 , 2015, 234851 | 20 |

| | | |
|------|--|------|
| 2141 | Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. 2015 , 2015, 308574 | 23 |
| 2140 | From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. 2015 , 2015, 896560 | 6 |
| 2139 | Helicobacter pylori-Induced Signaling Pathways Contribute to Intestinal Metaplasia and Gastric Carcinogenesis. 2015 , 2015, 737621 | 35 |
| 2138 | Antibody-based arrays in disease proteomics. 2015 , 15 | |
| 2137 | Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. 2015 , 6, 17764-76 | 104 |
| 2136 | Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. 2015 , 6, 26935-45 | 30 |
| 2135 | Recent advances in the molecular diagnostics of gastric cancer. 2015 , 21, 9838-52 | 80 |
| 2134 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. 2015 , 372, 2509-20 | 5560 |
| 2133 | The emerging complexity of gene fusions in cancer. 2015 , 15, 371-81 | 382 |
| 2132 | The cancer cell map initiative: defining the hallmark networks of cancer. 2015 , 58, 690-8 | 89 |
| 2131 | Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. 2015 , 26, 438-9 | 15 |
| 2130 | Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery. 2015 , 14, 1616-29 | 73 |
| 2129 | Prioritizing therapeutic targets using patient-derived xenograft models. 2015 , 1855, 223-34 | 23 |
| 2128 | Emerging kinase inhibitors of the treatment of gastric cancer. 2015 , 20, 479-93 | 10 |
| 2127 | Recent findings from the Human Proteome Project: opening the mass spectrometry toolbox to advance cancer diagnosis, surveillance and treatment. 2015 , 12, 279-93 | 14 |
| 2126 | Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. 2015 , 15, 322 | 21 |
| 2125 | Special Series: Advances in GI Cancer. 2015 , 33, 1717-20 | 8 |
| 2124 | MAGI: visualization and collaborative annotation of genomic aberrations. 2015 , 12, 483-4 | 18 |

| | | |
|------|--|-----|
| 2123 | PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. 2015 , 26, 1488-93 | 179 |
| 2122 | Computational and Statistical Epigenomics. 2015 , | 2 |
| 2121 | EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. 2015 , 15, 302-4 | 10 |
| 2120 | Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. 2015 , 3, 855-63 | 53 |
| 2119 | Epstein-Barr virus infection and gastric cancer: a systematic review. 2015 , 94, e792 | 78 |
| 2118 | Progress of cancer genomics. 2015 , 6, 557-60 | |
| 2117 | Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer. 2015 , 33, 3845-6 | 1 |
| 2116 | BayesPI-BAR: a new biophysical model for characterization of regulatory sequence variations. 2015 , 43, e147 | 11 |
| 2115 | Targeted therapy in gastroesophageal cancers: past, present and future. 2015 , 3, 316-29 | 19 |
| 2114 | Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche. 2015 , 28, 800-814 | 188 |
| 2113 | Identification of low abundance microbiome in clinical samples using whole genome sequencing. 2015 , 16, 265 | 67 |
| 2112 | Thyroid genomics: refining diagnosis, prognosis and treatment. 2015 , 2, 105-107 | |
| 2111 | Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. 2015 , 1, a000570 | 75 |
| 2110 | SNAPR: a bioinformatics pipeline for efficient and accurate RNA-seq alignment and analysis. 2015 , 1, 22-25 | 9 |
| 2109 | Update on Epstein-Barr virus and gastric cancer (review). 2015 , 46, 1421-34 | 165 |
| 2108 | SOX15 governs transcription in human stratified epithelia and a subset of esophageal adenocarcinomas. 2015 , 1, 598-609.e6 | 11 |
| 2107 | Frequent involvement of chromatin remodeler alterations in gastric field cancerization. 2015 , 357, 328-338 | 39 |
| 2106 | Runx3 at the interface of immunity, inflammation and cancer. 2015 , 1855, 131-43 | 40 |

| | | |
|------|---|----------|
| 2105 | Comprehensive characterization of the genomic alterations in human gastric cancer. 2015 , 137, 86-95 | 51 |
| 2104 | The immunology of Epstein-Barr virus-induced disease. 2015 , 33, 787-821 | 284 |
| 2103 | Pseudogene: promising signature for cancer reclassification : comment on "The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes", Nat Commun. 2014; 5:3963. 2015 , 32, 354 | 1 |
| 2102 | Emerging mAbs for the treatment of esophagogastric cancer. 2015 , 20, 63-74 | 1 |
| 2101 | Multistep tumorigenesis in peripheral T cell lymphoma. 2015 , 102, 523-7 | 23 |
| 2100 | Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. 2015 , 27, 1075-86 | 8 |
| 2099 | RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance. 2015 , 19, 22-32 | 41 |
| 2098 | Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. 2015 , 21, 1944-50 | 62 |
| 2097 | Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. 2015 , 112, 1107-12 | 112 |
| 2096 | Molecular and genetic properties of tumors associated with local immune cytolytic activity. 2015 , 160, 48-61 | 1834 |
| 2095 | Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. 2015 , 26, 332-9 | 20 |
| 2094 | Microsatellite instability: an update. 2015 , 89, 899-921 | 118 |
| 2093 | Integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ as prognostic, diagnostic, and therapeutic targets in gastric cancer. 2015 , 18, 784-95 | 36 |
| 2092 | Systems oncology: toward the clinical application of cancer systems biology. 2015 , 11, 553-5 | 4 |
| 2091 | Differential DNA mismatch repair underlies mutation rate variation across the human genome. <i>Nature</i> , 2015 , 521, 81-4 | 50.4 224 |
| 2090 | Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma. 2015 , 149, 1142-1152.e3 | 22 |
| 2089 | From standard to new genome-based therapy of gastric cancer. 2015 , 9, 1023-6 | 5 |
| 2088 | Sirtuin-4 (SIRT4) is downregulated and associated with some clinicopathological features in gastric adenocarcinoma. 2015 , 72, 135-9 | 37 |

| | | |
|------|---|-----|
| 2087 | The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. 2015 , 113, 365-71 | 325 |
| 2086 | Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. 2015 , 34, 479-96 | 74 |
| 2085 | DNA methylation as a molecular biomarker in gastric cancer. 2015 , 7, 475-86 | 91 |
| 2084 | Molecular Pathogenesis of Helicobacter pylori-Related Gastric Cancer. 2015 , 44, 625-38 | 14 |
| 2083 | Recognition of and recent issues in hereditary diffuse gastric cancer. 2015 , 50, 831-43 | 17 |
| 2082 | Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells. 2015 , 11, 1703-13 | 87 |
| 2081 | Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma. 2015 , 15, 607-14 | 0 |
| 2080 | Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature. 2015 , 5, 73 | 23 |
| 2079 | Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. 2015 , 149, 1153-1162.e3 | 250 |
| 2078 | Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. 2015 , 95, 165-78 | 24 |
| 2077 | Genomic landscape of cutaneous T cell lymphoma. 2015 , 47, 1011-9 | 247 |
| 2076 | Integrative Epigenomics. 2015 , 127-139 | |
| 2075 | Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. 2015 , 5, 11251 | 104 |
| 2074 | Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas. 2015 , 89, 10110-4 | 23 |
| 2073 | An overview of new biomolecular pathways in pathogen-related cancers. 2015 , 11, 1625-39 | 11 |
| 2072 | Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication. 2015 , 44, 609-24 | 16 |
| 2071 | Epidemiology of Gastric Cancer. 2015 , 23-34 | 76 |
| 2070 | Pathology of Gastric Cancer. 2015 , 57-76 | |

| | | |
|------|---|------|
| 2069 | Current and Future Therapies for Advanced Gastric Cancer. 2015 , 14, 239-50 | 25 |
| 2068 | Helicobacter pylori infection and gastric carcinoma. 2015 , 21, 984-90 | 40 |
| 2067 | Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. 2015 , 3, 1123-1129 | 98 |
| 2066 | Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. 2015 , 7, 1037-51 | 6 |
| 2065 | Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. 2015 , 20, 499-507 | 56 |
| 2064 | Role of c-mesenchymal-epithelial transition pathway in gastric cancer. 2015 , 16, 1195-207 | 9 |
| 2063 | Screening in GI Cancers: The Role of Genetics. 2015 , 33, 1721-8 | 20 |
| 2062 | Controversies in the treatment of local and locally advanced gastric and esophageal cancers. 2015 , 33, 1754-9 | 60 |
| 2061 | Update on metastatic gastric and esophageal cancers. 2015 , 33, 1760-9 | 138 |
| 2060 | A system level analysis of gastric cancer across tumor stages with RNA-seq data. 2015 , 11, 1925-32 | 9 |
| 2059 | Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. 2015 , 21, 449-56 | 1031 |
| 2058 | Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. 2015 , 33, 664-70 | 2 |
| 2057 | Immunotherapy in upper GI malignancies. 2015 , 16, 20 | 8 |
| 2056 | Chemoradiation for gastric cancer: controversies, updates and novel techniques. 2015 , 88, 20150027 | 2 |
| 2055 | Progression risk assessments of individual non-invasive gastric neoplasms by genomic copy-number profile and mucin phenotype. 2015 , 8, 6 | 4 |
| 2054 | Molecular Pathology Informatics. 2015 , 8, 187-94 | 3 |
| 2053 | Research in Computational Molecular Biology. 2015 , | 3 |
| 2052 | Applications of NGS to Screen FFPE Tumours for Detecting Fusion Transcripts. 2015 , 155-177 | |

| | | |
|------|---|------|
| 2051 | Proceedings of the second international molecular pathological epidemiology (MPE) meeting. 2015 , 26, 959-72 | 30 |
| 2050 | Targeting Wnts at the source—new mechanisms, new biomarkers, new drugs. 2015 , 14, 1087-94 | 80 |
| 2049 | Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. 2015 , 33, 1737-44 | 30 |
| 2048 | The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. 2015 , 30, 107-21 | 69 |
| 2047 | Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. 2015 , 16, 17 | 43 |
| 2046 | Biologics in combination with chemotherapy for gastric cancer: is this the answer?. 2015 , 16, 955-60 | 2 |
| 2045 | Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. 2015 , 161, 205-14 | 1388 |
| 2044 | Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells. 2015 , 14, 1213-23 | 24 |
| 2043 | Metastatic gastric cancer in the last two decades: goals achieved and future promises. 2015 , 11, 2633-2636 | 4 |
| 2042 | Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. 2015 , 42, 801-19 | 64 |
| 2041 | PD-1 and PD-L1 blockade in gastrointestinal malignancies. 2015 , 41, 893-903 | 44 |
| 2040 | Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. 2015 , 112, 12492-7 | 36 |
| 2039 | Personalizing the management of gastroesophageal cancer. 2015 , 12, 447-451 | |
| 2038 | Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. 2015 , 5, 1271-81 | 126 |
| 2037 | Mutational analysis by next generation sequencing of gastric type dysplasia occurring in hyperplastic polyps of the stomach: Mutations in gastric hyperplastic polyps. 2015 , 99, 468-73 | 11 |
| 2036 | The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. 2015 , 6, 123-33 | 32 |
| 2035 | EBV and human cancer. 2015 , 47, e130 | 41 |
| 2034 | Features of Gastric Carcinoma With Lymphoid Stroma Associated With Epstein-Barr Virus. 2015 , 13, 1738-1744 | 42 |

| | | |
|------|---|------|
| 2033 | Biomarkers and novel agents in esophago-gastric cancer: are we making progress?. 2015 , 15, 1103-19 | 4 |
| 2032 | A mutational signature in gastric cancer suggests therapeutic strategies. 2015 , 6, 8683 | 103 |
| 2031 | Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. 2015 , 8, 373-83 | 15 |
| 2030 | Precision medicine in oncology drug development: a pharma perspective. 2015 , 20, 1455-63 | 21 |
| 2029 | Novel biomarkers for the identification and targeted therapy of gastric cancer. 2015 , 9, 1217-26 | 6 |
| 2028 | Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. 2015 , 112, E4410-7 | 196 |
| 2027 | MicroRNA-7/NF- κ B signaling regulatory feedback circuit regulates gastric carcinogenesis. 2015 , 210, 613-27 | 64 |
| 2026 | Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. 2015 , 47, e134 | 48 |
| 2025 | The full-length DNA sequence of Epstein Barr virus from a human gastric carcinoma cell line, SNU-719. 2015 , 51, 329-37 | 9 |
| 2024 | The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. 2015 , 10, 456-67 | 42 |
| 2023 | Comprehensive assessment of cancer missense mutation clustering in protein structures. 2015 , 112, E5486-95 | 142 |
| 2022 | Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. 2015 , 16, 193 | 17 |
| 2021 | Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. 2015 , 22 Suppl 3, S1508-15 | 20 |
| 2020 | Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. 2015 , 163, 506-19 | 1055 |
| 2019 | Are Epstein-Barr Virus-positive and -negative Gastric Carcinomas, With Lymphoid Stroma, Single Entity or Different Entities?. 2015 , 13, 1745-7 | 1 |
| 2018 | Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. 2015 , 42, 713-23 | 10 |
| 2017 | The consensus molecular subtypes of colorectal cancer. 2015 , 21, 1350-6 | 2332 |
| 2016 | [Quinze questions importantes à se poser en oncologie en 2015]. 2015 , 102, S22-6 | 1 |

| | | |
|------|--|-----|
| 2015 | LncRNAs: emerging biomarkers in gastric cancer. 2015 , 11, 2427-41 | 76 |
| 2014 | Screening and Early Detection of Gastric Cancer: East Versus West. 2015 , 95, 1053-66 | 42 |
| 2013 | DNA Methylation Predicts Progression of Human Gastric Lesions. 2015 , 24, 1607-13 | 21 |
| 2012 | Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers. 2015 , 46, 1640-6 | 19 |
| 2011 | Host Gene Expression Is Regulated by Two Types of Noncoding RNAs Transcribed from the Epstein-Barr Virus BamHI A Rightward Transcript Region. 2015 , 89, 11256-68 | 47 |
| 2010 | Molecular classification and prediction in gastric cancer. 2015 , 13, 448-58 | 47 |
| 2009 | Comparison of variations detection between whole-genome amplification methods used in single-cell resequencing. 2015 , 4, 37 | 107 |
| 2008 | Epigenetic silencing of tumor suppressor genes during in vitro Epstein-Barr virus infection. 2015 , 112, E5199-207 | 39 |
| 2007 | The stomach in health and disease. 2015 , 64, 1650-68 | 190 |
| 2006 | KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. 2015 , 467, 383-92 | 5 |
| 2005 | Clonality: A New Marker for Gastric Cancer Survival. 2015 , 42, 517-519 | 1 |
| 2004 | Molecular Pathways: Targeting ATR in Cancer Therapy. 2015 , 21, 4780-5 | 151 |
| 2003 | Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. 2015 , 33, 1152-8 | 359 |
| 2002 | Nasopharyngeal Cancer: Molecular Landscape. 2015 , 33, 3346-55 | 98 |
| 2001 | Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. 2015 , 82, 212-23 | 35 |
| 2000 | Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. 2015 , 8, 86 | 27 |
| 1999 | Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. 2015 , 36, 7385-94 | 41 |
| 1998 | Identifying therapeutic targets in gastric cancer: the current status and future direction. 2016 , 48, 90-6 | 13 |

| | | |
|------|--|-----|
| 1997 | The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical-genomic driver associations. 2015 , 7, 112 | 58 |
| 1996 | MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and Snail. 2015 , 6, e2000 | 81 |
| 1995 | The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. 2015 , 19, 201-11 | 66 |
| 1994 | Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. 2015 , 148, 137-147.e9 | 85 |
| 1993 | Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. 2015 , 9, 967-96 | 99 |
| 1992 | Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis. 2015 , 12, 7-8 | 7 |
| 1991 | Automation processes-accelerators-tools for enriching integrated asset information. 2016 , | |
| 1990 | PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. 2016 , 7, 24269-83 | 178 |
| 1989 | Microsatellite Instability and its Significance to Hereditary and Sporadic Cancer. 2016 , | 2 |
| 1988 | Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. 2016 , 7, 32113-28 | 81 |
| 1987 | The Role of Prion Protein Expression in Predicting Gastric Cancer Prognosis. 2016 , 7, 984-90 | 9 |
| 1986 | SNHG8 is identified as a key regulator of Epstein-Barr virus(EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression. 2016 , 7, 80990-81002 | 36 |
| 1985 | Assessment of Epstein-Barr virus nucleic acids in gastric but not in breast cancer by next-generation sequencing of pooled Mexican samples. 2016 , 111, 200-8 | 2 |
| 1984 | Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma. 2016 , 9, 4539-48 | 2 |
| 1983 | Protein Profiling Gastric Cancer and Neighboring Control Tissues Using High-Content Antibody Microarrays. 2016 , 5, | 5 |
| 1982 | Discovery of signature genes in gastric cancer associated with prognosis. 2016 , 63, 239-45 | 24 |
| 1981 | Considerations about gastric cancer proteomics. 2016 , 43, 395-397 | 1 |
| 1980 | Immunological battlefield in gastric cancer and role of immunotherapies. 2016 , 22, 6373-84 | 22 |

| | | |
|------|---|-----|
| 1979 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. 2016 , 7, 69060-69074 | 21 |
| 1978 | Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. 2016 , 22, 1190-201 | 48 |
| 1977 | Molecular alterations in gastric cancer with special reference to the early-onset subtype. 2016 , 22, 2460-74 | 37 |
| 1976 | Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. 2016 , 35, 104-11 | 11 |
| 1975 | Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. 2016 , 7, 32925-32 | 191 |
| 1974 | The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. 2016 , 7, 750-762 | 35 |
| 1973 | Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. 2016 , 7, 44608-44620 | 31 |
| 1972 | Molecular profiling of biliary tract cancer: a target rich disease. 2016 , 7, 797-803 | 53 |
| 1971 | Ethnicity-related differences in tumor immunity: a new possible explanation for gastric cancer prognostic variability?. 2016 , 1, 11 | 5 |
| 1970 | (), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor?. 2016 , 1, 3 | 2 |
| 1969 | as target in gastric adenocarcinoma. 2016 , 1, 59 | 1 |
| 1968 | Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers. 2016 , 7, 763-770 | 1 |
| 1967 | Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial. 2016 , 1, 46 | 6 |
| 1966 | Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. 2016 , 22, 1279-88 | 43 |
| 1965 | The era of laparoscopic surgery for gastric cancer: what is the present territory and what will be next?. 2016 , 1, 42 | 1 |
| 1964 | Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. 2016 , 7, 8055-66 | 28 |
| 1963 | Dabrafenib in metastatic melanoma: a monocentric 'real life' experience. 2016 , 10, 624 | 3 |
| 1962 | Mutations of Chromatin Structure Regulating Genes in Human Malignancies. 2016 , 17, 411-37 | 14 |

| | | |
|------|---|-----|
| 1961 | Aberrant DNA Methylation and Histone Modifications in Cancer. 2016 , 1-9 | |
| 1960 | Serological response to Epstein-Barr virus early antigen is associated with gastric cancer and human immunodeficiency virus infection in Zambian adults: a case-control study. 2016 , 23, 45 | 14 |
| 1959 | Integrated epigenomic analyses of enhancer as well as promoter regions in gastric cancer. 2016 , 7, 25620-31 | 10 |
| 1958 | Prognostic Importance of Cell Cycle Regulators Cyclin D1 () and Cyclin-Dependent Kinase Inhibitor 1B (p27) in Sporadic Gastric Cancers. 2016 , 2016, 9408190 | 3 |
| 1957 | Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. 2016 , 2016, 9214056 | 12 |
| 1956 | Role of Viral miRNAs and Epigenetic Modifications in Epstein-Barr Virus-Associated Gastric Carcinogenesis. 2016 , 2016, 6021934 | 20 |
| 1955 | Mast Cell Interaction with Neutrophils in Human Gastric Carcinomas: Ultrastructural Observations. 2016 , 2016, 6891971 | 4 |
| 1954 | Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. 2016 , 9, 7235-7245 | 15 |
| 1953 | KIF2A Overexpression and Its Association with Clinicopathologic Characteristics and Poor Prognoses in Patients with Gastric Cancer. 2016 , 2016, 7484516 | 15 |
| 1952 | Networks and Consortia for Epigenetic Drug Discovery. 2016 , 143-166 | 1 |
| 1951 | Morphological and Cellular Features of Innate Immune Reaction in Helicobacter pylori Gastritis: A Brief Review. 2016 , 17, | 21 |
| 1950 | Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease?. 2016 , 49, 150-7 | 21 |
| 1949 | Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. 2016 , 7, 49322-49333 | 643 |
| 1948 | Epstein-Barr Virus: Diseases Linked to Infection and Transformation. 2016 , 7, 1602 | 65 |
| 1947 | Frizzled7: A Promising Achilles' Heel for Targeting the Wnt Receptor Complex to Treat Cancer. 2016 , 8, | 59 |
| 1946 | Immunotherapy for Gastroesophageal Cancer. 2016 , 5, | 35 |
| 1945 | Comparison between two amplicon-based sequencing panels of different scales in the detection of somatic mutations associated with gastric cancer. 2016 , 17, 833 | 24 |
| 1944 | EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus. 2016 , 16, 406 | 23 |

| | | |
|------|---|-----|
| 1943 | PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. 2016 , 12, e1005642 | 72 |
| 1942 | Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data. 2016 , 11, e0152792 | 36 |
| 1941 | TCGA Expedition: A Data Acquisition and Management System for TCGA Data. 2016 , 11, e0165395 | 38 |
| 1940 | Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas. 2016 , 11, e0168237 | 2 |
| 1939 | Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer. 2016 , 7, 25315-27 | 31 |
| 1938 | Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. 2016 , 16, 1-7 | 41 |
| 1937 | FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. 2016 , 7, 84587-84593 | 8 |
| 1936 | Epstein-Barr Virus. 2016 , 523-547 | |
| 1935 | A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. 2016 , 7, 55343-55351 | 119 |
| 1934 | Genome-wide DNA methylation profiles altered by Helicobacter pylori in gastric mucosa and blood leukocyte DNA. 2016 , 7, 37132-37144 | 17 |
| 1933 | Clinical Genomics: Challenges and Opportunities. 2016 , 26, 97-113 | 7 |
| 1932 | Current and emerging therapies in unresectable and recurrent gastric cancer. 2016 , 22, 4812-23 | 40 |
| 1931 | Epstein-Barr Virus and Gastric Cancer Risk: A Meta-analysis With Meta-regression of Case-control Studies. 2016 , 49, 97-107 | 35 |
| 1930 | Comprehensive mutation profiling of mucinous gastric carcinoma. 2016 , 240, 137-48 | 24 |
| 1929 | Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy. 2016 , 24, 246-52 | 11 |
| 1928 | Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. 2016 , 22, 4309-21 | 127 |
| 1927 | Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. 2016 , 40, 1133-42 | 62 |
| 1926 | Combinatorial epigenetic deregulation by Helicobacter pylori and Epstein-Barr virus infections in gastric tumourigenesis. 2016 , 239, 245-9 | 14 |

| | | |
|------|--|----|
| 1925 | Gastric cancer adjuvant therapy. 2016 , 30, 581-91 | 11 |
| 1924 | Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma. 2016 , 23, 4238-4246 | 5 |
| 1923 | Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. 2016 , 55, 193-214 | 50 |
| 1922 | Current perspectives toward the identification of key players in gastric cancer microRNA dysregulation. 2016 , 138, 1337-49 | 27 |
| 1921 | CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin α clustering and invasiveness in gastric cancer. 2016 , 138, 1207-19 | 99 |
| 1920 | Low density of CD204-positive M2-type tumor-associated macrophages in Epstein-Barr virus-associated gastric cancer: a clinicopathologic study with digital image analysis. 2016 , 56, 74-80 | 20 |
| 1919 | Stem Cells Antigen-1 Enriches for a Cancer Stem Cell-Like Subpopulation in Mouse Gastric Cancer. 2016 , 34, 1177-87 | 9 |
| 1918 | New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. 2016 , 22, 4283-90 | 26 |
| 1917 | Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/ β -catenin signaling pathway mutations. 2016 , 122, 1689-96 | 17 |
| 1916 | Molecular mechanisms of gastric cancer initiation and progression by <i>Helicobacter pylori</i> . 2016 , 29, 304-10 | 18 |
| 1915 | Apatinib for the treatment of gastric cancer. 2016 , 10, 887-92 | 38 |
| 1914 | Insights into next developments in advanced gastric cancer. 2016 , 28, 367-75 | 12 |
| 1913 | Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. 2016 , 55, 626-39 | 63 |
| 1912 | Recent advances in proximal gastric carcinoma. 2016 , 17, 421-32 | 22 |
| 1911 | <i>Helicobacter</i> Species Identified in Captive Sooty Mangabeys (<i>Cercocebus atys</i>) with Metastatic Gastric Adenocarcinoma. 2016 , 21, 175-85 | 4 |
| 1910 | Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer. 2016 , 14, 1313-1320 | 16 |
| 1909 | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. 2016 , 5, 805 | 44 |
| 1908 | Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. 2016 , 6, 24466 | 31 |

| | | |
|------|---|-----|
| 1907 | Insights into roles of the miR-1, -133 and -206 family in gastric cancer (Review). 2016 , 36, 1191-8 | 15 |
| 1906 | The Human Virome in Health and Disease. 2016 , 156-166 | |
| 1905 | Divergent viral presentation among human tumors and adjacent normal tissues. 2016 , 6, 28294 | 44 |
| 1904 | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. 2016 , 146, 647-669 | 30 |
| 1903 | Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. 2016 , 8, 136 | 48 |
| 1902 | Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. 2016 , 6, 21319 | 50 |
| 1901 | Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells. 2016 , 107, 1919-1928 | 9 |
| 1900 | A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association. 2016 , 4, 71 | 44 |
| 1899 | TFIIIS.h, a new target of p53, regulates transcription efficiency of pro-apoptotic bax gene. 2016 , 6, 23542 | 10 |
| 1898 | Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. 2016 , 40, 1496-1506 | 108 |
| 1897 | CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. 2016 , 6, 21519 | 27 |
| 1896 | Prognostic relevance of expression in gastric cancer. 2016 , 12, 4708-4716 | 13 |
| 1895 | Specific expression and methylation of SLIT1, SLIT2, SLIT3, and miR-218 in gastric cancer subtypes. 2016 , 48, 2497-507 | 18 |
| 1894 | A protein and mRNA expression-based classification of gastric cancer. 2016 , 29, 772-84 | 87 |
| 1893 | Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. 2016 , 59, 160-170 | 56 |
| 1892 | Anti-Helicobacter pylori Antibody Profiles in Epstein-Barr virus (EBV)-Positive and EBV-Negative Gastric Cancer. 2016 , 21, 153-7 | 22 |
| 1891 | Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial. 2016 , 114, 855-62 | 39 |
| 1890 | Dysregulated FGF signalling in neoplastic disorders. 2016 , 53, 126-35 | 54 |

| | | |
|------|--|----------|
| 1889 | FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. 2016 , 29, 1095-103 | 49 |
| 1888 | Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. 2016 , 76, 3826-37 | 40 |
| 1887 | Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis. 2016 , 23, 3684-3692 | 10 |
| 1886 | High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability. 2016 , 142, 1817-24 | 3 |
| 1885 | Emerging molecular classifications and therapeutic implications for gastric cancer. 2016 , 35, 49 | 28 |
| 1884 | The Role of Inflammatory Responses in Mouse Gastric Tumorigenesis. 2016 , 325-338 | |
| 1883 | High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. 2016 , 6, 838-851 | 176 |
| 1882 | The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. 2016 , 11, 593-603 | 12 |
| 1881 | Personalised Treatment in Gastric Cancer: Myth or Reality?. 2016 , 18, 41 | 11 |
| 1880 | Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. <i>Nature</i> , 2016 , 534, 402-6 | 50.4 403 |
| 1879 | miR-148a downregulates the expression of transforming growth factor- β and SMAD2 in gastric cancer. 2016 , 48, 1877-85 | 15 |
| 1878 | Novel targets in the treatment of advanced gastric cancer: a perspective review. 2016 , 8, 113-25 | 44 |
| 1877 | Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma. 2016 , 38, 1589-99 | 8 |
| 1876 | Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>Eur Urol</i> 2015;68:970-7. 2016 , 70, e71 | 5 |
| 1875 | Construction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901. 2016 , 48, 474-81 | 12 |
| 1874 | Expression and prognostic value of miR-92a in patients with gastric cancer. 2016 , 37, 9483-91 | 21 |
| 1873 | Gastric Lgr5(+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice. 2016 , 26, 838-49 | 58 |
| 1872 | Stromal-Based Signatures for the Classification of Gastric Cancer. 2016 , 76, 2573-86 | 28 |

| | | |
|------|---|------|
| 1871 | Recent insights in the therapeutic management of patients with gastric cancer. 2016 , 48, 984-94 | 26 |
| 1870 | What gastric cancer proteomic studies show about gastric carcinogenesis?. 2016 , 37, 9991-10010 | 10 |
| 1869 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. 2016 , 17, 717-726 | 716 |
| 1868 | Encouraging results for PD-1 inhibition in gastric cancer. 2016 , 17, 682-683 | 13 |
| 1867 | Evolving treatments for advanced gastric cancer: appraisal of the survival trend. 2016 , 16, 717-29 | 3 |
| 1866 | LncRNA GCLnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. 2016 , 6, 784-801 | 245 |
| 1865 | Gastric cancer. 2016 , 388, 2654-2664 | 1152 |
| 1864 | Helicobacter pylori: Pathogenic enablers - toxic relationships in the stomach. 2016 , 13, 317-8 | 8 |
| 1863 | Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?. 2016 , 16, 305-18 | 77 |
| 1862 | Deregulation of Rho GTPases in cancer. 2016 , 7, 123-38 | 127 |
| 1861 | [Molecular Pathological Aspects in Visceral Surgery]. 2016 , 141, 220-8 | |
| 1860 | Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?. 2016 , 17, 21 | 4 |
| 1859 | Methylation and expression of Epstein-Barr virus latent membrane protein 1, 2A and 2B in EBV-associated gastric carcinomas and cell lines. 2016 , 48, 673-80 | 10 |
| 1858 | Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency. 2016 , 24, 320-5 | 18 |
| 1857 | The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines. 2016 , 22, 797-805 | 61 |
| 1856 | Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. 2016 , 35, 5807-5816 | 12 |
| 1855 | The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. 2016 , 12, 1833-46 | 13 |
| 1854 | Chances, risks and limitations of neoadjuvant therapy in surgical oncology. 2016 , 1, 3-11 | 3 |

| | | |
|------|---|-----|
| 1853 | BARHL2 Methylation Using Gastric Wash DNA or Gastric Juice Exosomal DNA is a Useful Marker For Early Detection of Gastric Cancer in an H. pylori-Independent Manner. 2016 , 7, e184 | 42 |
| 1852 | Expression of Helios in gastric tumor cells predicts better survival in gastric cancer patients. 2016 , 142, 2375-82 | 4 |
| 1851 | Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review. 2016 , 16, 400 | 29 |
| 1850 | Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. 2016 , 48, 1131-41 | 233 |
| 1849 | Distal Esophageal Adenocarcinoma and Gastric Adenocarcinoma: Time for a Shared Research Agenda. 2016 , 908, 1-8 | 1 |
| 1848 | Gastric biomarkers: a global review. 2016 , 14, 212 | 67 |
| 1847 | Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies. 2016 , 13, 929-939 | 1 |
| 1846 | The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. 2016 , 48, 1283-1289 | 19 |
| 1845 | Potentially Curable Cancers of the Esophagus and Stomach. 2016 , 91, 1307-18 | 1 |
| 1844 | Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation. 2016 , 2, 505-518 | 34 |
| 1843 | Frequent EBV positivity in conventional adenocarcinomas occurring simultaneously with EBV-associated gastric cancers. 2016 , 48, 616-8 | 2 |
| 1842 | Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. 2016 , 6, 1230-1236 | 196 |
| 1841 | Epstein-Barr virus: more than 50 years old and still providing surprises. 2016 , 16, 789-802 | 378 |
| 1840 | Variegated RHOA mutations in human cancers. 2016 , 44, 1123-1129 | 18 |
| 1839 | The genomic landscape of schwannoma. 2016 , 48, 1339-1348 | 74 |
| 1838 | Proteomics approach to identify biomarkers for upper gastrointestinal cancer. 2016 , 13, 1041-1053 | 3 |
| 1837 | Is targeted therapy possible for patients with gastric adenocarcinoma?. 2016 , 17, 2371-2374 | 2 |
| 1836 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2016 , 27, v38-v49 | 796 |

| | | |
|------|--|-----|
| 1835 | Targeting deficient DNA damage repair in gastric cancer. 2016 , 17, 1757-66 | 10 |
| 1834 | Sox2 Suppresses Gastric Tumorigenesis in Mice. 2016 , 16, 1929-41 | 46 |
| 1833 | The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. 2016 , 6, | 204 |
| 1832 | Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. 2016 , 23, 3786-3791 | 1 |
| 1831 | Isoproterenol regulates CD44 expression in gastric cancer cells through STAT3/MicroRNA373 cascade. 2016 , 105, 89-101 | 17 |
| 1830 | DNA methylation dynamics: identification and functional annotation. 2016 , 15, 470-484 | 13 |
| 1829 | Are virus-induced cancers more sensitive to checkpoint inhibitors?. 2016 , 12, 2665-2668 | 10 |
| 1828 | Expression of aurora kinase A correlates with the Wnt-modulator RACGAP1 in gastric cancer. 2016 , 5, 516-26 | 13 |
| 1827 | Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity. 2016 , 113, 46-54 | 24 |
| 1826 | MET in gastric cancer--discarding a 10% cutoff rule. 2016 , 68, 241-53 | 31 |
| 1825 | [Infections and epigenetic changes in cancer]. 2016 , 87, 245-9 | |
| 1824 | Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation. 2016 , 49, 1755-65 | 9 |
| 1823 | SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. 2016 , 76, 6735-6746 | 79 |
| 1822 | Studying Cancer Evolution in Barrett's Esophagus and Esophageal Adenocarcinoma. 2016 , 908, 213-36 | 1 |
| 1821 | The Japanese Viewpoint on the Histopathology of Early Gastric Cancer. 2016 , 908, 331-46 | 6 |
| 1820 | Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. 2016 , 908, 371-91 | 34 |
| 1819 | Helicobacter pylori, Cancer, and the Gastric Microbiota. 2016 , 908, 393-408 | 45 |
| 1818 | Genomics Study of Gastric Cancer and Its Molecular Subtypes. 2016 , 908, 419-39 | 9 |

| | | |
|------|---|-----|
| 1817 | Recapitulating Human Gastric Cancer Pathogenesis: Experimental Models of Gastric Cancer. 2016 , 908, 441-78 | 6 |
| 1816 | Rnd3 in Cancer: A Review of the Evidence for Tumor Promoter or Suppressor. 2016 , 14, 1033-1044 | 32 |
| 1815 | The multi-omic landscape of transcription factor inactivation in cancer. 2016 , 8, 89 | 20 |
| 1814 | How to Screen for Hereditary Cancers in General Pathology Practice. 2016 , 140, 899-909 | 2 |
| 1813 | Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. 2016 , 115, 655-63 | 19 |
| 1812 | Dimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation. 2016 , 20, 2148-2159 | 10 |
| 1811 | Immunohistochemistry as a Practical Tool in Molecular Pathology. 2016 , 140, 766-9 | 12 |
| 1810 | Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1. 2016 , 24, 1550-61 | 29 |
| 1809 | Aurora kinase and RUNX: Reaching beyond transcription. 2016 , 15, 2999-3000 | 3 |
| 1808 | Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis. 2016 , 240, 304-314 | 35 |
| 1807 | Applications of integrative OMICs approaches to gene regulation studies. 2016 , 4, 283-301 | 4 |
| 1806 | ASCO update: gastric cancer. 2016 , 9, 219-221 | |
| 1805 | Targeted Treatment of Esophagogastric Cancer. 2016 , 39, 788-794 | 1 |
| 1804 | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. 2016 , 140, 1345-1363 | 64 |
| 1803 | Inhibition of Rho-Associated Kinase 1/2 Attenuates Tumor Growth in Murine Gastric Cancer. 2016 , 18, 500-11 | 23 |
| 1802 | Transcriptome analysis of paired primary colorectal carcinoma and liver metastases reveals fusion transcripts and similar gene expression profiles in primary carcinoma and liver metastases. 2016 , 16, 539 | 19 |
| 1801 | Genomics of Esophageal Cancer and Biomarkers for Early Detection. 2016 , 908, 237-63 | 6 |
| 1800 | Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. 2016 , 21, 1200-1211 | 164 |

| | | |
|------|--|-----|
| 1799 | Whole-exome sequencing identifies multiple loss-of-function mutations of NF- κ B pathway regulators in nasopharyngeal carcinoma. 2016 , 113, 11283-11288 | 107 |
| 1798 | Gastric cancer: current and evolving treatment landscape. 2016 , 35, 83 | 36 |
| 1797 | Variegated RHOA mutations in adult T-cell leukemia/lymphoma. 2016 , 127, 596-604 | 77 |
| 1796 | [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "la carte" treatment?]. 2016 , 103, 643-50 | 3 |
| 1795 | Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. 2016 , 107, 391-7 | 129 |
| 1794 | Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. 2016 , 37, 843-857 | 9 |
| 1793 | Co-expressed miRNAs in gastric adenocarcinoma. 2016 , 108, 93-101 | 28 |
| 1792 | Risk factors of lymph node metastasis in early gastric carcinomas diagnosed by WHO criteria in 379 Chinese patients. 2016 , 17, 526-537 | 23 |
| 1791 | Immunotherapy for oesophagogastric cancer. 2016 , 16, 1197-207 | 6 |
| 1790 | ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma. 2016 , 14, 1009-1018 | 16 |
| 1789 | Association between polymorphisms in segregation genes BUB1B and TTK and gastric cancer risk. 2016 , 50, 297-307 | 21 |
| 1788 | Transcription Factor NKX6.3 Sheds Light on Gastric Cancer Progression. 2016 , 9, 9-10 | 2 |
| 1787 | Increased global transcription activity as a mechanism of replication stress in cancer. 2016 , 7, 13087 | 150 |
| 1786 | Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. 2016 , 48, 1500-1507 | 139 |
| 1785 | Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus. 2016 , 1, 16026 | 56 |
| 1784 | NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. 2016 , 1, e000009 | 13 |
| 1783 | Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. 2016 , 7, 12983 | 78 |
| 1782 | Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. 2016 , 6, 26483 | 15 |

| | | |
|------|---|-----|
| 1781 | Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. 2016 , 6, 27702 | 38 |
| 1780 | Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. 2016 , 6, 22982 | 13 |
| 1779 | Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. 2016 , 49, 235-42 | 7 |
| 1778 | Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer. 2016 , 113, E7535-E7544 | 106 |
| 1777 | Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. 2016 , 10, 1551-1558 | 38 |
| 1776 | Progress and prospects for the discovery of biomarkers for gastric cancer: a focus on proteomics. 2016 , 13, 1131-1139 | 9 |
| 1775 | Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. 2016 , 17, 1628-1629 | 6 |
| 1774 | Pathogenesis: Infections causing gastric cancer. 2016 , 1, 16038 | 7 |
| 1773 | Antiangiogenic therapies in gastric cancer: trusting the pathway. 2016 , 27, 2141-2143 | 2 |
| 1772 | Immunotherapy in Gastrointestinal Malignancies. 2016 , 27-69 | |
| 1771 | Clinical Relevance and Molecular Phenotypes in Gastric Cancer, of TP53 Mutations and Gene Expressions, in Combination With Other Gene Mutations. 2016 , 6, 34822 | 12 |
| 1770 | Integrating Epigenomics into the Understanding of Biomedical Insight. 2016 , 10, 267-289 | 14 |
| 1769 | Epigenetic Mechanisms in Lynch Syndrome. 2016 , 1-9 | 1 |
| 1768 | NOTCH receptors in gastric and other gastrointestinal cancers: oncogenes or tumor suppressors?. 2016 , 15, 80 | 31 |
| 1767 | Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma. 2016 , 9, 52 | 16 |
| 1766 | Companion diagnostics 2016 , 31, 406-411 | |
| 1765 | Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy. 2016 , 40, 1326-33 | 7 |
| 1764 | Eradication of Infection Restores ki67, p53, and Cyclin D1 Immunoreactivity in the Human Gastric Epithelium. 2016 , 9, 73-78 | 2 |

| | | |
|------|---|-----|
| 1763 | Surface Antigen Profiling of Helicobacter pylori-Infected and -Uninfected Gastric Cancer Cells Using Antibody Microarray. 2016 , 21, 417-27 | 4 |
| 1762 | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. 2016 , 142, 1727-38 | 56 |
| 1761 | Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. 2016 , 9, 29 | 17 |
| 1760 | Epigenetic and genetic variation in GATA5 is associated with gastric disease risk. 2016 , 135, 895-906 | 8 |
| 1759 | [Grading of tumors in the tubular digestive tract : Esophagus, stomach, colon and rectum]. 2016 , 37, 293-8 | 3 |
| 1758 | Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines. 2016 , 76, 4619-26 | 27 |
| 1757 | Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma. 2016 , 56, 16-21 | 29 |
| 1756 | Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. 2016 , 111, 290-302 | 93 |
| 1755 | Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. 2016 , 114, 1387-94 | 29 |
| 1754 | Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. 2016 , 34, 2728-35 | 138 |
| 1753 | Implementation of next generation sequencing in clinical molecular diagnostic laboratories: advantages, challenges and potential. 2016 , 1, 109-120 | 20 |
| 1752 | PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. 2016 , 55, 182-9 | 44 |
| 1751 | The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives. 2016 , 1, 4-11 | 8 |
| 1750 | Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. 2016 , 12, 911-22 | 41 |
| 1749 | M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers. 2016 , 76, 3895-903 | 20 |
| 1748 | Differences in TGF- β signaling and clinicopathologic characteristics of histologic subtypes of gastric cancer. 2016 , 16, 60 | 12 |
| 1747 | miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF- κ B signaling in gastric carcinogenesis. 2016 , 15, 9 | 44 |
| 1746 | Epigenetic impact of infection on carcinogenesis: mechanisms and applications. 2016 , 8, 10 | 75 |

| | | |
|------|---|-----|
| 1745 | Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis. 2016 , 35, 16 | 32 |
| 1744 | Genomic alterations and molecular subtypes of gastric cancers in Asians. 2016 , 35, 42 | 17 |
| 1743 | Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. 2016 , 76, 4090-9 | 22 |
| 1742 | Rolle des Pathologen in Hinblick auf therapeutische Entscheidungen beim Magenkarzinom. 2016 , 22, 400-405 | |
| 1741 | How Can Gastric Cancer Molecular Profiling Guide Future Therapies?. 2016 , 22, 534-544 | 45 |
| 1740 | Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type. 2016 , 55, 460-71 | 75 |
| 1739 | Function and diagnostic value of Anosmin-1 in gastric cancer progression. 2016 , 138, 721-30 | 45 |
| 1738 | Targeting JAK kinase in solid tumors: emerging opportunities and challenges. 2016 , 35, 939-51 | 143 |
| 1737 | Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. 2016 , 65, 1296-305 | 49 |
| 1736 | Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. 2016 , 15, 289-96 | 10 |
| 1735 | Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. 2016 , 7, 10499 | 80 |
| 1734 | Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer. 2016 , 37, 9399-410 | 10 |
| 1733 | A panoply of errors: polymerase proofreading domain mutations in cancer. 2016 , 16, 71-81 | 205 |
| 1732 | The kinome 'at large' in cancer. 2016 , 16, 83-98 | 167 |
| 1731 | High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing. 2016 , 29, 182-93 | 35 |
| 1730 | New era of integrated cancer biomarker discovery using reverse-phase protein arrays. 2016 , 31, 35-45 | 27 |
| 1729 | Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. 2016 , 372, 187-91 | 100 |
| 1728 | Large-scale profiling of microRNAs for The Cancer Genome Atlas. 2016 , 44, e3 | 85 |

| | | |
|------|---|-----|
| 1727 | Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications. 2016 , 13, 69-70 | 15 |
| 1726 | Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort. 2016 , 69, 70-5 | 14 |
| 1725 | Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. 2016 , 23, 943-50 | 70 |
| 1724 | Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. 2016 , 37, 127-40 | 8 |
| 1723 | Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. 2016 , 76, 13-26 | 7 |
| 1722 | Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. 2016 , 19, 31-41 | 42 |
| 1721 | Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. 2016 , 161, 97-110 | 49 |
| 1720 | Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach. 2016 , 28, e35-44 | 14 |
| 1719 | Integrative clustering methods of multi-omics data for molecule-based cancer classifications. 2016 , 4, 58-67 | 37 |
| 1718 | Sleeping Beauty transposon mutagenesis identifies genes that cooperate with mutant Smad4 in gastric cancer development. 2016 , 113, E2057-65 | 28 |
| 1717 | Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. 2016 , 37, 356-65 | 30 |
| 1716 | Clinicopathological and molecular alterations in early gastric cancers with the microsatellite instability-high phenotype. 2016 , 138, 1689-97 | 27 |
| 1715 | Mouse models for gastric cancer: Matching models to biological questions. 2016 , 31, 1257-72 | 28 |
| 1714 | Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. 2016 , 130, 95-190 | 120 |
| 1713 | C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits. 2016 , 150, 1183-1195.e16 | 39 |
| 1712 | Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. 2016 , 136, 1002-1011 | 40 |
| 1711 | Highly Efficient CRISPR/Cas9-Mediated Cloning and Functional Characterization of Gastric Cancer-Derived Epstein-Barr Virus Strains. 2016 , 90, 4383-93 | 51 |
| 1710 | Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability. 2016 , 76, 1724-32 | 86 |

| | | |
|------|---|-----|
| 1709 | Intestine-specific homeobox (ISX) induces intestinal metaplasia and cell proliferation to contribute to gastric carcinogenesis. 2016 , 51, 949-60 | 7 |
| 1708 | Molecular Pathology Informatics. 2016 , 36, 57-66 | 1 |
| 1707 | Microsatellite Instability as a Biomarker for PD-1 Blockade. 2016 , 22, 813-20 | 470 |
| 1706 | Quality assurance in clinical trials--the role of pathology. 2016 , 468, 83-92 | 7 |
| 1705 | Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. 2016 , 11, 469-77 | 31 |
| 1704 | Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. 2016 , 48, 356-8 | 111 |
| 1703 | Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. 2016 , 11, 283-312 | 72 |
| 1702 | Clinical Applications of Epigenomics. 2016 , 271-295 | 0 |
| 1701 | Molecular classification of gastric cancer. 2016 , 27, 763-9 | 109 |
| 1700 | In Epstein-Barr virus-associated gastric carcinoma a high density of CD66b-positive tumor-associated neutrophils is associated with intestinal-type histology and low frequency of lymph node metastasis. 2016 , 468, 539-48 | 14 |
| 1699 | Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. 2016 , 23, 295-301 | 61 |
| 1698 | Application of next-generation sequencing in gastrointestinal and liver tumors. 2016 , 374, 187-91 | 4 |
| 1697 | The possibility of clinical sequencing in the management of cancer. 2016 , 46, 399-406 | 24 |
| 1696 | Monoclonal antibodies for treating gastric cancer: promises and pitfalls. 2016 , 16, 759-69 | 6 |
| 1695 | Clinical impact of tumour biology in the management of gastroesophageal cancer. 2016 , 13, 348-60 | 100 |
| 1694 | Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer. 2016 , 23, 1986-92 | 11 |
| 1693 | Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns. 2016 , 96, 661-71 | 37 |
| 1692 | Translating gastric cancer genomics into targeted therapies. 2016 , 100, 141-6 | 35 |

| | | |
|------|---|------|
| 1691 | Emerging immunotherapy for the treatment of esophageal cancer. 2016 , 25, 667-77 | 21 |
| 1690 | Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss?. 2016 , 34, 1431-2 | 7 |
| 1689 | Epigenetics - A Different Way of Looking at Genetics. 2016 , | |
| 1688 | Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. 2016 , 53, 25-34 | 45 |
| 1687 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. 2016 , 19, 687-95 | 24 |
| 1686 | Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. 2016 , 27, 494-501 | 89 |
| 1685 | Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. 2016 , 23, 1225-33 | 13 |
| 1684 | Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. 2016 , 150, 931-43 | 156 |
| 1683 | Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions. 2016 , 150, 918-30.e13 | 73 |
| 1682 | Epigenetic Alterations in Epstein-Barr Virus-Associated Diseases. 2016 , 879, 39-69 | 21 |
| 1681 | Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?. 2016 , 34, 401-3 | 14 |
| 1680 | Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. 2016 , 99, 1-12 | 16 |
| 1679 | TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. 2016 , 44, e71 | 1155 |
| 1678 | Proteogenomics for understanding oncology: recent advances and future prospects. 2016 , 13, 297-308 | 16 |
| 1677 | AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells. 2016 , 411, 299-305 | 20 |
| 1676 | Is signet-ring cell carcinoma a specific entity among gastric cancers?. 2016 , 19, 1027-1040 | 38 |
| 1675 | An optimization of the LC-MS/MS workflow for deep proteome profiling on an Orbitrap Fusion. 2016 , 8, 425-434 | 7 |
| 1674 | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. 2016 , 34, 443-51 | 361 |

| | | |
|------|---|-----|
| 1673 | Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010. 2016 , 19, 1114-1124 | 8 |
| 1672 | Rates of lymph node metastasis and survival in T1a gastric adenocarcinoma in Western populations. 2016 , 83, 1184-1192.e1 | 24 |
| 1671 | RHOA mutation may be associated with diffuse-type gastric cancer progression, but is it gain or loss?. 2016 , 19, 326-328 | 6 |
| 1670 | Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. 2016 , 374, 135-45 | 753 |
| 1669 | Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. 2016 , 44, 1105-17 | 34 |
| 1668 | Fukutin, identified by the Escherichia coli ampicillin secretion trap (CAST) method, participates in tumor progression in gastric cancer. 2016 , 19, 443-452 | 6 |
| 1667 | Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. 2016 , 22, 971-83 | 70 |
| 1666 | Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. 2016 , 27, 127-33 | 52 |
| 1665 | miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. 2016 , 39, 23-33 | 85 |
| 1664 | Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development. 2016 , 35, 2133-44 | 17 |
| 1663 | Evaluation of somatic copy number estimation tools for whole-exome sequencing data. 2016 , 17, 185-92 | 35 |
| 1662 | Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. 2016 , 19, 421-430 | 10 |
| 1661 | Validation and calibration of next-generation sequencing to identify Epstein-Barr virus-positive gastric cancer in The Cancer Genome Atlas. 2016 , 19, 676-681 | 10 |
| 1660 | A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. 2016 , 65, 9-18 | 99 |
| 1659 | An atlas of gastric PIWI-interacting RNA transcriptomes and their utility for identifying signatures of gastric cancer recurrence. 2016 , 19, 660-665 | 53 |
| 1658 | RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases. 2016 , 19, 403-411 | 37 |
| 1657 | Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. 2017 , 20, 164-174 | 12 |
| 1656 | Identification of new susceptibility loci for gastric non-cardia adenocarcinoma: pooled results from two Chinese genome-wide association studies. 2017 , 66, 581-587 | 51 |

| | | |
|------|--|-----|
| 1655 | Application of CRISPR-mediated genome engineering in cancer research. 2017 , 387, 10-17 | 11 |
| 1654 | Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. 2017 , 66, 794-801 | 274 |
| 1653 | Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. 2017 , 20, 156-163 | 50 |
| 1652 | Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. 2017 , 17, 528-534 | 7 |
| 1651 | Genetic differences stratified by PCR-based microsatellite analysis in gastric intramucosal neoplasia. 2017 , 20, 286-296 | 12 |
| 1650 | Gastrokine 1 inhibits gastric cancer cell migration and invasion by downregulating RhoA expression. 2017 , 20, 274-285 | 27 |
| 1649 | REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype. 2017 , 36, 182-193 | 32 |
| 1648 | Comparison of Clinicopathologic Parameters and Survivals Between Epstein-Barr Virus-positive and Her2-positive Gastric Cancers. 2017 , 25, 609-614 | 8 |
| 1647 | Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization. 2017 , 25, 12-24 | 67 |
| 1646 | Genome-wide analysis of DNA copy number alterations in early and advanced gastric cancers. 2017 , 56, 527-537 | 14 |
| 1645 | Advanced gastric adenocarcinoma: optimizing therapy options. 2017 , 10, 263-271 | 16 |
| 1644 | [Gastric tumors and tumor precursors]. 2017 , 38, 75-86 | 5 |
| 1643 | Biomarkers in Tumor Microenvironment? Upregulation of Fibroblast Activation Protein- β Correlates with Gastric Cancer Progression and Poor Prognosis. 2017 , 21, 38-44 | 14 |
| 1642 | Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. 2017 , 4, 72-75 | |
| 1641 | Amplified 7q21-22 gene MCM7 and its intronic miR-25 suppress COL1A2 associated genes to sustain intestinal gastric cancer features. 2017 , 56, 1590-1602 | 22 |
| 1640 | Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. 2017 , 33, 749-759 | 50 |
| 1639 | CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. 2017 , 8, 13897 | 42 |
| 1638 | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. 2017 , 35, 446-464 | 176 |

| | | |
|------|--|----|
| 1637 | Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer. 2017 , 21, 179-185 | 20 |
| 1636 | Immunotherapy and patients treated for cancer with microsatellite instability. 2017 , 104, 42-51 | 45 |
| 1635 | Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 2017 , 110, 106-116 | 29 |
| 1634 | HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation. 2017 , 9, 181-197 | 46 |
| 1633 | Murine Models of Gastric Corpus Preneoplasia. 2017 , 3, 11-26 | 48 |
| 1632 | The NF1 gene in tumor syndromes and melanoma. 2017 , 97, 146-157 | 92 |
| 1631 | Translating genomic profiling to gastrointestinal cancer treatment. 2017 , 13, 919-934 | 7 |
| 1630 | Helicobacter pylori-Induced Changes in Gastric Acid Secretion and Upper Gastrointestinal Disease. 2017 , 400, 227-252 | 26 |
| 1629 | AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. 2017 , 16, 566-577 | 74 |
| 1628 | Anti-angiogenesis: disappointment in localised oesophagogastric cancer. 2017 , 18, 278-279 | 1 |
| 1627 | EPSIN 3, A Novel p53 Target, Regulates the Apoptotic Pathway and Gastric Carcinogenesis. 2017 , 19, 185-195 | 6 |
| 1626 | Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. 2017 , 77, 509-519 | 60 |
| 1625 | Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. 2017 , 168, 460-472.e14 | 75 |
| 1624 | Molecular classification of gastric cancer. 2017 , 17, 293-301 | 47 |
| 1623 | Pathogenesis of Gastric Cancer: Genetics and Molecular Classification. 2017 , 400, 277-304 | 60 |
| 1622 | Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis. 2017 , 400, 305-323 | 17 |
| 1621 | Epstein-Barr virus gene expression and latency pattern in gastric carcinomas: a systematic review. 2017 , 13, 567-579 | 25 |
| 1620 | Current Progress in the Adjuvant Treatment of Gastric Cancer. 2017 , 26, 225-239 | 8 |

| | | |
|------|--|-----|
| 1619 | The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?. 2017 , 6, e1293215 | 75 |
| 1618 | Novel Insights into Gastric Cancer: Methylation of R-spondins and Regulation of LGR5 by SP1. 2017 , 15, 776-785 | 10 |
| 1617 | [Novel pharmaceutical treatment approaches for gastric cancer]. 2017 , 38, 87-92 | 0 |
| 1616 | Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. 2017 , 174, 145-172 | 19 |
| 1615 | [Immune response and digestive cancers: Prognostic and therapeutic implications]. 2017 , 37, 111-116 | 1 |
| 1614 | [Current biomarkers for gastric cancer]. 2017 , 38, 93-97 | 8 |
| 1613 | Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. 2017 , 26, 313-324 | 1 |
| 1612 | Gastric cancer management: Kinases as a target therapy. 2017 , 44, 613-622 | 21 |
| 1611 | Gastric Cancer Genomics: Advances and Future Directions. 2017 , 3, 211-217 | 43 |
| 1610 | Perioperative chemotherapy for resectable gastric cancer - what is the evidence?. 2017 , 52, 647-653 | 9 |
| 1609 | Integrated expression analysis identifies transcription networks in mouse and human gastric neoplasia. 2017 , 56, 535-547 | 14 |
| 1608 | The prognostic and potentially predictive value of the Lauri classification in oesophageal adenocarcinoma. 2017 , 76, 27-35 | 18 |
| 1607 | DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. 2017 , 140, 2587-2595 | 21 |
| 1606 | Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. 2017 , 3, 1197-1203 | 256 |
| 1605 | High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. 2017 , 77, 2464-2475 | 71 |
| 1604 | Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. 2017 , 104, 877-884 | 22 |
| 1603 | SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation. 2017 , 7, | 36 |
| 1602 | The importance of regulatory ubiquitination in cancer and metastasis. 2017 , 16, 634-648 | 90 |

| | | |
|------|---|-----|
| 1601 | PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer. 2017 , 115-146 | |
| 1600 | Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer. 2017 , 212, 195-204 | 23 |
| 1599 | Quantitative global proteome and lysine succinylome analyses provide insights into metabolic regulation and lymph node metastasis in gastric cancer. 2017 , 7, 42053 | 29 |
| 1598 | Cadherin 5 expression correlates with poor survival in human gastric cancer. 2017 , 70, 217-221 | 14 |
| 1597 | Proteogenomic analysis of NCC-S1M, a gastric cancer stem cell-like cell line that responds to anti-PD-1. 2017 , 484, 631-635 | 3 |
| 1596 | Effect of annexin A7 suppression on the apoptosis of gastric cancer cells. 2017 , 429, 33-43 | 14 |
| 1595 | MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. 2017 , 10, 197-214 | 82 |
| 1594 | Differential regulation analysis reveals dysfunctional regulatory mechanism involving transcription factors and microRNAs in gastric carcinogenesis. 2017 , 77, 12-22 | 8 |
| 1593 | A population genetics perspective on the determinants of intra-tumor heterogeneity. 2017 , 1867, 109-126 | 29 |
| 1592 | Novel Targeted Therapies for Esophagogastric Cancer. 2017 , 26, 293-312 | 10 |
| 1591 | The Current Status of Immunotherapies in Esophagogastric Cancer. 2017 , 26, 277-292 | 2 |
| 1590 | Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer. 2017 , 15, 2 | 19 |
| 1589 | Gastric cancer in FAP: a concerning rise in incidence. 2017 , 16, 371-376 | 50 |
| 1588 | The Relationship Between DOT1L, Histone H3 Methylation, and Genome Stability in Cancer. 2017 , 3, 18-27 | 3 |
| 1587 | Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner. 2017 , 21, 1329-1341 | 28 |
| 1586 | NF- κ B mediated transcription of DARPP-32 prevents -induced cell death. 2017 , 66, 761-762 | 7 |
| 1585 | Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. 2017 , 153, 191-204.e16 | 101 |
| 1584 | Advanced gastric cancer: is there an optimal chemotherapy regimen?. 2017 , 2, 123-132 | |

1583 Systems Biology and Genomics. **2017**, 1-10

1582 Molecular subtypes in cancers of the gastrointestinal tract. **2017**, 14, 333-342

79

1581 Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer. **2017**, 84, 210-217

7

1580 Effect of anti-PD-1 antibody, nivolumab on early gastric cancer. **2017**, 6, 98-103

0

1579 Future Directions in Improving Outcomes for Patients with Gastric and Esophageal Cancer. **2017**, 31, 545-552

6

1578 Chromosomal Instability in Gastric Cancer Biology. **2017**, 19, 412-420

27

1577 Tumor budding in intestinal-type gastric adenocarcinoma is associated with nodal metastasis and recurrence. **2017**, 68, 26-33

22

1576 Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features. **2017**, 23, 4855-4864

28

1575 Coexpressed modular gene expression reveals inverse correlation between immune responsive transcription and aggressiveness in gastric tumours. **2017**, 66, 941-954

1

1574 Intrinsic Molecular Processes: Impact on Mutagenesis. **2017**, 3, 357-371

4

1573 Epstein-Barr virus infection induces genome-wide de novo DNA methylation in non-neoplastic gastric epithelial cells. **2017**, 242, 391-399

28

1572 Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. **2017**, 45, 2973-2985

115

1571 Elevated T cell activation score is associated with improved survival of breast cancer. **2017**, 164, 689-696

25

1570 Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma. **2017**, 18, e243

1

1569 Gastric Cancer With Primitive Enterocyte Phenotype: An Aggressive Subgroup of Intestinal-type Adenocarcinoma. **2017**, 41, 989-997

27

1568 Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. **2017**, 23, 703-713

1638

1567 Gastric Cancer. **2017**, 397-408

1

1566 Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer. **2017**, 36, 5134-5144

41

| | | |
|------|---|-----|
| 1565 | βp63 is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. 2017 , 114, E3964-E3973 | 36 |
| 1564 | Dietary metabolites derived from gut microbiota: critical modulators of epigenetic changes in mammals. 2017 , 75, 374-389 | 109 |
| 1563 | Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. 2017 , 10, 86 | 55 |
| 1562 | Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. 2017 , 56, 651-659 | 30 |
| 1561 | 1,25-Dihydroxyvitamin D suppresses gastric cancer cell growth through VDR- and mutant p53-mediated induction of p21. 2017 , 179, 88-97 | 29 |
| 1560 | Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. 2017 , 15, 1106-1116 | 46 |
| 1559 | PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study. 2017 , 96, e5730 | 3 |
| 1558 | A three-lncRNA expression signature associated with the prognosis of gastric cancer patients. 2017 , 6, 1154-1164 | 48 |
| 1557 | Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. 2017 , 28, 1005-1014 | 35 |
| 1556 | IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. 2017 , 16, 77 | 61 |
| 1555 | Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-βcatenin signaling pathway. 2017 , 8, 98 | 23 |
| 1554 | Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer. 2017 , 6, 235-244 | 3 |
| 1553 | Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. 2017 , 56, 16-25 | 51 |
| 1552 | A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer. 2017 , 5, 524-534 | 40 |
| 1551 | ARHGAP18 Downregulation by miR-200b Suppresses Metastasis of Triple-Negative Breast Cancer by Enhancing Activation of RhoA. 2017 , 77, 4051-4064 | 50 |
| 1550 | Hedgehog signaling pathway as a potential target in the treatment of advanced gastric cancer. 2017 , 39, 1010428317692266 | 9 |
| 1549 | Update on Gastroesophageal Adenocarcinoma Targeted Therapies. 2017 , 31, 511-527 | 14 |
| 1548 | How to stomach an epigenetic insult: the gastric cancer epigenome. 2017 , 14, 467-478 | 85 |

| | | |
|------|--|-----|
| 1547 | New agents on the horizon in gastric cancer. 2017 , 28, 1767-1775 | 51 |
| 1546 | Single disease entity for both chromosomal instable subtype gastric adenocarcinoma and esophageal adenocarcinoma. 2017 , 18, 319-322 | 2 |
| 1545 | Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. 2017 , 153, 536-549.e26 | 63 |
| 1544 | Advances in therapeutic options for esophageal and esophagogastric junctional adenocarcinoma. 2017 , 5, 549-557 | |
| 1543 | Gastric Cancer as Preventable Disease. 2017 , 15, 1833-1843 | 119 |
| 1542 | Therapeutic Vaccine of Gastric Cancer. 2017 , 131-147 | |
| 1541 | Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. 2017 , 28, 1207-1216 | 22 |
| 1540 | Immune Checkpoint Blockade and Gastric Cancer. 2017 , 115-130 | 2 |
| 1539 | Irradiated VEGF164-modified tumor cell vaccine protected mice from the parental tumor challenge. 2017 , 28, 197-205 | 1 |
| 1538 | The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. 2017 , 45, 13-22 | 105 |
| 1537 | Allelic imbalance of somatic mutations in cancer genomes and transcriptomes. 2017 , 7, 1653 | 24 |
| 1536 | Current trends in electrochemical sensing and biosensing of DNA methylation. 2017 , 97, 384-399 | 36 |
| 1535 | A molecular portrait of microsatellite instability across multiple cancers. 2017 , 8, 15180 | 288 |
| 1534 | Aberrant expression of AID and AID activators of NF- κ B and PAX5 is irrelevant to EBV-associated gastric cancers, but is associated with carcinogenesis in certain EBV-non-associated gastric cancers. 2017 , 13, 4133-4140 | 4 |
| 1533 | The effect of EBV on WIF1, NLK, and APC gene methylation and expression in gastric carcinoma and nasopharyngeal cancer. 2017 , 89, 1844-1851 | 18 |
| 1532 | Epstein-Barr virus infection and breast invasive ductal carcinoma in Egyptian women: A single center experience. 2017 , 29, 77-82 | 14 |
| 1531 | High ubiquitin-specific protease 44 expression induces DNA aneuploidy and provides independent prognostic information in gastric cancer. 2017 , 6, 1453-1464 | 16 |
| 1530 | Gastric adenocarcinoma. 2017 , 3, 17036 | 251 |

| | | |
|------|--|-----|
| 1529 | Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers. 2017 , 174, 4666-4683 | 26 |
| 1528 | miR-564 is downregulated in gastric carcinoma and targets E2F3. 2017 , 13, 4155-4160 | 14 |
| 1527 | EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients. 2017 , 471, 216-221 | 7 |
| 1526 | Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. 2017 , 23, 6002-6011 | 21 |
| 1525 | Gastric Cancer in the Era of Precision Medicine. 2017 , 3, 348-358 | 66 |
| 1524 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. 2017 , 14, 562-576 | 102 |
| 1523 | Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. 2017 , 147, 500-506 | 36 |
| 1522 | Intratumoral heterogeneity in gastric cancer: a new challenge to face. 2017 , 28, 912-913 | 19 |
| 1521 | Notch as a Driver of Gastric Epithelial Cell Proliferation. 2017 , 3, 323-330 | 26 |
| 1520 | The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models. 2017 , 3, 331-338 | 39 |
| 1519 | Regulation of Gastric Metaplasia, Dysplasia, and Neoplasia by Bone Morphogenetic Protein Signaling. 2017 , 3, 339-347 | 14 |
| 1518 | Gastrin and Gastric Cancer. 2017 , 4, 75-83 | 39 |
| 1517 | Antiangiogenic Therapy in Gastroesophageal Cancer. 2017 , 31, 499-510 | 6 |
| 1516 | Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. 2017 , 7, 630-651 | 34 |
| 1515 | Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma. 2017 , 31, 529-544 | 5 |
| 1514 | Beyond precision surgery: Molecularly motivated precision care for gastric cancer. 2017 , 43, 856-864 | 10 |
| 1513 | Anti-Angiogenics in Gastroesophageal Cancer. 2017 , 1-19 | |
| 1512 | The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer. 2017 , 31, 485-498 | 3 |

| | | |
|------|---|----|
| 1511 | Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. 2017 , 7, 738 | 7 |
| 1510 | Perspectives of HER2-targeting in gastric and esophageal cancer. 2017 , 26, 531-540 | 40 |
| 1509 | Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. 2017 , 6, e1293213 | 25 |
| 1508 | Liver metastases from gastric carcinoma: A Case report and review of the literature. 2017 , 41, 222-230 | 6 |
| 1507 | The Gastric Microbiome and Its Influence on Gastric Carcinogenesis: Current Knowledge and Ongoing Research. 2017 , 31, 389-408 | 23 |
| 1506 | Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification. 2017 , 35, 325-332 | 4 |
| 1505 | A global burden of gastric cancer: the major impact of China. 2017 , 11, 651-661 | 58 |
| 1504 | Immunotherapy for gastric cancers: emerging role and future perspectives. 2017 , 10, 609-619 | 26 |
| 1503 | Expression of NUA2 in gastric cancer tissue and its effects on the proliferation of gastric cancer cells. 2017 , 13, 676-680 | 5 |
| 1502 | DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. 2017 , 12, 416-432 | 66 |
| 1501 | Silencing of ATP4B of ATPase H/K Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells. 2017 , 25, 317-329 | 13 |
| 1500 | Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade. 2017 , 242, 206-220 | 22 |
| 1499 | Predictive biomarkers along gastric cancer pathogenetic pathways. 2017 , 17, 417-425 | 22 |
| 1498 | A High Ki67/BCL2 Index Could Predict Lower Disease-Free and Overall Survival in Intestinal-Type Gastric Cancer. 2017 , 58, 158-168 | 10 |
| 1497 | The enigmatic oncogene and tumor suppressor-like properties of RAD54B: Insights into genome instability and cancer. 2017 , 56, 513-523 | 10 |
| 1496 | Roles of RUNX in Solid Tumors. 2017 , 962, 299-320 | 14 |
| 1495 | Runx3 in Immunity, Inflammation and Cancer. 2017 , 962, 369-393 | 21 |
| 1494 | Clinical significance of spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia in Epstein-Barr virus-associated and Epstein-Barr virus-negative gastric cancer. 2017 , 63, 128-138 | 9 |

| | | |
|------|---|----------|
| 1493 | A unified model of the hierarchical and stochastic theories of gastric cancer. 2017 , 116, 973-989 | 23 |
| 1492 | Genetics of Gastric Cancer. 2017 , 97, 345-370 | 29 |
| 1491 | The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. 2017 , 17, 459-470 | 9 |
| 1490 | Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. 2017 , 24, 2655-2668 | 37 |
| 1489 | Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective. 2017 , 3, 359-366 | 4 |
| 1488 | The AGA/Funderburg Award in Gastric Cancer: Twenty-five Years of Advances in Gastric Cancer Research. 2017 , 152, 1262-1266 | 1 |
| 1487 | MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. 2017 , 123, 1061-1070 | 25 |
| 1486 | Genomic pathobiology of gastric carcinoma. 2017 , 67, 63-71 | 8 |
| 1485 | Immunotherapy for Gastrointestinal Cancer. 2017 , | 0 |
| 1484 | Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1 immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. 2017 , 30, 427-439 | 105 |
| 1483 | Adult gastric stem cells and their niches. 2017 , 6, e261 | 19 |
| 1482 | Integrated genomic characterization of oesophageal carcinoma. <i>Nature</i> , 2017 , 541, 169-175 | 50.4 965 |
| 1481 | Cancer genomics: Spot the difference. <i>Nature</i> , 2017 , 541, 162-163 | 50.4 6 |
| 1480 | PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. 2017 , 103, 52-57 | 21 |
| 1479 | Rho GTPases: Anti- or pro-neoplastic targets?. 2017 , 36, 3213-3222 | 60 |
| 1478 | Authors' reply - Re: Wang et al. Controversial role of the possible oxyntic stem cell marker ASPM in gastric cancer. 2017 , 241, 562-563 | 1 |
| 1477 | Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. 2017 , 16, 319-327 | 7 |
| 1476 | The search for simplicity: is this compatible with precision medicine?. 2017 , 28, 10-12 | 1 |

| | | |
|------|---|------|
| 1475 | Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. 2017 , 13, 2265-2275 | 8 |
| 1474 | Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation. 2017 , 14, 5409-5417 | 15 |
| 1473 | EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells. 2017 , 494, 550-555 | 27 |
| 1472 | Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. 2017 , 86, 305-317 | 17 |
| 1471 | Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. 2017 , 8, 1081 | 13 |
| 1470 | Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: A better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. 2017 , 7, 13967 | 27 |
| 1469 | Pan-cancer analysis reveals presence of pronounced DNA methylation drift in CpG island methylator phenotype clusters. 2017 , 9, 1341-1352 | 10 |
| 1468 | The pattern of lymph node metastases in microsatellite unstable gastric cancer. 2017 , 43, 2341-2348 | 15 |
| 1467 | Pathologische Einteilung und Diagnostik des Ösophagus- und Magenkarzinoms. 2017 , 12, 394-400 | |
| 1466 | Gastrointestinal Cancers. 2017 , 589-625 | 1 |
| 1465 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. 2017 , 390, 2461-2471 | 1123 |
| 1464 | Cross-Sectional Location of Gastric Cancer Affects the Long-Term Survival of Patients as Tumor Invasion Deepens. 2017 , 24, 3947-3953 | 2 |
| 1463 | Health Informatics Data Analysis. 2017 , | |
| 1462 | Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. 2017 , 54, 414-432 | 10 |
| 1461 | Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. 2017 , 34, 186 | 5 |
| 1460 | Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. 2017 , 23, 7543-7549 | 8 |
| 1459 | Gastric cancer: The gastric microbiota - bacterial diversity and implications. 2017 , 14, 692-693 | 19 |
| 1458 | Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. 2017 , 8, 1050 | 75 |

| | | |
|------|--|-----|
| 1457 | Decreased expression of lncRNA VPS9D1-AS1 in gastric cancer and its clinical significance. 2017 , 21, 23-28 | 36 |
| 1456 | Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis. 2017 , 114, 9683-9688 | 24 |
| 1455 | Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. 2017 , 6, e1356150 | 27 |
| 1454 | Chemotherapy for advanced gastric cancer. 2017 , 8, CD004064 | 248 |
| 1453 | Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. 2017 , 84, 290-303 | 89 |
| 1452 | Molecular Characteristics of Patient-Derived Tumor Xenografts: Similarities to Patient Tumors and Relevance for Biomarker Discovery. 2017 , 227-243 | 1 |
| 1451 | Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. 2017 , 13, 1981-1990 | 24 |
| 1450 | Genetic variants in PPP2CA are associated with gastric cancer risk in a Chinese population. 2017 , 7, 11499 | 6 |
| 1449 | Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. 2017 , 93, 387-394 | 24 |
| 1448 | The roles of ubiquitin modifying enzymes in neoplastic disease. 2017 , 1868, 456-483 | 29 |
| 1447 | Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer. 2017 , 9, 1329-1335 | 5 |
| 1446 | Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?. 2017 , 43, 1835-1845 | 3 |
| 1445 | Analysis of somatic microsatellite indels identifies driver events in human tumors. 2017 , 35, 951-959 | 72 |
| 1444 | Network-based machine learning and graph theory algorithms for precision oncology. 2017 , 1, 25 | 43 |
| 1443 | Gastric cancer: Basic aspects. 2017 , 22 Suppl 1, e12412 | 20 |
| 1442 | Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. 2017 , 8, 524 | 69 |
| 1441 | Tumour virology in the era of high-throughput genomics. 2017 , 372, | 17 |
| 1440 | Epstein-Barr virus-associated lymphomas. 2017 , 372, | 181 |

| | | |
|------|---|------|
| 1439 | Big Health Data Mining. 2017 , 169-184 | |
| 1438 | Future Clinical Trials: Genetically Driven Trials. 2017 , 26, 791-797 | 3 |
| 1437 | Forward and backward evolutionary processes and allele frequency spectrum in a cancer cell population. 2017 , 117, 43-50 | 13 |
| 1436 | Regulation of tumour related genes by dynamic epigenetic alteration at enhancer regions in gastric epithelial cells infected by Epstein-Barr virus. 2017 , 7, 7924 | 20 |
| 1435 | The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2. 2017 , 10, 644-648 | 1 |
| 1434 | Clinicopathological and molecular stability and methylation analyses of gastric papillary adenocarcinoma. 2017 , 49, 596-603 | 3 |
| 1433 | Epstein-Barr Virus miR-BART6-3p Inhibits the RIG-I Pathway. 2017 , 9, 574-586 | 51 |
| 1432 | Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. 2017 , 22, 1169-1177 | 10 |
| 1431 | P53 deregulation in Epstein-Barr virus-associated gastric cancer. 2017 , 404, 37-43 | 19 |
| 1430 | UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. 2017 , 19, 649-658 | 2229 |
| 1429 | LncRNA TRERNA1 Function as an Enhancer of SNAI1 Promotes Gastric Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition. 2017 , 8, 291-299 | 40 |
| 1428 | Genetic variants in gastric cancer: Risks and clinical implications. 2017 , 103, 101-111 | 23 |
| 1427 | RPS27a enhances EBV-encoded LMP1-mediated proliferation and invasion by stabilizing of LMP1. 2017 , 491, 303-309 | 13 |
| 1426 | Molecular genetics and targeted therapy of WNT-related human diseases (Review). 2017 , 40, 587-606 | 112 |
| 1425 | Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing. 2017 , 243, 165-175 | 8 |
| 1424 | Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. 2017 , 32, 155-168.e6 | 61 |
| 1423 | Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. 2017 , 220, 125-132 | 29 |
| 1422 | Cytokine expression associated with Helicobacter pylori and Epstein-Barr virus infection in gastric carcinogenesis. 2017 , 125, 808-815 | 9 |

| | | |
|------|--|-----|
| 1421 | Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. 2017 , 23, 4441-4449 | 213 |
| 1420 | Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. 2017 , 117, 775-782 | 53 |
| 1419 | Activin signaling is an essential component of the TGF- β -induced pro-metastatic phenotype in colorectal cancer. 2017 , 7, 5569 | 33 |
| 1418 | Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression. 2017 , 77, 5349-5359 | 25 |
| 1417 | Angiogenesis inhibitors in early development for gastric cancer. 2017 , 26, 1007-1017 | 23 |
| 1416 | High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. 2017 , 41, 106-115 | 54 |
| 1415 | Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells. 2017 , 92, 164-172 | 10 |
| 1414 | Epstein-Barr virus: a master epigenetic manipulator. 2017 , 26, 74-80 | 31 |
| 1413 | Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. 2017 , 32, 204-220.e15 | 391 |
| 1412 | Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms. 2017 , 16, 2780-2791 | 16 |
| 1411 | Immunogenetic Profiling for Gastric Cancers Identifies Sulfated Glycosaminoglycans as Major and Functional B Cell Antigens in Human Malignancies. 2017 , 20, 1073-1087 | 32 |
| 1410 | Chromosomal breaks at FRA18C: association with reduced expression, altered oncogenic signaling and increased gastric cancer survival. 2017 , 1, 9 | 4 |
| 1409 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head | 299 |
| 1408 | The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions. 2017 , 26, 1564-1574 | 15 |
| 1407 | Precision medicine in gastric cancer: where are we now?. 2017 , 2, 193-204 | |
| 1406 | Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. 2017 , 2, 29 | 12 |
| 1405 | Transmembrane helix connectivity in Orai1 controls two gates for calcium-dependent transcription. 2017 , 10, | 53 |
| 1404 | A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. 2017 , 21, 1968-1981 | 127 |

| | | |
|------|---|-----|
| 1403 | Actionable gene-based classification toward precision medicine in gastric cancer. 2017 , 9, 93 | 41 |
| 1402 | Identification of the key miRNAs associated with survival time in stomach adenocarcinoma. 2017 , 14, 4563-4572 | 4 |
| 1401 | A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. 2017 , 117, 1846-1854 | 51 |
| 1400 | Biology is king and continues to rule. 2017 , 154, 1448-1449 | |
| 1399 | Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer. 2017 , 96, e7224 | 7 |
| 1398 | [Gastric tumors]. 2017 , 38, 65-66 | |
| 1397 | MeCP2 regulated glycogenes contribute to proliferation and apoptosis of gastric cancer cells. 2017 , 27, 306-317 | 8 |
| 1396 | Somatic mutations in ZFH4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients. 2017 , 7, 4951 | 20 |
| 1395 | Milestones in gastric cancer. 2017 , 10, 33-37 | 0 |
| 1394 | Lgr5-expressing chief cells drive epithelial regeneration and cancer in the oxyntic stomach. 2017 , 19, 774-786 | 138 |
| 1393 | Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. 2017 , 7, 2262 | 6 |
| 1392 | Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. 2017 , 18, 667-674.e1 | 11 |
| 1391 | Revealing common disease mechanisms shared by tumors of different tissues of origin through semantic representation of genomic alterations and topic modeling. 2017 , 18, 105 | 1 |
| 1390 | Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. 2017 , 15, 92 | 11 |
| 1389 | Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. 2017 , 9, 57 | 42 |
| 1388 | Distinguishing potential bacteria-tumor associations from contamination in a secondary data analysis of public cancer genome sequence data. 2017 , 5, 9 | 34 |
| 1387 | Genomics and epidemiology for gastric adenocarcinomas. 2017 , 37, | 6 |
| 1386 | A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. 2017 , 35, 463-472 | 17 |

| | | |
|------|--|----|
| 1385 | Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation. 2017 , 96, e7181 | 18 |
| 1384 | How Tumor Virology Evolved into Cancer Biology and Transformed Oncology. 2017 , 1, 1-18 | 6 |
| 1383 | Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. 2017 , 11, 203-211 | 18 |
| 1382 | Cancer predisposition syndromes: lessons for truly precision medicine. 2017 , 241, 226-235 | 10 |
| 1381 | Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. 2017 , 23, 2673-2680 | 36 |
| 1380 | Lymphoepithelioma-like gastric carcinoma: clinicopathological characteristics and infection status. 2017 , 210, 159-168 | 13 |
| 1379 | Molecular key to understand the gastric cancer biology in elderly patients-The role of microsatellite instability. 2017 , 115, 344-350 | 15 |
| 1378 | HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. 2017 , 16, 228-238 | 25 |
| 1377 | Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer. 2017 , 26, 188-196 | 88 |
| 1376 | Emerging links among Chromosome Instability (CIN), cancer, and aging. 2017 , 56, 791-803 | 13 |
| 1375 | Genomic landscape of gastric cancer: molecular classification and potential targets. 2017 , 60, 126-137 | 13 |
| 1374 | Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?. 2017 , 20, 31-42 | 12 |
| 1373 | Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. 2017 , 36, 1200-1210 | 24 |
| 1372 | signeR: an empirical Bayesian approach to mutational signature discovery. 2017 , 33, 8-16 | 63 |
| 1371 | The impact of heterogeneity in phosphoinositide 3-kinase pathway in human cancer and possible therapeutic treatments. 2017 , 64, 116-124 | 8 |
| 1370 | Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. 2017 , 20, 465-474 | 16 |
| 1369 | Distinct expression profile of key molecules in crawling-type early gastric carcinoma. 2017 , 20, 612-619 | 4 |
| 1368 | Chemotherapy for advanced gastric cancer: future perspective in Japan. 2017 , 20, 102-110 | 8 |

| | | |
|------|---|-----|
| 1367 | Global chemotherapy development for gastric cancer. 2017 , 20, 92-101 | 24 |
| 1366 | Mechanisms for the induction of gastric cancer by Helicobacter pylori infection: aberrant DNA methylation pathway. 2017 , 20, 8-15 | 62 |
| 1365 | Decitabine inhibits tumor cell proliferation and up-regulates e-cadherin expression in Epstein-Barr virus-associated gastric cancer. 2017 , 89, 508-517 | 12 |
| 1364 | Inactivation of Capicua drives cancer metastasis. 2017 , 49, 87-96 | 92 |
| 1363 | The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. 2017 , 31, 893-903 | 132 |
| 1362 | Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. 2017 , 62, 397-405 | 31 |
| 1361 | Current Trends and Alternative Scenarios in EBV Research. 2017 , 1532, 1-32 | 6 |
| 1360 | Genomic Amplification of (PD-L1) in Small-Cell Lung Cancer. 2017 , 23, 1220-1226 | 74 |
| 1359 | Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. 2017 , 23, 1586-1597 | 89 |
| 1358 | Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. 2017 , 20, 407-415 | 130 |
| 1357 | C-C motif chemokine receptors in gastric cancer. 2018 , 8, 3-8 | 12 |
| 1356 | Methylation modification in gastric cancer and approaches to targeted epigenetic therapy (Review). 2017 , 50, 1921-1933 | 19 |
| 1355 | Gastric Carcinomas With Lymphoid Stroma: Categorization and Comparison With Solid-Type Colonic Carcinomas. 2017 , 148, 477-484 | 6 |
| 1354 | Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. 2018 , 15, 2756-2762 | 14 |
| 1353 | IFN γ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. 2017 , 7, 17810 | 52 |
| 1352 | Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. 2017 , 32, 351-363 | 13 |
| 1351 | The intricate interplay between MSI and polymorphisms of DNA repair enzymes in gastric cancer H.pylori associated. 2017 , 32, 471-478 | 3 |
| 1350 | Depletion of somatic mutations in splicing-associated sequences in cancer genomes. 2017 , 18, 213 | 8 |

| | | |
|------|---|----|
| 1349 | Comparison between mononucleotide and dinucleotide marker panels in gastric cancer with loss of hMLH1 or hMSH2 expression. 2017 , 32, e352-e356 | 5 |
| 1348 | MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer. 2017 , 9, 114 | 48 |
| 1347 | Genetic Profiling of Cancers of the Digestive System: Biological Insights and Clinical Implications. 2017 , 84, 306-322 | 5 |
| 1346 | Improving Gastric Cancer Outcome Prediction Using Single Time-Point Artificial Neural Network Models. 2017 , 16, 1176935116686062 | 13 |
| 1345 | A mutational co-occurrence network of a stomach adenocarcinoma using an association index. 2017 , | 0 |
| 1344 | Tissue-Agnostic Drug Development. 2017 , 37, 222-230 | 12 |
| 1343 | Interaction of Epstein-Barr virus genes with human gastric carcinoma transcriptome. 2017 , 8, 38399-38412 | 8 |
| 1342 | Targeted therapies for gastric cancer: failures and hopes from clinical trials. 2017 , 8, 57654-57669 | 75 |
| 1341 | Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. 2017 , 1, | 0 |
| 1340 | Gastric Cancer with Liver Metastasis (GCLM) and the Importance of Dormant Cancer Stem Cells. 2017 , | |
| 1339 | Microsatellite Instability Testing Using Next-Generation Sequencing Data and Therapy Implications.. 2017 , 1, 1-4 | 6 |
| 1338 | Gastric Cancer in Southern Europe: High-Risk Disease. 2017 , 37, 261-266 | 2 |
| 1337 | Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with -amplified gastric cancer. 2017 , 8, 79546-79555 | 16 |
| 1336 | Molecular and Clinical Characterization of a Claudin-Low Subtype of Gastric Cancer.. 2017 , 1, 1-10 | 4 |
| 1335 | Malignant Gastric Tumours: The Role of Pathologist in the Diagnosis and for Therapeutic Decisions. 2017 , | |
| 1334 | Personalisierte Tumorthherapie bei metastasierten gastrointestinalen Tumoren. 2017 , 46, 536-543 | |
| 1333 | Clinical Implications of Molecular Heterogeneity of Gastric Cancer. 2017 , | |
| 1332 | Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer. 2017 , 12, 5331-5343 | 66 |

| | | |
|------|--|-----|
| 1331 | Gastric Cancer: A Stem Cell Disease?. 2017 , | 2 |
| 1330 | Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis. 2017 , 8, 3296-3308 | 2 |
| 1329 | The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer. 2017 , 18, | 15 |
| 1328 | Immunotherapy in Gastrointestinal Cancers. 2017 , 2017, 4346576 | 45 |
| 1327 | Molecular classification of esophagogastric junction carcinoma correlated with prognosis. 2017 , 10, 4765-4772 | 4 |
| 1326 | Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. 2017 , 9, 849-867 | 44 |
| 1325 | Interpreting whole genome and exome sequencing data of individual gastric cancer samples. 2017 , 18, 517 | 6 |
| 1324 | MicroRNA-647 Targets SRF-MYH9 Axis to Suppress Invasion and Metastasis of Gastric Cancer. 2017 , 7, 3338-3353 | 53 |
| 1323 | PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. 2017 , 7, 1-11 | 29 |
| 1322 | Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis. 2017 , 10, 919-926 | 47 |
| 1321 | Epstein-Barr Virus Associated Gastric Carcinoma: The Americas Perspective. 2017 , | 2 |
| 1320 | Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry Imaging in the Study of Gastric Cancer: A Mini Review. 2017 , 18, | 15 |
| 1319 | EBV and Apoptosis: The Viral Master Regulator of Cell Fate?. 2017 , 9, | 44 |
| 1318 | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. 2017 , 18, | 52 |
| 1317 | Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. 2017 , 8, 418-429 | 18 |
| 1316 | Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer. 2017 , 9, | 28 |
| 1315 | Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. 2017 , 18, | 234 |
| 1314 | Gastrin and Gastric Cancer. 2017 , 8, 1 | 82 |

| | | |
|------|--|-----|
| 1313 | Inflammation, DNA Damage, and Gastric Tumorigenesis. 2017 , 8, 20 | 43 |
| 1312 | Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint. 2017 , 8, 73 | 21 |
| 1311 | Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective. 2017 , 4, 25 | 7 |
| 1310 | Elevated Levels of Interferon- Are Associated with High Levels of Epstein-Barr Virus Reactivation in Patients with the Intestinal Type of Gastric Cancer. 2017 , 2017, 7069242 | 6 |
| 1309 | A Multicriteria Approach to Find Predictive and Sparse Models with Stable Feature Selection for High-Dimensional Data. 2017 , 2017, 7907163 | 9 |
| 1308 | Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. 2017 , 38, 19-27 | 26 |
| 1307 | Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. 2017 , 2017, 7869802 | 58 |
| 1306 | 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. 2017 , 6, 119-130 | 263 |
| 1305 | Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. 2017 , 8, 7452-7463 | 132 |
| 1304 | Impact of Stem Cell Genes in Gastric Cancer. 2017 , | |
| 1303 | Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. 2017 , 12, e0176045 | 22 |
| 1302 | Transcriptome-wide analysis of alternative RNA splicing events in Epstein-Barr virus-associated gastric carcinomas. 2017 , 12, e0176880 | 18 |
| 1301 | PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. 2017 , 12, e0182692 | 125 |
| 1300 | Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. 2017 , 12, e0183891 | 12 |
| 1299 | Significant associations between driver gene mutations and DNA methylation alterations across many cancer types. 2017 , 13, e1005840 | 21 |
| 1298 | Construction of a combinatorial pipeline using two somatic variant 'calling' methods 'for whole exome sequence data of gastric cancer. 2017 , 64, 233-240 | |
| 1297 | Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. 2017 , 17, 837 | 3 |
| 1296 | miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β -catenin/EMT signaling cascade in gastric cancer. 2017 , 17, 886 | 42 |

| | | |
|------|---|----|
| 1295 | Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. 2017 , 10, 74 | 30 |
| 1294 | The significance of a nineteenth century definition in the era of genomics: linitis plastica. 2017 , 15, 123 | 28 |
| 1293 | Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry. 2017 , 15, 206 | 17 |
| 1292 | PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. 2017 , 10, 146 | 57 |
| 1291 | Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. 2017 , 36, 160 | 49 |
| 1290 | Uncoordinated expression of DNA methylation-related enzymes in human cancer. 2017 , 10, 61 | 6 |
| 1289 | Predicting cancer type from tumour DNA signatures. 2017 , 9, 104 | 25 |
| 1288 | Expression of the c-MET, HGF and VEGF biomarkers in intestinal and diffuse gastric cancer in the Brazilian population: a pilot study for the standardization of the quantitative PCR technique. 2017 , 37, | |
| 1287 | Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?. 2017 , 5, 84 | 4 |
| 1286 | Aktuelle Strategien zur Therapie des Magenkarzinoms. 2017 , 12, 302-310 | |
| 1285 | NGSCheckMate: software for validating sample identity in next-generation sequencing studies within and across data types. 2017 , 45, e103 | 43 |
| 1284 | MicroRNA-454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen-activated protein kinase 1. 2018 , 39, 1494-1504 | 8 |
| 1283 | miR-206 inhibits cancer initiating cells by targeting EHF in gastric cancer. 2017 , 38, 1688-1694 | 4 |
| 1282 | Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. 2017 , 8, 67094-67103 | 25 |
| 1281 | Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types. 2017 , 8, 87292-87306 | 13 |
| 1280 | Visual Display of 5p-arm and 3p-arm miRNA Expression with a Mobile Application. 2017 , 2017, 6037168 | 5 |
| 1279 | Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. 2017 , 53, 140-146 | 4 |
| 1278 | Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. 2017 , 8, 69888-69905 | 14 |

| | | |
|------|---|-----|
| 1277 | EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. 2017 , 8, 63901-63910 | 26 |
| 1276 | POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. 2017 , 8, 26732-26743 | 29 |
| 1275 | Molecular Testing for Gastrointestinal Cancer. 2017 , 51, 103-121 | 44 |
| 1274 | First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. 2017 , 8, 111795-111806 | 5 |
| 1273 | PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. 2017 , 18, | 46 |
| 1272 | Virus de Epstein-Barr y su relación con el desarrollo del cáncer. 2017 , 30, 131-145 | 6 |
| 1271 | Molecular Prognostic Factors in Gastric Cancer. 2017 , | |
| 1270 | Recent advances in understanding Epstein-Barr virus. 2017 , 6, 386 | 40 |
| 1269 | Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. 2017 , 8, 513-522 | 20 |
| 1268 | APPL1 promotes the migration of gastric cancer cells by regulating Akt2 phosphorylation. 2017 , 51, 1343-13514 | |
| 1267 | Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells. 2017 , 8, 39345-39355 | 9 |
| 1266 | Troy is expressed in human stomach mucosa and a novel putative prognostic marker of intestinal type gastric cancer. 2017 , 8, 50557-50569 | 9 |
| 1265 | High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. 2017 , 8, 14988-14994 | 25 |
| 1264 | Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). 2017 , 35, 3671-3677 | 77 |
| 1263 | Hypermutation and microsatellite instability in gastrointestinal cancers. 2017 , 8, 112103-112115 | 46 |
| 1262 | OncoKB: A Precision Oncology Knowledge Base. 2017 , 2017, | 699 |
| 1261 | Landscape of Microsatellite Instability Across 39 Cancer Types. 2017 , 2017, | 332 |
| 1260 | Gastric Cancer in Asia: Unique Features and Management. 2017 , 37, 279-291 | 18 |

| | | |
|------|---|-----|
| 1259 | Immunotherapy for Esophageal and Gastric Cancer. 2017 , 37, 292-300 | 38 |
| 1258 | Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. 2017 , 1, | 18 |
| 1257 | Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer. 2017 , 8, 28990-29013 | 34 |
| 1256 | The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. 2017 , 8, 38850-38862 | 23 |
| 1255 | Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. 2017 , 8, 148-163 | 54 |
| 1254 | Upregulation of ZBTB7A exhibits a tumor suppressive role in gastric cancer cells. 2018 , 17, 2635-2641 | 12 |
| 1253 | Microarray analysis of long non-coding RNAs related to microRNA-148b in gastric cancer. 2017 , 64, 199-208 | 7 |
| 1252 | Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. 2017 , 8, 379-386 | 14 |
| 1251 | Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. 2017 , 8, 405-417 | 11 |
| 1250 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. 2017 , 8, 387-404 | 18 |
| 1249 | Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now. 2017 , 8, 1109-1113 | 0 |
| 1248 | Regorafenib in gastric cancer. 2017 , 2, 16 | 1 |
| 1247 | The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study. 2017 , 2, 29 | 1 |
| 1246 | Databases and tools for constructing signal transduction networks in cancer. 2017 , 50, 12-19 | 3 |
| 1245 | Distinct Chemopreventive Effects of Aspirin in Diffuse and Intestinal-Type Gastric Cancer. 2018 , 11, 279-286 | 8 |
| 1244 | Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for -Amplified Gastroesophageal Adenocarcinoma. 2018 , 8, 696-713 | 76 |
| 1243 | Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. 2018 , 359, 920-926 | 712 |
| 1242 | Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features. 2018 , 42, 453-462 | 26 |

| | | |
|------|--|-----|
| 1241 | The crucial role of multiomic approach in cancer research and clinically relevant outcomes. 2018 , 9, 77-102 | 114 |
| 1240 | A proteomic landscape of diffuse-type gastric cancer. 2018 , 9, 1012 | 97 |
| 1239 | Spatiotemporal homogeneity and distinctness of the T-cell receptor β chain repertoires in Epstein-Barr virus-associated primary and metastatic nasopharyngeal carcinomas. 2018 , 143, 610-620 | 7 |
| 1238 | A viral map of gastrointestinal cancers. 2018 , 199, 188-200 | 10 |
| 1237 | Molecular profiling and comprehensive genome-wide analysis of somatic copy number alterations in gastric intramucosal neoplasias based on microsatellite status. 2018 , 21, 765-775 | 9 |
| 1236 | Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway. 2018 , 7, 1369-1383 | 13 |
| 1235 | Whole-exome sequencing of a meningeal melanocytic tumour reveals activating CYSLTR2 and EIF1AX hotspot mutations and similarities to uveal melanoma. 2018 , 35, 127-130 | 10 |
| 1234 | Long non-coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1. 2018 , 12, 799-813 | 62 |
| 1233 | LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3 β signaling. 2018 , 41, 2755-2763 | 8 |
| 1232 | Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases. 2018 , 75, 2111-2124 | 14 |
| 1231 | Peptides from legumes with antigastrointestinal cancer potential: current evidence for their molecular mechanisms. 2018 , 20, 13-18 | 18 |
| 1230 | Chilean Gastric Cancer Task Force: A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients. 2018 , 97, e0419 | 7 |
| 1229 | YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. 2018 , 78, 3306-3320 | 71 |
| 1228 | Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers. 2018 , 9, 1520 | 64 |
| 1227 | Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. 2018 , 8, 6150 | 13 |
| 1226 | PIEZO1 functions as a potential oncogene by promoting cell proliferation and migration in gastric carcinogenesis. 2018 , 57, 1144-1155 | 36 |
| 1225 | Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer. 2018 , 50, 1-11 | 15 |
| 1224 | Epigenetic Regulation of Tumor Suppressors by Enhances EBV-Induced Proliferation of Gastric Epithelial Cells. 2018 , 9, | 18 |

| | | |
|------|---|------|
| 1223 | The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. 2018 , 7, e1457602 | 6 |
| 1222 | Mutational signatures of DNA mismatch repair deficiency in and human cancers. 2018 , 28, 666-675 | 61 |
| 1221 | DNA mismatch repair in cancer. 2018 , 189, 45-62 | 171 |
| 1220 | Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology. 2018 , 2, 106-115 | 4 |
| 1219 | Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases. 2018 , 11, | 5 |
| 1218 | REG3A overexpression suppresses gastric cancer cell invasion, proliferation and promotes apoptosis through PI3K/Akt signaling pathway. 2018 , 41, 3167-3174 | 8 |
| 1217 | A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. 2018 , 19, 71-86 | 76 |
| 1216 | BRAF papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors. 2018 , 40, 1707-1718 | 2 |
| 1215 | Smad4/Fascin index is highly prognostic in patients with diffuse type EBV-associated gastric cancer. 2018 , 214, 475-481 | 4 |
| 1214 | Zinc-finger protein 471 suppresses gastric cancer through transcriptionally repressing downstream oncogenic PLS3 and TFAP2A. 2018 , 37, 3601-3616 | 21 |
| 1213 | Oncogenic Signaling Pathways in The Cancer Genome Atlas. 2018 , 173, 321-337.e10 | 1124 |
| 1212 | Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). 2018 , | 25 |
| 1211 | FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro. 2018 , 12, 993-1003 | 24 |
| 1210 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. 2018 , 23, 239-254.e6 | 405 |
| 1209 | Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. 2018 , 21, 925-935 | 10 |
| 1208 | Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. 2018 , 109, 1166-1176 | 21 |
| 1207 | Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. 2018 , 3, e000326 | 40 |
| 1206 | Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. 2018 , 53, 1186-1195 | 37 |

| | | |
|------|--|----|
| 1205 | BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis. 2018 , 9, 203 | 41 |
| 1204 | The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion. 2018 , 68, 39-45 | 22 |
| 1203 | Morphologic and Immunohistochemical Appraisal of Primary Gastric Carcinomas. 2018 , 26, e107-e115 | 2 |
| 1202 | Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. 2018 , 87, 1566-1575 | 32 |
| 1201 | miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. 2018 , 9, 92 | 83 |
| 1200 | PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma. 2018 , 37, 2213-2224 | 29 |
| 1199 | Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. 2018 , 10, 1758834017746040 | 40 |
| 1198 | Classifying next-generation sequencing data using a zero-inflated Poisson model. 2018 , 34, 1329-1335 | 9 |
| 1197 | A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers. 2018 , 24, 1905-1916 | 8 |
| 1196 | Molecular Targeted Therapy of Bladder Cancer. 2018 , 159-180 | |
| 1195 | First-line treatment of apatinib in elderly patient of advanced gastric carcinoma: A case report of NGS-driven targeted therapy. 2018 , 19, 355-358 | |
| 1194 | Meta-analysis of the prognostic value of CpG island methylator phenotype in gastric cancer. 2018 , 105, e61-e68 | 8 |
| 1193 | An orthotopic mouse model of gastric cancer invasion and metastasis. 2018 , 8, 825 | 22 |
| 1192 | Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. 2018 , 29, 1037-1048 | 61 |
| 1191 | Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. 2018 , 143, 167-178 | 23 |
| 1190 | Wnt Signaling in Adult Epithelial Stem Cells and Cancer. 2018 , 153, 21-79 | 17 |
| 1189 | Injury, repair, inflammation and metaplasia in the stomach. 2018 , 596, 3861-3867 | 38 |
| 1188 | Translation in Immunology. 2018 , 1-11 | |

| | | |
|------|---|-----|
| 1187 | Pancancer analysis identifies prognostic high-APOBEC1 expression level implicated in cancer in-frame insertions and deletions. 2018 , 39, 327-335 | 12 |
| 1186 | Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues. 2018 , 115, 1328-1333 | 50 |
| 1185 | Krüppel-like Factor 4 Suppresses Serine/Threonine Kinase 33 Activation and Metastasis of Gastric Cancer through Reversing Epithelial-Mesenchymal Transition. 2018 , 24, 2440-2451 | 20 |
| 1184 | Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer. 2018 , 6, 276-287 | 46 |
| 1183 | Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. 2018 , 90, 26-33 | 13 |
| 1182 | Network science in clinical trials: A patient-centered approach. 2018 , 52, 135-150 | 6 |
| 1181 | Plasma magnesium is inversely associated with Epstein-Barr virus load in peripheral blood and Burkitt lymphoma in Uganda. 2018 , 52, 70-74 | 10 |
| 1180 | Polymerase epsilon mutations and concomitant κ -microglobulin mutations in cancer. 2018 , 647, 31-38 | 9 |
| 1179 | LKB1 inactivation occurs in a subset of esophageal adenocarcinomas and is sufficient to drive tumor cell proliferation. 2018 , 155, 1891-1899 | 1 |
| 1178 | Gastric cancer in Latin America. 2018 , 53, 124-129 | 5 |
| 1177 | Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. 2018 , 33, 137-150.e5 | 113 |
| 1176 | Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. 2018 , 364, 494-503 | 49 |
| 1175 | Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. 2018 , 51, 36-49 | 37 |
| 1174 | Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. 2018 , 52, 241-252 | 9 |
| 1173 | Clinical Utility of a STAT3-Regulated miRNA-200 Family Signature with Prognostic Potential in Early Gastric Cancer. 2018 , 24, 1459-1472 | 29 |
| 1172 | Precision Molecular Pathology of Bladder Cancer. 2018 , | |
| 1171 | EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. 2018 , 21, 731-741 | 7 |
| 1170 | HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. 2018 , 71, 600-607 | 14 |

| | | |
|------|---|-----|
| 1169 | Tumor Deposits in Gastric Cancer. 2018 , 83-108 | |
| 1168 | Aberrant alternative splicing of RHOA is associated with loss of its expression and activity in diffuse-type gastric carcinoma cells. 2018 , 495, 1942-1947 | 8 |
| 1167 | The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients. 2018 , 25, 99-104 | 9 |
| 1166 | Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. 2018 , 110, 316-320 | 113 |
| 1165 | PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability. 2018 , 110, 221-222 | 5 |
| 1164 | Combining gene essentiality with feature selection method to explore multi-cancer biomarkers. 2018 , 172, 241-247 | 2 |
| 1163 | LncRNA Expression Signature in Prediction of the Prognosis of Lung Adenocarcinoma. 2018 , 22, 20-28 | 12 |
| 1162 | A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer. 2018 , 29, 127-132 | 11 |
| 1161 | ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. 2018 , 122, 179-193 | 25 |
| 1160 | Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. 2018 , 7, e1356144 | 77 |
| 1159 | Genetic features of multicentric/multifocal intramucosal gastric carcinoma. 2018 , 143, 1923-1934 | 13 |
| 1158 | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. 2018 , 9, 1777 | 116 |
| 1157 | Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. 2018 , 18, 378 | 3 |
| 1156 | Differential networking meta-analysis of gastric cancer across Asian and American racial groups. 2018 , 12, 51 | 6 |
| 1155 | Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. 2018 , 11, 20 | 25 |
| 1154 | Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies. 2018 , 41, 266-271 | 15 |
| 1153 | Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer. 2018 , 41, 272-280 | 23 |
| 1152 | Targeted therapy according to next generation sequencing-based panel sequencing. 2018 , 64, 9-14 | 10 |

| | | |
|------|--|-----|
| 1151 | Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. 2018 , 3, 489-498 | 58 |
| 1150 | Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. 2018 , 23, 1092-1102 | 28 |
| 1149 | Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. 2018 , 33, 721-735.e8 | 228 |
| 1148 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. 2018 , 4, e180013 | 834 |
| 1147 | Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. 2018 , 117, 829-839 | 39 |
| 1146 | Integrative Analysis of Omics Big Data. 2018 , 1754, 109-135 | 26 |
| 1145 | CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8/Foxp3 T cells. 2018 , 472, 643-651 | 8 |
| 1144 | C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. 2018 , 7, e1433517 | 13 |
| 1143 | Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. 2018 , 94, 104-114 | 37 |
| 1142 | Loss of NF- κ B1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner. 2018 , 48, 570-583.e8 | 39 |
| 1141 | Regulation and Function of the PD-L1 Checkpoint. 2018 , 48, 434-452 | 783 |
| 1140 | Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. 2018 , 45, 133-150 | 2 |
| 1139 | Low scavenger receptor class B type I expression is associated with gastric adenocarcinoma tumor aggressiveness. 2018 , 15, 4604-4610 | 3 |
| 1138 | Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. 2018 , 44, 626-631 | 12 |
| 1137 | Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. 2018 , 18, 357-370 | 3 |
| 1136 | Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. 2018 , 19, 629-638 | 108 |
| 1135 | Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models. 2018 , 118, 972-984 | 5 |
| 1134 | Multi-omics analysis identifies pathways and genes involved in diffuse-type gastric carcinogenesis induced by E-cadherin, p53, and Smad4 loss in mice. 2018 , 57, 947-954 | 12 |

| | | |
|------|--|-----|
| 1133 | Filling Gaps in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancers. 2018 , 9, 290-296 | 21 |
| 1132 | Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. 2018 , 18, 262-269 | 2 |
| 1131 | Epstein-Barr virus in the pathogenesis of oral cancers. 2018 , 24, 497-508 | 38 |
| 1130 | Individualized analysis of differentially expressed miRNAs with application to the identification of miRNAs deregulated commonly in lung cancer tissues. 2018 , 19, 793-802 | 8 |
| 1129 | Association between telomere length and PIK3CA amplification in gastric cancer. 2018 , 18, 133-134 | 3 |
| 1128 | Expression of Phosphoinositide 3-Kinase p110 α and p110 β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma. 2018 , 26, 740-748 | 2 |
| 1127 | ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer. 2018 , 267, 504-513 | 224 |
| 1126 | Human Hairless Protein Roles in Skin/Hair and Emerging Connections to Brain and Other Cancers. 2018 , 119, 69-80 | 9 |
| 1125 | Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. 2018 , 267, 105-113 | 60 |
| 1124 | Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. 2018 , 85, 50-63 | 63 |
| 1123 | Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics. 2018 , 472, 369-382 | 32 |
| 1122 | Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. 2018 , 412, 208-215 | 9 |
| 1121 | Increased survival rates in gastric cancer, with a narrowing gender gap and widening socioeconomic status gap: A period analysis from 1984 to 2013. 2018 , 33, 837-846 | 16 |
| 1120 | Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. 2018 , 105, 159-167 | 123 |
| 1119 | Rnf43. 2018 , 71, 1-6 | 9 |
| 1118 | Comparing intestinal versus diffuse gastric cancer using a PEFf-oriented proteomic pipeline. 2018 , 171, 63-72 | 9 |
| 1117 | Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. 2018 , 8, 37-48 | 162 |
| 1116 | The oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma. 2018 , 22, 38-45 | 26 |

| | | |
|------|--|-----|
| 1115 | A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. 2018 , 85, 7-17 | 10 |
| 1114 | Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. 2018 , 26, e15-e21 | 159 |
| 1113 | Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. 2018 , 72, 556-568 | 26 |
| 1112 | Role of viruses in gastrointestinal cancer. 2018 , 233, 4000-4014 | 22 |
| 1111 | A system for detecting high impact-low frequency mutations in primary tumors and metastases. 2018 , 37, 185-196 | 17 |
| 1110 | A deep learning-based multi-model ensemble method for cancer prediction. 2018 , 153, 1-9 | 198 |
| 1109 | Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity. 2018 , 154, 140-153.e17 | 15 |
| 1108 | Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. 2018 , 57, 28-34 | 1 |
| 1107 | Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. 2018 , 154, 437-451 | 51 |
| 1106 | Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma. 2018 , 92, | 35 |
| 1105 | Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. 2018 , 14, 417-430 | 41 |
| 1104 | Molecular Diagnosis and Targeted Therapy for Gastric Cancer. 2018 , 63-80 | |
| 1103 | Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. 2018 , | 0 |
| 1102 | Medical management of gastric cancer: a 2017 update. 2018 , 7, 123-133 | 100 |
| 1101 | SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis. 2018 , 37, 1159-1174 | 28 |
| 1100 | HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. 2018 , 105, 363-370 | 8 |
| 1099 | Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. 2018 , 24, 1082-1089 | 58 |
| 1098 | Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. 2018 , 12, 229-235 | 37 |

| | | |
|------|---|-----|
| 1097 | The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus. 2018 , 71, 201-206 | 16 |
| 1096 | Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. 2018 , 52, 117-124 | 151 |
| 1095 | Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. 2018 , 21, 429-438 | 20 |
| 1094 | Viral sequences in human cancer. 2018 , 513, 208-216 | 60 |
| 1093 | PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. 2018 , 109, 43-53 | 141 |
| 1092 | Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. 2018 , 8, 49-58 | 180 |
| 1091 | Epigenetic drivers of tumourigenesis and cancer metastasis. 2018 , 51, 149-159 | 136 |
| 1090 | Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. 2018 , 21, 31-40 | 51 |
| 1089 | Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer. 2018 , 13, 803-818 | 1 |
| 1088 | Collaborating genomic, transcriptomic and microbiomic alterations lead to canine extreme intestinal polyposis. 2018 , 9, 29162-29179 | 7 |
| 1087 | Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. 2018 , 24, 266-273 | 13 |
| 1086 | Genetic Diversity and Treatment Implications in Gastric and Gastroesophageal Cancers: One Size Does Not Fit All. 2018 , 14, 227-228 | 1 |
| 1085 | Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. 2018 , 2, 1-14 | 11 |
| 1084 | Pathogenic germline mutations and familial predisposition to gastric cancer. 2018 , 2, | 6 |
| 1083 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. 2018 , 36, 2836-2844 | 296 |
| 1082 | Gastric Cancer: Recent Molecular Classification Advances, Racial Disparity, and Management Implications. 2018 , 14, 217-224 | 34 |
| 1081 | What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?. 2018 , 38, 249-261 | 2 |
| 1080 | Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. 2018 , 38, 280-291 | 4 |

| | | |
|------|--|----|
| 1079 | Detecting promoter methylation pattern of apoptotic genes and in gastric carcinoma patients undergoing chemotherapy. 2018 , 9, 295-302 | 4 |
| 1078 | Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?. 2018 , 10, 6407-6411 | 4 |
| 1077 | The coming of age: immunotherapy in gastrointestinal malignancies. 2018 , 9, 140-142 | 1 |
| 1076 | The direction of travel to better outcomes for patients with oesophago-gastric cancer. 2018 , 10, 1236-1238 | |
| 1075 | Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. 2018 , 9, 377-389 | 2 |
| 1074 | MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma. 2018 , 8, 17717 | 5 |
| 1073 | Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. 2018 , 24, 3583-3616 | 74 |
| 1072 | analyses for potential key genes associated with gastric cancer. 2018 , 6, e6092 | 44 |
| 1071 | Current Status of Gastrectomy for Cancer: ¶less Is Often More¶ 2018 , 96, 603-605 | |
| 1070 | Comprehensive and critical evaluation of individualized pathway activity measurement tools on pan-cancer data. 2018 , | 10 |
| 1069 | UEG Week 2018 Poster Presentations. 2018 , 6, A135 | 14 |
| 1068 | Identification of recurrent and novel mutations by whole-genome sequencing of colorectal tumors from the Han population in Shanghai, eastern China. 2018 , 18, 5361-5370 | 6 |
| 1067 | Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. 2018 , 9, 2447 | 63 |
| 1066 | Overexpression of SIRT4 inhibits the proliferation of gastric cancer cells through cell cycle arrest. 2019 , 17, 2171-2176 | 12 |
| 1065 | Metabolomic alterations and chromosomal instability status in gastric cancer. 2018 , 24, 3760-3769 | 15 |
| 1064 | Actionable gene alterations in an Asian population with triple-negative breast cancer. 2018 , 2, | 1 |
| 1063 | Long non-coding RNA lnc-GNAT1-1 inhibits gastric cancer cell proliferation and invasion through the Wnt/¶catenin pathway in Helicobacter ¶ylori infection. 2018 , 18, 4009-4015 | 14 |
| 1062 | Non-familial juvenile polyposis of the stomach with gastric cancers: a case report. 2018 , 4, 79 | 0 |

| | | |
|------|---|----|
| 1061 | The evolving role of endoscopy in the diagnosis of premalignant gastric lesions. 2018 , 7, | 14 |
| 1060 | Gastrointestinale Tumoren. Hoher medizinischer Bedarf für neue Therapieoptionen. 2018 , 41, 334-335 | |
| 1059 | Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. 2018 , 16, 290 | 6 |
| 1058 | Gastrointestinal cancer risk in patients with a family history of gastrointestinal cancer. 2018 , 71, 338-348 | 2 |
| 1057 | Unique MicroRNA and mRNA Interactions in β -Mutated Lung Adenocarcinoma. 2018 , 7, | 12 |
| 1056 | Gastric Cancer Cell Lines Have Different β -Regulated Expression Patterns but Share a Common Core of Altered Genes. 2018 , 2018, 5804376 | 9 |
| 1055 | β Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3 β . 2018 , 19, | 26 |
| 1054 | Tolerance of Chromosomal Instability in Cancer: Mechanisms and Therapeutic Opportunities. 2018 , 78, 6529-6535 | 19 |
| 1053 | Bayesian variable selection for parametric survival model with applications to cancer omics data. 2018 , 12, 49 | 7 |
| 1052 | MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. 2018 , 24, 3313-3329 | 72 |
| 1051 | Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. 2018 , 36-37, 45-52 | 11 |
| 1050 | A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. 2018 , 29, 2356-2362 | 25 |
| 1049 | Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. 2018 , 11, 8239-8250 | 23 |
| 1048 | Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer. 2018 , 10, 5283-5290 | 1 |
| 1047 | Molekulares Tumorboard für Magenkarzinom. 2018 , 33, 405-410 | |
| 1046 | EPH receptor A2 governs a feedback loop that activates Wnt/ β Catenin signaling in gastric cancer. 2018 , 9, 1146 | 26 |
| 1045 | LncRNA UCA1 promotes tumor metastasis by inducing miR-203/ZEB2 axis in gastric cancer. 2018 , 9, 1158 | 58 |
| 1044 | New drug developments in metastatic gastric cancer. 2018 , 11, 1756284818808072 | 14 |

| | | |
|------|--|----|
| 1043 | Using single nucleotide variations in single-cell RNA-seq to identify subpopulations and genotype-phenotype linkage. 2018 , 9, 4892 | 37 |
| 1042 | Immune and genomic signatures in oral (head and neck) cancer. 2018 , 4, e00880 | 12 |
| 1041 | GPRC5A: An Emerging Biomarker in Human Cancer. 2018 , 2018, 1823726 | 17 |
| 1040 | MUC16 mutation predicts a favorable clinical outcome and correlates decreased Warburg effect in gastric cancer. 2018 , 506, 780-786 | 6 |
| 1039 | Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach. 2018 , 155, 1852-1867 | 35 |
| 1038 | Resolving gastric cancer aetiology: an update in genetic predisposition. 2018 , 3, 874-883 | 43 |
| 1037 | Improvement of cancer subtype prediction by incorporating transcriptome expression data and heterogeneous biological networks. 2018 , 11, 119 | 5 |
| 1036 | Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. 2018 , 1, 193-208 | 3 |
| 1035 | Distinct molecular subtypes of gastric cancer: from LauriB to molecular pathology. 2018 , 9, 19427-19442 | 45 |
| 1034 | Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. 2019 , 32, 99-106 | 4 |
| 1033 | New therapeutic options opened by the molecular classification of gastric cancer. 2018 , 24, 1942-1961 | 25 |
| 1032 | Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. 2018 , 24, 2567-2581 | 46 |
| 1031 | Ferritin: A potential serum marker for lymph node metastasis in head and neck squamous cell carcinoma. 2019 , 17, 314-322 | 13 |
| 1030 | Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases. 2019 , 17, 2207-2214 | 6 |
| 1029 | Surgical treatment of gastric cancer: a 10-year experience in a high-volume university hospital. 2018 , 73, e543s | 27 |
| 1028 | New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. 2018 , 9, 10635-10649 | 32 |
| 1027 | HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. 2018 , 10, 159-171 | 8 |
| 1026 | Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. 2018 , 8, 5690-5702 | 33 |

| | | |
|------|--|-----|
| 1025 | A Positive Feedback Loop of SLP2 Activates MAPK Signaling Pathway to Promote Gastric Cancer Progression. 2018 , 8, 5744-5757 | 14 |
| 1024 | Types of Gastric Carcinomas. 2018 , 19, | 39 |
| 1023 | An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. 2018 , 18, 1261 | 20 |
| 1022 | RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. 2018 , 10, | 5 |
| 1021 | Molecular pathways in the development and treatment of oesophageal cancer. 2018 , 36-37, 9-15 | 14 |
| 1020 | Copy number variation profile in noninvasive prenatal testing (NIPT) can identify co-existing maternal malignancies: Case reports and a literature review. 2018 , 57, 871-877 | 10 |
| 1019 | Association between Polymorphisms in Inflammatory Response-Related Genes and the Susceptibility, Progression and Prognosis of the Diffuse Histological Subtype of Gastric Cancer. 2018 , 9, | 9 |
| 1018 | Promotion of Cell Proliferation through Inhibition of Cell Autophagy Signalling Pathway by Rab3IP is Restrained by MicroRNA-532-3p in Gastric Cancer. 2018 , 9, 4363-4373 | 22 |
| 1017 | Oxymatrine Synergistically Potentiates the Antitumor Effects of Cisplatin in Human Gastric Cancer Cells. 2018 , 9, 4527-4535 | 7 |
| 1016 | Multiple genetic mutations caused by NKX6.3 depletion contribute to gastric tumorigenesis. 2018 , 8, 17609 | 4 |
| 1015 | MSIpred: a python package for tumor microsatellite instability classification from tumor mutation annotation data using a support vector machine. 2018 , 8, 17546 | 27 |
| 1014 | Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. 2018 , 9, 560-572 | 5 |
| 1013 | Whole genome MBD-seq and RRBS analyses reveal that hypermethylation of gastrointestinal hormone receptors is associated with gastric carcinogenesis. 2018 , 50, 1-14 | 13 |
| 1012 | Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. 2018 , 8, 386 | 123 |
| 1011 | Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies. 2018 , 7, | 6 |
| 1010 | The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer. 2018 , 29-56 | 1 |
| 1009 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. 2018 , 50, 1399-1411 | 94 |
| 1008 | Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer. 2018 , 109, 3263-3271 | 8 |

| | | |
|------|---|-----|
| 1007 | Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer. 2018 , 109, 3461-3470 | 3 |
| 1006 | Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies. 2018 , 8, 13978 | 53 |
| 1005 | RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway. 2018 , 19, 1128-1138 | 8 |
| 1004 | MicroRNA Expression Profiles in Gastric Carcinogenesis. 2018 , 8, 14393 | 46 |
| 1003 | Role of Tyrosine Kinases in Gastrointestinal Malignancies. 2018 , | |
| 1002 | Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. 2018 , 43, 1014-1032 | 86 |
| 1001 | Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. 2018 , 38, 5569-5580 | 32 |
| 1000 | Emerging Therapies in the Management of Advanced-Stage Gastric Cancer. 2018 , 9, 404 | 20 |
| 999 | Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. 2018 , 3, | 14 |
| 998 | LP1 from C Induces Autophagy, Apoptosis and Reduces Metastasis in Human Gastric Cancer Cell Line SGC-7901. 2018 , 19, | 13 |
| 997 | Pembrolizumab for the treatment of gastric cancer. 2018 , 18, 1177-1187 | 12 |
| 996 | Emerging evidence supports grouping by location of early gastric carcinoma for appropriate clinical management in Chinese patients. 2018 , 19, 730-736 | 5 |
| 995 | Whole-exome sequencing capture kit biases yield false negative mutation calls in TCGA cohorts. 2018 , 13, e0204912 | 11 |
| 994 | A semi-supervised deep learning method based on stacked sparse auto-encoder for cancer prediction using RNA-seq data. 2018 , 166, 99-105 | 44 |
| 993 | Onco-Multi-OMICS Approach: A New Frontier in Cancer Research. 2018 , 2018, 9836256 | 122 |
| 992 | Gastric cancer: Basic aspects. 2018 , 23 Suppl 1, e12523 | 21 |
| 991 | Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. 2018 , 22, 5899-5908 | 3 |
| 990 | Key elements involved in Epstein-Barr virus-associated gastric cancer and their network regulation. 2018 , 18, 146 | 23 |

| | | |
|-----|---|-----|
| 989 | Landscape of somatic mutations in gastric cancer assessed using next-generation sequencing analysis. 2018 , 16, 4863-4870 | 12 |
| 988 | Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making?. 2018 , 10, 172-183 | |
| 987 | Emerging role of precision medicine in biliary tract cancers. 2018 , 2, 21 | 19 |
| 986 | Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis. 2018 , 10, 3945-3954 | 7 |
| 985 | Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells. 2018 , 19, | 16 |
| 984 | The Predictive Value of Epstein-Barr Virus-Positivity in Patients Undergoing Gastrectomy Followed by Adjuvant Chemotherapy. 2018 , 54, 173-177 | 2 |
| 983 | Co-expression network analysis identified CDH11 in association with progression and prognosis in gastric cancer. 2018 , 11, 6425-6436 | 22 |
| 982 | DDX21 promotes gastric cancer proliferation by regulating cell cycle. 2018 , 505, 1189-1194 | 16 |
| 981 | Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer. 2018 , 11, 6969-6980 | 26 |
| 980 | Gastric Cancer: an Evolving Disease. 2018 , 16, 561-569 | 28 |
| 979 | RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. 2018 , 9, 4439 | 14 |
| 978 | Nectin1 expression is frequently decreased in gastric cancers. 2018 , 68, 557-562 | 2 |
| 977 | Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. 2018 , 44, 1-10 | 1 |
| 976 | 9 weeks that matter for patients with gastric cancer. 2018 , 19, 1418-1419 | 3 |
| 975 | [Metastatic stomach cancer: Clinical trials in Asia and in Occident]. 2018 , 105, 932-943 | 3 |
| 974 | Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. 2018 , 25, 1066-1080.e8 | 104 |
| 973 | Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer. 2018 , 97, e11387 | 22 |
| 972 | Role of serum EBV-VCA IgG detection in assessing gastric cancer risk and prognosis in Northern Chinese population. 2018 , 7, 5760-5774 | 3 |

| | | |
|-----|--|-----|
| 971 | Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment. 2018 , 6, 106 | 85 |
| 970 | Tipping the Scale Toward Gastric Disease: A Host-Pathogen Genomic Mismatch?. 2018 , 6, 199-207 | 5 |
| 969 | Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. 2018 , 11, 6525-6537 | 9 |
| 968 | A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. 2018 , 23, 882-897.e11 | 236 |
| 967 | Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations. 2018 , 17, 150 | 13 |
| 966 | Meta-analysis of prognostic and predictive factors: Towards individual participant data?. 2018 , 104, 224-226 | 1 |
| 965 | Transduced caudal-type homeobox (CDX) 2/CDX1 can induce growth inhibition on CDX-deficient gastric cancer by rapid intestinal differentiation. 2018 , 109, 3853-3864 | 6 |
| 964 | as a novel biomarker for alpha-fetoprotein-producing gastric cancer. 2018 , 10, 344-350 | 7 |
| 963 | The application of transgenic and gene knockout mice in the study of gastric precancerous lesions. 2018 , 214, 1929-1939 | 9 |
| 962 | Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. 2018 , 18, 1054 | 10 |
| 961 | ASO Author Reflections: Consideration of a Modified Classification System for Gastric Cancer Based on Lauren Subtypes. 2018 , 25, 679-680 | 2 |
| 960 | Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. 2018 , 71, 32-38 | 6 |
| 959 | Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. 2018 , 24, 6248-6256 | 55 |
| 958 | TAP: a targeted clinical genomics pipeline for detecting transcript variants using RNA-seq data. 2018 , 11, 79 | 8 |
| 957 | Novel prognostic biomarkers of gastric cancer based on gene expression microarray: COL12A1, GSTA3, FGA and FGG. 2018 , 18, 3727-3736 | 23 |
| 956 | KRAS, KIT and TP53 mutations in mother's and daughter's gastric cardia adenocarcinomas. 2018 , 13, 76-79 | 1 |
| 955 | A machine learning approach for somatic mutation discovery. 2018 , 10, | 44 |
| 954 | Factors Associated With Host Immune Response and Number of Lymph Nodes: A Large Retrospective Cohort Study. 2018 , 25, 3621-3628 | 2 |

- 953 Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer. **2018**, 10, 1758835918794628
- 952 Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. **2018**, 16, 247 5
- 951 Proposal for a New TNM Stage based on the 7 and 8 American Joint Committee on Cancer pTNM Staging Classification for Gastric Cancer. **2018**, 9, 3570-3576 11
- 950 Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancer. **2018**, 36, 171-182 88
- 949 Biomarkers of gastric cancer: Current topics and future perspective. **2018**, 24, 2818-2832 162
- 948 Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression. **2018**, 92, 52
- 947 Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability. **2018**, 14, e1007669 43
- 946 What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. **2018**, 19, 25
- 945 Genetic Alterations of TRAF Proteins in Human Cancers. **2018**, 9, 2111 37
- 944 Diffuse Gastric Cancer. **2018**,
- 943 The Thomsen-Friedenreich Antigen: A Highly Sensitive and Specific Predictor of Microsatellite Instability in Gastric Cancer. **2018**, 7, 8
- 942 Current therapeutic landscape for advanced gastroesophageal cancers. **2018**, 6, 78 5
- 941 Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery. **2018**, 9, 81-91 18
- 940 Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. **2018**, 75, 4151-4162 86
- 939 Analysis of key genes and signaling pathways involved in Helicobacter pylori-associated gastric cancer based on The Cancer Genome Atlas database and RNA sequencing data. **2018**, 23, e12530 21
- 938 Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. **2018**, 9, 196-207 13
- 937 Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. **2018**, 8, 1422-1437 66
- 936 Risk factors for gastric intraepithelial neoplasia in Chinese adults: a case-control study. **2018**, 10, 2605-2613 5

| | | |
|-----|--|-----|
| 935 | BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. 2018 , 16, e2005756 | 31 |
| 934 | Genome-wide Analyses on Single Disease Samples for Potential Biomarkers and Biological Features of Molecular Subtypes: A Case Study in Gastric Cancer. 2018 , 14, 833-842 | 1 |
| 933 | Knockdown of TIPE2 increases the proliferation in lipopolysaccharide-stimulated gastric cancer cells. 2018 , 18, 857 | 5 |
| 932 | MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. 2018 , 28, 719-729 | 57 |
| 931 | Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. 2018 , 24, 968-977 | 126 |
| 930 | Clinical impact of molecular classifications in gastric cancer. 2018 , 70, 225-232 | 8 |
| 929 | Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy. 2018 , 17, 19-30 | 5 |
| 928 | Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. 2018 , 150, 127-135 | 33 |
| 927 | Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells. 2018 , 40, 294-302 | 10 |
| 926 | Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins. 2018 , 431, 73-84 | 24 |
| 925 | Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/ β -catenin signaling activation (Review). 2018 , 42, 713-725 | 83 |
| 924 | Use of DNA flow cytometry in the diagnosis, risk stratification, and management of gastric epithelial dysplasia. 2018 , 31, 1578-1587 | 8 |
| 923 | Long noncoding RNA gastric cancer-related lncRNA1 mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4. 2018 , 9, 607 | 35 |
| 922 | DNMT1 mediates metabolic reprogramming induced by Epstein-Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma. 2018 , 9, 619 | 43 |
| 921 | HOXC10 promotes gastric cancer cell invasion and migration via regulation of the NF- κ B pathway. 2018 , 501, 628-635 | 17 |
| 920 | Molecular Diagnostics in Esophageal and Gastric Neoplasms: 2018 Update. 2018 , 38, 357-365 | 6 |
| 919 | Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. 2018 , 23, 1171-1177 | 19 |
| 918 | Risk factors for esophageal cancer: emphasis on infectious agents. 2018 , 1434, 319-332 | 13 |

| | | |
|-----|---|-----|
| 917 | Targeting Rac and Cdc42 GTPases in Cancer. 2018 , 78, 3101-3111 | 124 |
| 916 | HSP70/HSP90-Organizing Protein Contributes to Gastric Cancer Progression in an Autocrine Fashion and Predicts Poor Survival in Gastric Cancer. 2018 , 47, 879-892 | 17 |
| 915 | A Convergence-Based Framework for Cancer Drug Resistance. 2018 , 33, 801-815 | 104 |
| 914 | Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. 2018 , 9, 1920 | 48 |
| 913 | Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. 2018 , 29, 1377-1385 | 6 |
| 912 | RHOA mutations in cancer: Oncogenes or tumor suppressors?. 2018 , 121-138 | |
| 911 | Gastrointestinal Cytology. 2018 , 133-156 | |
| 910 | Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. 2018 , 17, 223-230 | 19 |
| 909 | Immune signatures correlate with L1 retrotransposition in gastrointestinal cancers. 2018 , 28, 1136-1146 | 26 |
| 908 | Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging?. 2018 , 25, 2703-2712 | 21 |
| 907 | Future applications of FGF/FGFR inhibitors in cancer. 2018 , 18, 861-872 | 45 |
| 906 | Clonal Structures of Regionally Synchronous Gastric Adenomas and Carcinomas. 2018 , 24, 4715-4725 | 6 |
| 905 | Radiation Therapy in Gastric Cancer. 2018 , 1-13 | |
| 904 | p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. 2018 , 217, 3183-3201 | 9 |
| 903 | GeneExpressScore Signature: a robust prognostic and predictive classifier in gastric cancer. 2018 , 12, 1871-1883 | 13 |
| 902 | Mechanisms of Gastrointestinal Malignancies. 2018 , 1615-1642 | 1 |
| 901 | Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer. 2018 , 119, 230-240 | 16 |
| 900 | Identification of significant biomarkers and pathways associated with gastric carcinogenesis by whole genome-wide expression profiling analysis. 2018 , 52, 955-966 | 14 |

| | | |
|-----|---|-----|
| 899 | Clinical Molecular Pathology. 2018 , 55-72 | |
| 898 | Epigenetic Biomarkers in Cancer Epidemiology. 2018 , 223-241 | |
| 897 | DNA methylation biomarkers for head and neck squamous cell carcinoma. 2018 , 13, 398-409 | 33 |
| 896 | Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. 2018 , 5, 14-20 | 2 |
| 895 | Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. 2018 , 11, 1171-1187 | 53 |
| 894 | Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. 2018 , 155, 799-814.e13 | 46 |
| 893 | Implication of HSP70 in the Pathogenesis of Gastric Cancer. 2018 , 113-130 | |
| 892 | Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues. 2018 , 8, 11456 | 7 |
| 891 | Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. 2018 , 19, | 32 |
| 890 | Promoter Methylation and Prediction/Prognosis of Gastric Cancer: A Systematic Review and Meta and Bioinformatic Analysis. 2018 , 9, 1932-1942 | 5 |
| 889 | Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. 2018 , 23, 1848-1872 | 7 |
| 888 | Familial aggregation of gastric cancer with microsatellite instability. 2018 , 118, 287-293 | 2 |
| 887 | DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer. 2018 , 40, 1203-1222 | 33 |
| 886 | CENP-E as a target for cancer therapy: Where are we now?. 2018 , 208, 192-200 | 7 |
| 885 | Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis. 2018 , 37, 115 | 7 |
| 884 | Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. 2018 , 29, 2052-2060 | 241 |
| 883 | Identification of Potential Key Genes Associated With the Pathogenesis and Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis. 2018 , 9, 265 | 92 |
| 882 | Inhibition of RAD54B suppresses proliferation and promotes apoptosis in hepatoma cells. 2018 , 40, 1233-1242 | 7 |

- 881 The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. **2018**, 10, 1758835918786228
- 880 EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes. **2018**, 10, 29
- 879 Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. **2018**, 24, 5272-5281 13
- 878 Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit. **2018**, 24, 5574-5584 67
- 877 Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. **2018**, 102, 128-137 15
- 876 Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. **2018**, 19, 1047-1068 9
- 875 Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?. **2018**, 63, 58-65 7
- 874 Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis. **2018**, 109, 2957-2969 19
- 873 Elevated TFAP4 regulates lncRNA TRERNA1 to promote cell migration and invasion in gastric cancer. **2018**, 40, 923-931 10
- 872 Gastric Cancer: Pathology and Genetics. **2018**, 77-77
- 871 Role of microRNAs and Exosomes in and Epstein-Barr Virus Associated Gastric Cancers. **2018**, 9, 636 43
- 870 Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues. **2018**, 25, 2767-2775 28
- 869 Rab3IP interacts with SSX2 and enhances the invasiveness of gastric cancer cells. **2018**, 503, 2563-2568 6
- 868 Inhibition of the miR-192/215-Rab11-FIP2 axis suppresses human gastric cancer progression. **2018**, 9, 778 12
- 867 The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. **2018**, 20, 71 36
- 866 Clinical Importance of Epstein-Barr Virus-Associated Gastric Cancer. **2018**, 10, 44
- 865 Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. **2018**, 10, 13
- 864 Wnt Signalling in Gastrointestinal Epithelial Stem Cells. **2018**, 9, 37

| | | |
|-----|---|-----|
| 863 | Integrative Analysis of Dysregulated lncRNA-Associated ceRNA Network Reveals Functional lncRNAs in Gastric Cancer. 2018 , 9, | 47 |
| 862 | Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis. 2018 , 52, 978-988 | 6 |
| 861 | Current status of gastrectomy for cancer: "Less is often more". 2018 , 96, 603-605 | 0 |
| 860 | ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. 2018 , 37, 5982-5996 | 62 |
| 859 | Characterizing Metastatic -Positive Gastric Cancer at the Haplotype. 2017 , 19, | 11 |
| 858 | The Pattern of Signatures in Gastric Cancer Prognosis. 2018 , 19, | 41 |
| 857 | Proposed Molecular and miRNA Classification of Gastric Cancer. 2018 , 19, | 40 |
| 856 | The Microenvironment in Epstein-Barr Virus-Associated Malignancies. 2018 , 7, | 29 |
| 855 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. 2018 , 24, 1449-1458 | 577 |
| 854 | Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer. 2018 , 16, 127 | 18 |
| 853 | Modification of the TNM Staging System for Stage II/III Gastric Cancer Based on a Prognostic Single Patient Classifier Algorithm. 2018 , 18, 142-151 | 11 |
| 852 | Expression and prognostic value of cell-cycle-associated genes in gastric adenocarcinoma. 2018 , 18, 81 | 13 |
| 851 | Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. 2018 , 18, 99 | 34 |
| 850 | Preoperative therapy and long-term survival in gastric cancer: One size does not fit all. 2018 , 27, 575-583 | 7 |
| 849 | Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade. 2018 , 78, 5107-5123 | 25 |
| 848 | A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. 2018 , 24, 515-527 | 49 |
| 847 | Characterization of long non-coding RNAs and MEF2C-AS1 identified as a novel biomarker in diffuse gastric cancer. 2018 , 11, 1080-1089 | 18 |
| 846 | Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. 2018 , 130, 13-26 | 20 |

| | | |
|-----|---|----|
| 845 | Screening for gastric cancer with magnetically controlled capsule gastroscopy in asymptomatic individuals. 2018 , 88, 466-474.e1 | 37 |
| 844 | The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. 2018 , 19, | 15 |
| 843 | Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. 2018 , 7, | 11 |
| 842 | DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways. 2018 , 38, 45 | 38 |
| 841 | Novel Systemic Therapies for Advanced Gastric Cancer. 2018 , 18, 1-19 | 25 |
| 840 | Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies. 2018 , 2018, 2732408 | 9 |
| 839 | Microsatellite instability in prostate cancer by PCR or next-generation sequencing. 2018 , 6, 29 | 58 |
| 838 | Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. 2018 , 25, 2027-2033 | 12 |
| 837 | Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. 2018 , 430, 123-132 | 28 |
| 836 | Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. 2018 , 66, 104-113 | 57 |
| 835 | Borrmann Type 1 Cancer is Associated with a High Recurrence Rate in Locally Advanced Gastric Cancer. 2018 , 25, 2044-2052 | 8 |
| 834 | Downregulated PITX1 Modulated by MiR-19a-3p Promotes Cell Malignancy and Predicts a Poor Prognosis of Gastric Cancer by Affecting Transcriptionally Activated PDCD5. 2018 , 46, 2215-2231 | 22 |
| 833 | Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients. 2018 , 18, 508 | 17 |
| 832 | Prognostic value of Dickkopf-1 and Ectenin expression in advanced gastric cancer. 2018 , 18, 506 | 19 |
| 831 | Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. 2018 , 16, 22 | 10 |
| 830 | HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. 2018 , 20, 8 | 30 |
| 829 | Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations. 2018 , 2, 37-46 | 26 |
| 828 | Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. 2018 , 50, 389-401 | 24 |

| | | |
|-----|---|----|
| 827 | Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma. 2018 , 78, 79-88 | 32 |
| 826 | A novel dual-marker expression panel for easy and accurate risk stratification of patients with gastric cancer. 2018 , 7, 2463-2471 | 6 |
| 825 | Regulatory mechanisms of PD-L1 expression in cancer cells. 2018 , 67, 1481-1489 | 46 |
| 824 | Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients. 2018 , 2018, 3249436 | 5 |
| 823 | UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability. 2018 , 9, 847 | 29 |
| 822 | Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity. 2018 , 19, | 38 |
| 821 | Molecular Pathogenesis of Gastric Adenocarcinoma. 2018 , | |
| 820 | The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. 2018 , 18, 430-441 | 1 |
| 819 | Small benzothiazole molecule induces apoptosis and prevents metastasis through DNA interaction and c-MYC gene supression in diffuse-type gastric adenocarcinoma cell line. 2018 , 294, 118-127 | 6 |
| 818 | Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. 2018 , 18, 1085-1092 | 3 |
| 817 | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. 2018 , 6, | 35 |
| 816 | Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival. 2018 , 473, 687-695 | 15 |
| 815 | Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. 2018 , 85, 44-51 | 8 |
| 814 | Long Noncoding RNA EGFR-AS1 Promotes Cell Proliferation by Increasing EGFR mRNA Stability in Gastric Cancer. 2018 , 49, 322-334 | 27 |
| 813 | Sh-MARCH8 Inhibits Tumorigenesis via PI3K Pathway in Gastric Cancer. 2018 , 49, 306-321 | 8 |
| 812 | MicroRNA-21-5p promotes proliferation of gastric cancer cells through targeting SMAD7. 2018 , 11, 4901-4911 | 9 |
| 811 | Associations of Epstein-Barr Virus-Positive Gastric Adenocarcinoma with Circulating Mediators of Inflammation and Immune Response. 2018 , 10, | 5 |
| 810 | A microsatellite based multiplex PCR method for the detection of chromosomal instability in gastric cancer. 2018 , 8, 12551 | 4 |

| | | |
|-----|---|-----|
| 809 | Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition. 2018 , 24, 6556-6569 | 44 |
| 808 | Current advances of targeting HGF/c-Met pathway in gastric cancer. 2018 , 6, 247 | 18 |
| 807 | Genomic landscape and mutational impacts of recurrently mutated genes in cancers. 2018 , 6, 910-923 | 8 |
| 806 | Association of Antioxidative Enzymes Polymorphisms with Efficacy of Platin and Fluorouracil-Based Adjuvant Therapy in Gastric Cancer. 2018 , 48, 2247-2257 | 6 |
| 805 | Frequent fusion in highly metastatic diffuse-type gastric cancer with relatively early onset. 2018 , 9, 29336-29350 | 50 |
| 804 | Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. 2018 , 23, 1319-1327 | 61 |
| 803 | MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way. 2018 , 4, 1698-1699 | 3 |
| 802 | Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. 2018 , 4, 1691-1698 | 83 |
| 801 | Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis. 2018 , 174, 856-869.e17 | 131 |
| 800 | Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells. 2018 , 8, 11879 | 19 |
| 799 | Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer. 2018 , 9, 181-186 | 30 |
| 798 | Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer. 2018 , 9, 861 | 13 |
| 797 | Live-Cell Imaging of DNA Methylation Based on Synthetic-Molecule/Protein Hybrid Probe. 2018 , 18, 1672-1680z | |
| 796 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. 2018 , 392, 123-133 | 624 |
| 795 | Epigenetic silencing of miR-1271 enhances MEK1 and TEAD4 expression in gastric cancer. 2018 , 7, 3411 | 17 |
| 794 | Progress in gastric cancer. 2018 , 70, 157-159 | 53 |
| 793 | Molecular Basis of Diseases of the Gastrointestinal Tract. 2018 , 387-415 | 1 |
| 792 | RHO GTPases in cancer: known facts, open questions, and therapeutic challenges. 2018 , 46, 741-760 | 40 |

| | | |
|-----|--|-----|
| 791 | Anti-EGFR therapy in oesophagogastric cancer: precise but not enough. 2018 , 29, 1884-1885 | 1 |
| 790 | Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift. 2018 , 11, 1756284818775054 | 10 |
| 789 | Multilevel omic data clustering reveals variable contribution of methylator phenotype to integrative cancer subtypes. 2018 , 10, 1289-1299 | 4 |
| 788 | EBV-Encoded Latent Genes. 2018 , 1045, 377-394 | 23 |
| 787 | Gastric cancer surgery. 2018 , 70, 155 | 0 |
| 786 | A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. 2018 , 14, e1005965 | 109 |
| 785 | Current state of therapeutic development for rare cancers in Japan, and proposals for improvement. 2018 , 109, 1731-1737 | 5 |
| 784 | Checkpoint blockade in esophagogastric cancer. 2018 , 118, 77-85 | 8 |
| 783 | Prevalence of multiple infections and the risk of gastric adenocarcinoma development at earlier age. 2018 , 92, 62-68 | 26 |
| 782 | High expression of the ANKRD49 protein is associated with progression and poor prognosis of gastric cancer. 2018 , 22, 649-656 | 3 |
| 781 | Gastritis-Infection-Cancer Sequence of Epstein-Barr Virus-Associated Gastric Cancer. 2018 , 1045, 437-457 | 12 |
| 780 | Oesophageal stenting: Status quo and future challenges. 2018 , 91, 20170935 | 7 |
| 779 | Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. 2018 , 1434, 342-359 | 40 |
| 778 | Germline genetic variants were interactively associated with somatic alterations in gastric cancer. 2018 , 7, 3912-3920 | 2 |
| 777 | Gastric Cardiac Cancer. 2018 , | 2 |
| 776 | Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. 2018 , 21, 1064-1070 | 18 |
| 775 | Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors. 2019 , 101-121 | |
| 774 | E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. 2019 , 22, 273-286 | 19 |

| | | |
|-----|--|-----|
| 773 | New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. 2019 , 22, 77-90 | 27 |
| 772 | Implementing precision cancer medicine in the genomic era. 2019 , 55, 16-27 | 16 |
| 771 | Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. 2019 , 22, 69-76 | 31 |
| 770 | Combinatory low methylation statuses of SAT- β and L1 are associated with shortened survival time in patients with advanced gastric cancer. 2019 , 22, 37-47 | 11 |
| 769 | The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. 2019 , 22, 113-122 | 13 |
| 768 | Geographic variation in molecular subtype for gastric adenocarcinoma. 2019 , 68, 1340-1341 | 4 |
| 767 | Epstein-Barr Virus and Cancer. 2019 , 14, 29-53 | 154 |
| 766 | Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases. 2019 , 22, 323-334 | 10 |
| 765 | Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. 2019 , 22, 355-362 | 9 |
| 764 | FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. 2019 , 38, 33-46 | 29 |
| 763 | Solid-type poorly differentiated adenocarcinoma of the stomach: clinicopathological and molecular characteristics and histogenesis. 2019 , 22, 314-322 | 7 |
| 762 | Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer. 2019 , 38, 273-290 | 23 |
| 761 | A bacterial genotoxin causes virus reactivation and genomic instability in Epstein-Barr virus infected epithelial cells pointing to a role of co-infection in viral oncogenesis. 2019 , 144, 98-109 | 3 |
| 760 | Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. 2019 , 270, 309-316 | 107 |
| 759 | The Role of Deubiquitinases in Oncovirus and Host Interactions. 2019 , 2019, 2128410 | 7 |
| 758 | The Global Landscape of EBV-Associated Tumors. 2019 , 9, 713 | 149 |
| 757 | Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. 2019 , 11, 509-517 | 12 |
| 756 | Microbial carcinogenesis: Lactic acid bacteria in gastric cancer. 2019 , 1872, 188309 | 52 |

| | | |
|-----|---|----|
| 755 | Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. 2019 , 10, 3574 | 58 |
| 754 | Physical Simulation Experimental Study on Fault Activation based on Total Station Polar Coordinate Method. 2019 , 37, 4491-4502 | 1 |
| 753 | Rho GTPases in cancer: friend or foe?. 2019 , 38, 7447-7456 | 61 |
| 752 | Overexpression of TWA1 predicts poor prognosis in patients with gastric cancer. 2019 , 215, 152594 | 2 |
| 751 | A panel of DNA methylated markers predicts metastasis of pNM gastric carcinoma: a prospective cohort study. 2019 , 121, 529-536 | 6 |
| 750 | Identification of candidates for driver oncogenes in scirrhou-type gastric cancer cell lines. 2019 , 110, 2643-2651 | 6 |
| 749 | VEGF-C induced by TGF- β signaling in gastric cancer enhances tumor-induced lymphangiogenesis. 2019 , 19, 799 | 16 |
| 748 | Biological Significance of Tumor Heterogeneity in Esophageal Squamous Cell Carcinoma. 2019 , 11, | 28 |
| 747 | Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer. 2019 , 8, e1649961 | 7 |
| 746 | Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. 2019 , 5, 1-10 | 3 |
| 745 | Histone chaperone CHAF1A impacts the outcome of fluoropyrimidines-based adjuvant therapy in gastric cancer by regulating the expression of thymidylate synthetase. 2019 , 716, 144034 | 4 |
| 744 | Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer. 2019 , 39, 4003-4010 | 8 |
| 743 | Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications. 2019 , 24, e1321-e1330 | 11 |
| 742 | Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group. 2019 , 11, 6815-6827 | 8 |
| 741 | Avelumab in gastric cancer. 2019 , 11, 759-768 | 8 |
| 740 | Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin. 2019 , 10, 3800 | 15 |
| 739 | Emergence of Mutation as a Biomarker and an Actionable Target in Solid Cancers. 2019 , 24, e1303-e1314 | 30 |
| 738 | A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors. 2019 , 12, 51-59 | |

| | | |
|-----|---|----|
| 737 | Role of tumor gene mutations in treatment response to immune checkpoint blockades. 2019 , 2, 100-109 | 5 |
| 736 | Clustered protocadherins methylation alterations in cancer. 2019 , 11, 100 | 17 |
| 735 | Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. 2019 , 18, 674-686 | 14 |
| 734 | The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. 2019 , 10, 3094-3101 | 5 |
| 733 | High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. 2019 , 4, | 6 |
| 732 | HCCR-1 is a Novel Prognostic Indicator for Gastric Cancer and Promotes Cell Proliferation. 2019 , 10, 3533-3542 | 1 |
| 731 | The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. 2019 , 10, 3108 | 36 |
| 730 | Low Expression of GLIS2 Gene Might Associate with Radiosensitivity of Gastric Cancer. 2019 , 2019, 2934925 | 3 |
| 729 | Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue. 2019 , 9, 9675 | 6 |
| 728 | Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments. 2019 , 2019, 6270784 | 34 |
| 727 | Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer. 2019 , 2019, 8103142 | 14 |
| 726 | Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. 2019 , 11, 6397-6410 | 11 |
| 725 | Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. 2019 , 9, 1388-1405 | 78 |
| 724 | Staging systems for gastric cancer: more complex than TNM. 2019 , 4, 44 | 1 |
| 723 | Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. 2019 , 166, 547-555 | 33 |
| 722 | Systematic analysis of the intersection of disease mutations with protein modifications. 2019 , 12, 109 | 4 |
| 721 | MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression. 2019 , 52, e8341 | 23 |
| 720 | High-Expression HBO1 Predicts Poor Prognosis in Gastric Cancer. 2019 , 152, 517-526 | 8 |

| | | |
|-----|--|----|
| 719 | EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells. 2019 , 116, 14144-14153 | 9 |
| 718 | PRKDC is a prognostic marker for poor survival in gastric cancer patients and regulates DNA damage response. 2019 , 215, 152509 | 6 |
| 717 | Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. 2019 , 10, 1337 | 63 |
| 716 | Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis. 2019 , 8, | 20 |
| 715 | Next-generation sequencing and biomarkers for gastric cancer: what is the future?. 2019 , 11, 1758835919848189 | |
| 714 | -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. 2019 , 24, 1462-1468 | 6 |
| 713 | The Role of Wnt and R-spondin in the Stomach During Health and Disease. 2019 , 7, | 13 |
| 712 | [Study of gastric adenocarcinomas association with the Epstein-Barr virus-encoded small RNAs].. 2022 , 84, 5-12 | 0 |
| 711 | Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer.. 2022 , 25, 542 | 1 |
| 710 | Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.. 2022 , 13, 783695 | 0 |
| 709 | Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. 2022 , 10, 23 | |
| 708 | Dissection of Immune Profiles in Microsatellite Stable and Low Microsatellite Instability Colon Adenocarcinoma by Multiomics Data Analysis.. 2022 , 2022, 8588164 | |
| 707 | Gastric Cancer and Viruses: A Fine Line between Friend or Foe.. 2022 , 10, | 2 |
| 706 | Panel Informativity Optimizer (PIO): an R package to improve cancer NGS panel informativity.. 2022 , | |
| 705 | Target Therapy and Immunotherapy For Gastric Cancer - Recent Updates. 2022 , 18, | 0 |
| 704 | Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study.. 2022 , 1 | |
| 703 | Viral Pathogens in Oesophageal and Gastric Cancer.. 2022 , 11, | 0 |
| 702 | Open and minimally invasive gastrectomy in Eastern and Western patient populations: A review of the literature and reasons for differences in outcomes.. 2022 , | 0 |

| | | |
|-----|---|---|
| 701 | Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers.. 2022 , 13, 810539 | |
| 700 | KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.. 2022 , 1 | 0 |
| 699 | Experimental evolution in TP53 deficient gastric organoids recapitulates tumorigenesis. | 0 |
| 698 | Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review.. 2022 , 10, 860985 | 3 |
| 697 | Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.. 2022 , 13, 378 | 1 |
| 696 | Loss of PBRM1 alters promoter histone modifications and activates ALDH1A1 to drive renal cell carcinoma.. 2022 , | 0 |
| 695 | CDC25B Inhibition by menadione: a potential new therapeutical approach.. 2022 , | |
| 694 | Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer.. 2022 , | 0 |
| 693 | Decreased Expression of Cell Adhesion Molecule 4 in Gastric Adenocarcinoma and Its Prognostic Implications.. 2022 , 12, | 1 |
| 692 | Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.. 2022 , 20, 133 | 3 |
| 691 | Prognostic Epstein-Barr Virus (EBV) miRNA biomarkers for survival outcome in EBV-associated epithelial malignancies: Systematic review and meta-analysis.. 2022 , 17, e0266893 | 1 |
| 690 | Table_1.docx. 2019 , | |
| 689 | DataSheet_1.pdf. 2019 , | |
| 688 | Data_Sheet_1.pdf. 2020 , | |
| 687 | Data_Sheet_2.docx. 2020 , | |
| 686 | Data_Sheet_1.PDF. 2019 , | |
| 685 | Table_1.XLSX. 2018 , | |
| 684 | Table_10.XLSX. 2018 , | |

683 Table_11.XLSX. 2018,

682 Table_2.XLSX. 2018,

681 Table_3.XLSX. 2018,

680 Table_4.XLSX. 2018,

679 Table_5.XLSX. 2018,

678 Table_6.XLSX. 2018,

677 Table_7.xlsx. 2018,

676 Table_8.XLSX. 2018,

675 Table_9.XLSX. 2018,

674 Image_1.TIF. 2020,

673 Image_2.TIF. 2020,

672 Image_3.TIF. 2020,

671 Table_1.XLSX. 2020,

670 Table_2.XLSX. 2020,

669 Table_3.XLSX. 2020,

668 Table_4.XLSX. 2020,

667 Data_Sheet_1.docx. 2020,

666 Data_Sheet_1.pdf. 2020,

665 Data_Sheet_2.PDF. 2020,

664 Table_1.XLSX. 2020,

663 Data_Sheet_1.docx. 2020,

662 Table_1.xls. 2020,

661 Table_2.xls. 2020,

660 Table_3.doc. 2020,

659 Table_4.doc. 2020,

658 Image_1.JPEG. 2020,

657 Image_2.JPEG. 2020,

656 Image_3.JPEG. 2020,

655 Image_4.JPEG. 2020,

654 Image_5.JPEG. 2020,

653 Table_1.DOCX. 2020,

652 Table_2.DOCX. 2020,

651 Table_3.XLSX. 2020,

650 Table_4.XLSX. 2020,

649 Table_5.DOCX. 2020,

648 Table_6.DOCX. 2020,

647 Data_Sheet_1.docx. **2020**,

646 Table_1.XLSX. **2019**,

645 Table_2.XLSX. **2019**,

644 Table_3.XLSX. **2019**,

643 Table_4.XLSX. **2019**,

642 Table_5.XLSX. **2019**,

641 Table_6.XLSX. **2019**,

640 Table_7.DOCX. **2019**,

639 Data_Sheet_1.docx. **2020**,

638 Table_1.xlsx. **2019**,

637 Table_2.xlsx. **2019**,

636 Table_3.xlsx. **2019**,

635 Table_4.xlsx. **2019**,

634 Table_5.xlsx. **2019**,

633 Table_6.xlsx. **2019**,

632 Table_7.xlsx. **2019**,

631 Data_Sheet_1.docx. **2020**,

630 Table_1.docx. **2019**,

629 Data_Sheet_1.PDF. 2020,

628 Data_Sheet_2.PDF. 2020,

627 Table_1.DOCX. 2020,

626 Table_2.DOCX. 2020,

625 Data_Sheet_1.pdf. 2020,

624 Table_2.xlsx. 2020,

623 Table_3.xlsx. 2020,

622 Table_1.docx. 2020,

621 Table_2.docx. 2020,

620 Data_Sheet_1.pdf. 2020,

619 Image_1.pdf. 2020,

618 Image_10.pdf. 2020,

617 Image_2.pdf. 2020,

616 Image_3.pdf. 2020,

615 Image_4.pdf. 2020,

614 Image_5.pdf. 2020,

613 Image_6.pdf. 2020,

612 Image_7.pdf. 2020,

611 Image_8.pdf. 2020,

610 Image_9.pdf. 2020,

609 Table_1.DOCX. 2019,

608 Table_2.DOCX. 2019,

607 Table_3.DOCX. 2019,

606 Data_Sheet_1.pdf. 2019,

605 Table_1.xlsx. 2019,

604 Table_1.DOCX. 2020,

603 Table_1.docx. 2019,

602 Table_2.xlsx. 2019,

601 Image_1.TIF. 2020,

600 Image_2.TIF. 2020,

599 Data_Sheet_1.docx. 2020,

598 Table_1.xls. 2020,

597 Table_2.xls. 2020,

596 Table_3.xls. 2020,

595 Table_4.xls. 2020,

594 Table_5.xls. 2020,

593 Table_6.xlsx. **2020**,

592 Data_Sheet_1.xlsx. **2020**,

591 DataSheet_1.docx. **2021**,

590 Image_1.TIF. **2020**,

589 Image_2.TIF. **2020**,

588 Image_3.TIF. **2020**,

587 Image_4.TIF. **2020**,

586 Image_5.TIF. **2020**,

585 Image_6.TIF. **2020**,

584 Data_Sheet_1.docx. **2019**,

583 Image_1.pdf. **2019**,

582 Image_2.pdf. **2019**,

581 Table_1.XLS. **2020**,

580 Clinicopathological characteristics, survival outcome and prognostic factors of very young gastric cancer.. **2022**, 1

579 Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer.. **2022**, 109019 1

578 Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse.. **2022**, 0

577 Sevoflurane Suppresses the Growth, Metastasis, and Invasion of Endometrial Carcinoma Cells via miR-195-5p/JAK2 Axis.. **2022**, 2022, 2398101 0

576 [Profilin 2 is highly expressed in gastric cancer and promotes tumor cell proliferation and migration].. **2022**, 42, 215-222

| | | |
|-----|---|---|
| 575 | Is there still a place for conventional histopathology in the age of molecular medicine? Laurfi classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. 2021 , 36, 587-613 | 3 |
| 574 | Expression Patterns of Glycosylation Regulators Define Tumor Microenvironment and Immunotherapy in Gastric Cancer.. 2022 , 10, 811075 | 0 |
| 573 | Patient-derived organoids as a model for tumor research. 2022 , | 1 |
| 572 | Clinical value of CDH1 gene in gastric cancer. 2022 , 11, 74 | |
| 571 | FastViFi: Fast and accurate detection of (Hybrid) Viral DNA and RNA.. 2022 , 4, lqac032 | |
| 570 | Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response.. 2022 , 13, 890922 | 1 |
| 569 | Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer.. 2022 , 13, 854211 | 0 |
| 568 | An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma.. 2022 , 2022, 3035073 | |
| 567 | RNF43 R117fs mutant positively regulates Wnt/ β -catenin signaling by failing to internalize FZD expressed on the cell surface.. 2022 , 12, 7013 | 0 |
| 566 | A Genomic Signature Reflecting Fibroblast Infiltration Into Gastric Cancer Is Associated With Prognosis and Treatment Outcomes of Immune Checkpoint Inhibitors.. 2022 , 10, 862294 | |
| 565 | Current and future strategies for radiation therapy in gastric cancer.. 2022 , 125, 1161-1175 | 0 |
| 564 | Neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction.. 2022 , | 1 |
| 563 | Systematic molecular analysis of the human secretome and membrane proteome in gastrointestinal adenocarcinomas.. 2022 , | |
| 562 | The Immune Microenvironment in Gastric Cancer: Prognostic Prediction.. 2022 , 12, 836389 | 0 |
| 561 | Putative Clinical Potential of Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients.. 2022 , 14, | 0 |
| 560 | Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning. 2022 , 13, | 0 |
| 559 | Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer.. 2022 , | |
| 558 | RHOA takes the RHOad less traveled to cancer.. 2022 , | 2 |

| | | |
|-----|---|---|
| 557 | Next generation sequencing analysis of gastric cancer identifies the leukemia inhibitory factor receptor (LIFR) as a driving factor in gastric cancer progression and as a predictor of poor prognosis. | |
| 556 | Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021. 1 | |
| 555 | Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.. 2022, | 0 |
| 554 | Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology.. 2022, 79, 102474 | 1 |
| 553 | Self-Renewal and Cancers of the Gastric Epithelium: An Update and the Role of the Lectin TFF1 as an Antral Tumor Suppressor. 2022, 23, 5377 | 1 |
| 552 | Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma.. 2022, | 0 |
| 551 | Genome-Scale Metabolic Model Analysis of Metabolic Differences between Lauren Diffuse and Intestinal Subtypes in Gastric Cancer.. 2022, 14, | 0 |
| 550 | Molecular pathogenesis and emerging targets of gastric adenocarcinoma.. 2022, 125, 1079-1095 | 1 |
| 549 | The molecular characteristics of gastric cancer patients living in Qinghai-Tibetan Plateau.. 2022, 22, 244 | 0 |
| 548 | Molecular Subtyping of Cancer Based on Robust Graph Neural Network and Multi-Omics Data Integration. 2022, 13, | 1 |
| 547 | Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. 2022, 13, | 0 |
| 546 | Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report.. 2022, 20, 157 | |
| 545 | Deep Learning-Based Protein Features Predict Overall Survival and Chemotherapy Benefit in Gastric Cancer. 2022, 12, | 1 |
| 544 | Induction of FGFR4 by H. pylori via STAT3 with a feedforward activation loop involving SRC signaling in gastric cancer.. 2022, | 0 |
| 543 | A Novel Classification and Scoring Method Based on Immune-Related Transcription Factor Regulation Patterns in Gastric Cancer. 2022, 12, | 0 |
| 542 | Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages.. 2022, | 0 |
| 541 | A deep learning model and human-machine fusion for prediction of EBV-associated gastric cancer from histopathology.. 2022, 13, 2790 | 1 |
| 540 | Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.. 2022, 20, 233 | 0 |

- 539 PWWP2B promotes DNA end resection and homologous recombination.. **2022**, e53492 ○
- 538 Microsatellite instability and chemosensitivity in solid tumours. **2022**, 14, 175883592210993 1
- 537 The kinase activity of the cancer stem cell marker DCLK1 drives gastric cancer progression by reprogramming the stromal tumor landscape. ○
- 536 PD-L1 expression and overall survival in Asian and western patients with gastric cancer. ○
- 535 Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing. **2022**, 10, 4761-4775 ○
- 534 Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers. **2022**, ○
- 533 Clinical Significance of Epstein-Barr Virus and Helicobacter pylori Infection in Gastric Carcinoma. **2022**, 1
- 532 Comprehensive analysis of molecular mechanism and a novel prognostic signature based on small nuclear RNA biomarkers in gastric cancer patients. **2022**, 17, 991-1006 ○
- 531 The Research Progress of Forkhead Box P1 in EBV-Associated Gastric Cancer. **2022**, 12, 4897-4902 ○
- 530 The HIF-1 β as a Potent Inducer of the Hallmarks in Gastric Cancer. **2022**, 14, 2711 ○
- 529 Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer. **2022**, 194829 ○
- 528 The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma. 1
- 527 The Functions of PCNA in Tumor Stemness and Invasion. **2022**, 23, 5679 ○
- 526 Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer. ○
- 525 Características clínico-patológicas del adenocarcinoma gástrico asociado al virus de Epstein-Barr en una región de alta incidencia de cáncer gástrico en Colombia. **2022**, ○
- 524 Patient-Derived Xenograft: A More Standard Avatar Model in Preclinical Studies of Gastric Cancer. 12, ○
- 523 Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy. ○
- 522 Epstein-Barr Virus-Encoded BILF1 Orthologues From Porcine Lymphotropic Herpesviruses Display Common Molecular Functionality. **2022**, 13, ○

| | | |
|-----|--|---|
| 521 | Clinicopathologic and survival differences between adenocarcinoma of the distal oesophagus and gastro-oesophageal junction. | |
| 520 | Exploration of the Tumor Immune Landscape and Identification of Two Novel Immunotherapy-Related Genes for Epstein-Barr virus-associated Gastric Carcinoma via Integrated Bioinformatics Analysis. 2022 , 9, | 1 |
| 519 | A Novel DNA Repair Gene Signature for Immune Checkpoint Inhibitor-Based Therapy in Gastric Cancer. 2022 , 10, | 1 |
| 518 | Molecular Typing of Gastric Cancer Based on Invasion-Related Genes and Prognosis-Related Features. 12, | 0 |
| 517 | Characterization of the Prognostic Values of CXCL Family in EpsteinBarr Virus Associated Gastric Cancer. 2022 , 2022, 1-24 | 0 |
| 516 | Stem Cell Biomarkers and Tumorigenesis in Gastric Cancer. 2022 , 12, 929 | 1 |
| 515 | Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. | 0 |
| 514 | Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model. | 0 |
| 513 | The implications of cell-free DNAs derived from tumor viruses as biomarkers of associated cancers. | 0 |
| 512 | The Role of Surgery in Management of Gastric Cancer. 2022 , 421-430 | |
| 511 | Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer. 2022 , 12, | 0 |
| 510 | Immunotherapy in upper gastrointestinal malignancies. 2022 , 16, 123-126 | |
| 509 | Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa. 2022 , | 0 |
| 508 | Identification of oncogenic signaling pathways associated with the dimorphic metabolic dysregulations in gastric cancer subtypes. 2022 , 39, | |
| 507 | Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer. 13, | |
| 506 | Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma. | 0 |
| 505 | Discovering Immune-Mediated Mechanisms of Gastric Carcinogenesis Through Single-Cell RNA Sequencing. 13, | 0 |
| 504 | Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer. 2022 , 14, 1162-1174 | |

- 503 Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer. **2022**, 22,
- 502 Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy. ○
- 501 Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma. ○
- 500 Inflammation and Gastric Cancer. **2022**, 10, 35 1
- 499 Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. **2022**, 7, 100514
- 498 A case of gastric lesion with hypoechoic area in the submucosa. **2022**,
- 497 The current state of molecular profiling in gastrointestinal malignancies. **2022**, 17, ○
- 496 Prognostic Role of M6A-Associated Immune Genes and Cluster-Related Tumor Microenvironment Analysis: A Multi-Omics Practice in Stomach Adenocarcinoma. 10, ○
- 495 Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer. **2022**, 2022, 1-11
- 494 Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. **2022**, 20, ○
- 493 Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers. ○
- 492 The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. **2022**, 22,
- 491 Kinase Activity of PAR1b, Which Mediates Nuclear Translocation of the BRCA1 Tumor Suppressor, Is Potentiated by Nucleic Acid-Mediated PAR1b Multimerization. **2022**, 23, 6634 ○
- 490 Epstein-Barr Virus and PD-L1 in Esophageal and Esophagogastric Junction Cancer: Differences According to Location and Histological Type.
- 489 Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. gutjnl-2022-327281 ○
- 488 Clinical significance of chromosomal integrity in gastric cancers. 039361552211062
- 487 The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics. 13, ○
- 486 Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. ○

- 485 Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models. *gutjnl-2022-327121* ○
- 484 KLF4 mutation shapes pathologic characteristics of foveolar-type gastric adenoma in *Helicobacter pylori*-naïve patients. **2022**, ○
- 483 Association of tumors having EpsteinBarr virus in surrounding lymphocytes with poor prognosis.
- 482 Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers. **2022**, 18, 16
- 481 Unsupervised Representation Learning for Tissue Segmentation in Histopathological Images: From Global to Local Contrast. **2022**, 1-1 ○
- 480 Management of Next-Generation Sequencing in Precision Medicine. **2022**, 149-176
- 479 Synaptotagmin 11 scaffolds MKK7/JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis. **2022**, 41, 1
- 478 The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer.
- 477 Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. 13,
- 476 Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study).
- 475 Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated with Perioperative Chemotherapy: A Retrospective Cohort Study. Publish Ahead of Print,
- 474 Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. 13, ○
- 473 Aquaporins in Cancer Biology. 12, 1
- 472 Targeting Wnt/βCatenin Signaling by TET1/FOXO4 Inhibits Metastatic Spreading and Self-Renewal of Cancer Stem Cells in Gastric Cancer. **2022**, 14, 3232 4
- 471 Somatic Mutation of FAT Family Genes Implicated Superior Prognosis in Patients With Stomach Adenocarcinoma. 9, ○
- 470 Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities. 1-24
- 469 LMP1 Induces p53 Protein Expression via the H19/miR-675-5p Axis. **2022**, 10, ○
- 468 Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma. **2022**, 14, 5271-5291 ○

| | | |
|-----|--|---|
| 467 | Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma. 2022 , | |
| 466 | An Immune Signature for Risk Stratification and Therapeutic Prediction in Helicobacter pylori-Infected Gastric Cancer. 2022 , 14, 3276 | 0 |
| 465 | DEMoS: A Deep Learning-based Ensemble Approach for Predicting the Molecular Subtypes of Gastric Adenocarcinomas from Histopathological Images. | 0 |
| 464 | A Novel Microbiome Signature in Gastric Cancer: A Two Independent Cohort Retrospective Analysis. Publish Ahead of Print, | 0 |
| 463 | Transcriptome sequencing of LMP2A-transfected gastric cancer cells identifies potential biomarkers in EBV-associated gastric cancer. | |
| 462 | Multi-omics analysis to screen potential therapeutic biomarkers for anti-cancer compounds. 2022 , e09616 | |
| 461 | Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. | 0 |
| 460 | Five EMT-related genes signature predicts overall survival and immune environment in microsatellite instability-high gastric cancer. | 1 |
| 459 | Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection. 12, | |
| 458 | ANP32E contributes to gastric cancer progression via NUF2 upregulation. 2022 , 26, | 0 |
| 457 | Driver Gene Alterations in Malignant Progression of Gastric Cancer. 12, | |
| 456 | Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. | 1 |
| 455 | Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance. 2022 , 41, | 1 |
| 454 | Multigene Expression Biomarkers and Score Systems for Predicting Therapeutic Benefit in Gastrointestinal Cancers. | |
| 453 | Advances in immunotherapy for metastatic esophageal cancer. 1-8 | |
| 452 | A Radiomics Nomogram Integrated With Clinic-Radiological Features for Preoperative Prediction of DNA Mismatch Repair Deficiency in Gastric Adenocarcinoma. 12, | |
| 451 | Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. 2022 , 10, e005041 | 3 |
| 450 | Liquid-liquid phase separation in tumor biology. 2022 , 7, | 1 |

| | | |
|-----|---|----|
| 449 | Clinical and pathologic characteristics of gastric adenocarcinoma associated with Epstein-Barr virus in a region with a high incidence of gastric cancer in Colombia. 2022 , | |
| 448 | Association of PD-1/PD-L1 expression and Epstein-Barr virus infection in patients with invasive breast cancer. 2022 , 17, | 0 |
| 447 | Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer. 13, | |
| 446 | Case Report: Pathogenesis With a Rare RHOA A161E Mutation in a Patient With Angioimmunoblastic T-Cell Lymphoma. 13, | 0 |
| 445 | Comparison of Diagnostic Efficacy of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT for Staging and Restaging of Gastric Cancer. 12, | 1 |
| 444 | Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives. 2022 , 10, 1614 | 0 |
| 443 | Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. gutjnl-2021-326483 | 0 |
| 442 | Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomas. | |
| 441 | Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer. 2022 , 14, 1515 | 1 |
| 440 | Prevalence of Primary Liver Cancer is Affected by Place of Birth in Hispanic People Residing in the United States: All of Us Research Program Report. 000313482211094 | |
| 439 | Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports. | 2 |
| 438 | Signaling factors potentially associated to the pathogenesis of Adult T-cell leukemia /lymphoma: A network-analysis and novel findings assessment. 2022 , 198875 | 0 |
| 437 | PD-L1 expression in EBV-associated gastric carcinomas. 2022 , 84, 5 | |
| 436 | Current Situation and Progress of Tumor-Suppressor Gene Related to Gastric Cancer in Liver Metastasis. 2022 , 12, 7172-7180 | |
| 435 | Rate of Epstein-Barr Virus in Gastric Adenocarcinoma in Egyptian Patients in View of the WHO Classification and Correlation with p16 Immunoreactivity. 2022 , 10, 1218-1225 | |
| 434 | A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. 13, | 0 |
| 433 | A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma. 13, | 1 |
| 432 | Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. 2022 , | 11 |

| | | |
|-----|---|----|
| 431 | RHOA protein expression correlates with clinical features in gastric cancer: a systematic review and meta-analysis. 2022 , 22, | |
| 430 | Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer. 2022 , 17, e0270591 | |
| 429 | Computational Analysis of Pathological Image Enables Interpretable Prediction for Microsatellite Instability. 12, | |
| 428 | Construction of a Prognostic Evaluation Model for Stomach Adenocarcinoma on the Basis of Immune-Related lncRNAs. | |
| 427 | Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy. 2022 , 14, 3740 | |
| 426 | Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes. | |
| 425 | Profiling chromosomal-level variations in gastric malignancies. | |
| 424 | Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer. | 0 |
| 423 | Clinicopathological and molecular characterization of early gastric adenocarcinoma in Helicobacter pylori-uninfected patients: emphasis on differentiated gastric adenocarcinoma. | |
| 422 | A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer. | 1 |
| 421 | Poorly cohesive cells gastric carcinoma including signet-ring cell cancer: Updated review of definition, classification and therapeutic management. 2022 , 14, 1406-1428 | 0 |
| 420 | When liquid-liquid phase separation meets viral infections. 13, | 2 |
| 419 | Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. 2022 , 71, 1724-1762 | 25 |
| 418 | Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors. 2022 , 14, 3750 | |
| 417 | Comprehensive Analysis of Genomic Alterations in Hepatoid Adenocarcinoma of the Stomach and Identification of Clinically Actionable Alterations. 2022 , 14, 3849 | 0 |
| 416 | Poorly Cohesive Gastric Cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively. Publish Ahead of Print, | 0 |
| 415 | Genomic and Epigenomic Characterization of Tumor Organoid Models. 2022 , 14, 4090 | |
| 414 | Estimating the global burden of Epstein-Barr virus associated gastric cancer: a systematic review and meta-analysis. 2022 , | 0 |

| | | |
|-----|--|---|
| 413 | Clinical value and influencing factors of establishing stomach cancer organoids by endoscopic biopsy. | 0 |
| 412 | Predicting the Prognostic Value of POLI Expression in Different Cancers via a Machine Learning Approach. 2022 , 23, 8571 | 0 |
| 411 | Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy. 13, | 0 |
| 410 | Expression of SASP, DNA Damage Response, and Cell Proliferation Factors in Early Gastric Neoplastic Lesions: Correlations and Clinical Significance. 28, | 1 |
| 409 | Analysis of immune status in gastric adenocarcinoma with different infiltrating patterns and origin sites. 13, | |
| 408 | OCT4-mediated transcription confers oncogenic advantage for a subset of gastric tumors with poor clinical outcome. | 0 |
| 407 | Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer. 2022 , 23, 1247-1268 | 2 |
| 406 | Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer. 13, | |
| 405 | Functional antagonism between CagA and DLC1 in gastric cancer. 2022 , 8, | |
| 404 | Accurate prediction of stomach adenocarcinomas of poorest and best prognosis with a combination of gene expression and clinical signatures. | |
| 403 | Clinicopathological difference between gastric cancer in the lesser curvature and gastric cancer in the greater curvature. 2022 , 101, e29984 | |
| 402 | EpsteinBarr virus and multiple sclerosis. | 7 |
| 401 | Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. 2022 , | 0 |
| 400 | Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. 12, | |
| 399 | Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer. | 1 |
| 398 | Single-Cell and Bulk RNA Sequencing Reveal Malignant Epithelial Cell Heterogeneity and Prognosis Signatures in Gastric Carcinoma. 2022 , 11, 2550 | |
| 397 | Feature Review Papers on Gastroesophageal Junction and Gastric Cancers. 2022 , 14, 3979 | |
| 396 | Surgical pathology of adenocarcinomas arising around or within the gastroesophageal junction. | |

| | | |
|-----|--|---|
| 395 | HERIZON-GEA-01: Zanidatamab + chemo + tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. | 2 |
| 394 | scRNA-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory. 2022 , 13, | 0 |
| 393 | Sensitivity towards HDAC inhibition is associated with RTK / MAPK pathway activation in gastric cancer. | 0 |
| 392 | Genomic features of Helicobacter pylori -naïve diffuse-type gastric cancer. | 1 |
| 391 | Profiling of gene fusion involving targetable genes in Chinese gastric cancer. 2022 , 14, 1528-1539 | |
| 390 | Retrospective Comparison of Chemotherapy Plus Anti-HER2 Therapies at First-line Treatment in Patients with Metastatic Gastric Adenocarcinoma. 468-476 | 0 |
| 389 | Molecular Characterization of Adenocarcinomas Arising in the Urinary Bladder Following Augmentation Cystoplasty: A Multi-Institutional Study. 2022 , | 0 |
| 388 | Gastric cancer with Epstein-Barr virus heterogeneity: Evaluation of the frequency, clinicopathologic features, and genomic profiles. 2022 , 238, 154108 | 0 |
| 387 | The integrated landscape of eRNA in gastric cancer reveals distinct immune subtypes with prognostic and therapeutic relevance. 2022 , 25, 105075 | 0 |
| 386 | Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors. 2022 , 238, 154110 | 0 |
| 385 | Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment. 2022 , 238, 154124 | 0 |
| 384 | The role of mixed lineage kinase 3 (MLK3) in cancers. 2022 , 238, 108269 | 0 |
| 383 | Successes and failures of immunotherapy for gastric cancer. 2022 , 27, 103343 | 0 |
| 382 | Diagnostic Applications of Nuclear Medicine: Gastric Cancers. 2022 , 1-18 | 0 |
| 381 | Multiple Epstein-Barr virus-associated Gastric Cancers Arising in a Patient with Autoimmune Gastritis. 2022 , | 1 |
| 380 | GZMA as a Potential Therapeutic Target Involved in Immune Infiltration in Breast Cancer. | 0 |
| 379 | PLK2 Single Nucleotide Variant in Gastric Cancer Patients Affects miR-23b-5p Binding. 22, | 0 |
| 378 | Diagnostic Applications of Nuclear Medicine: Gastric Cancers. 2022 , 829-846 | 0 |

- 377 The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers. **2022**, 20, 5065-5075 ○
- 376 European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. **2022**, 14, 175883592211188 ○
- 375 The Presence of Human Papillomavirus and Epstein-Barr Virus Infection in Gastric Cancer: A Systematic Study. **2022**, 24, 413-426 ○
- 374 Gastric Signet Ring Cell Carcinoma: An Overview. **2022**, 2, 8-16 ○
- 373 FGF/FGFR-related lncRNAs based classification predicts prognosis and guides therapy in gastric cancer. 13, ○
- 372 The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer. **2022**, 23, 9767 ○
- 371 Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study. **2022**, 1, 146-167 ○
- 370 Microsatellite instability/mismatch repair deficiency and activation of the Wnt/βcatenin signaling pathway in gastric adenocarcinoma of the fundic gland: A case report. **2022**, 101, e30311 ○
- 369 Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. **2022**, ○
- 368 Relationships among microbiota, gastric cancer, and immunotherapy. 13, ○
- 367 Fifty years of progress in gastric cancer. **2022**, 126, 865-871 ○
- 366 Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer. **2022**, 14, 4670 ○
- 365 Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. **2022**, 14, 4378 1
- 364 Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer. 13, ○
- 363 A nine-consensus prognostic gene-based prognostic signature, recognizing the dichotomized subgroups of gastric cancer patients with different clinical outcomes and therapeutic strategies. 13, ○
- 362 The KEAP1-NRF2 System and Esophageal Cancer. **2022**, 14, 4702 1
- 361 Genome-wide DNA methylation profiling of stomach cancer in the ethnic population of Mizoram, North East India. **2022**, 114, 110478 ○
- 360 Advances in the management of peritoneal malignancies. 1

| | | |
|-----|--|---|
| 359 | OpenPBTA: An Open Pediatric Brain Tumor Atlas. | 0 |
| 358 | Development and verification of an immune-related gene prognostic index for gastric cancer. 2022 , 12, | 1 |
| 357 | PTEN Expression Was Significantly Associated with PD-L1 Score but Not with EBV Infection in Gastric Cancer. Volume 15, 1011-1020 | 0 |
| 356 | V-set and immunoglobulin domain containing 1 (VSIG1) as an emerging target for epithelial-mesenchymal transition of gastric cancer. 2022 , 12, | 0 |
| 355 | Mechanisms of development and progression of pancreatic neoplasms. | 0 |
| 354 | MC180295 Inhibited EpsteinBarr Virus-Associated Gastric Carcinoma Cell Growth by Suppressing DNA Repair and the Cell Cycle. 2022 , 23, 10597 | 0 |
| 353 | Somatic Mutational Landscape in Mexican Patients: CDH1 Mutations and chr20q13.33 Amplifications Are Associated with Diffuse-Type Gastric Adenocarcinoma. 2022 , 23, 11116 | 0 |
| 352 | ARHGAP8-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer. | 0 |
| 351 | Identification of Potential miRNA-mRNA Regulatory Network Contributing to Parkinson's Disease. 2022 , 2022, 1-12 | 0 |
| 350 | Tubulovillous adenoma with high-grade dysplasia of the vulva harboring high tumor mutational burden and cancer-associated mutations: a case report. | 0 |
| 349 | Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial. | 2 |
| 348 | Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. 2022 , 13, | 2 |
| 347 | Neoantigens and their clinical applications in human gastrointestinal cancers. 2022 , 20, | 0 |
| 346 | Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies. 2022 , 14, 4498 | 0 |
| 345 | BAT26 Only Microsatellite Instability with High Tumor Mutation Burden: A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. 2022 , 23, 10730 | 0 |
| 344 | Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer. 2022 , 24, | 0 |
| 343 | Gastric Cancer. 2022 , 51, 501-518 | 0 |
| 342 | Does immunotherapy change the treatment paradigm in metastatic gastric cancer?. 2022 , 39, | 0 |

- 341 A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo. 13, ○
- 340 Identification of cuproptosis-associated lncRNAs signature and establishment of a novel nomogram for prognosis of stomach adenocarcinoma. 13, ○
- 339 Prediction of Epstein-Barr Virus Status in Gastric Cancer Biopsy Specimens Using a Deep Learning Algorithm. **2022**, 5, e2236408 ○
- 338 Diagnosis and clinical implication of collision gastric adenocarcinomas: a case report. **2022**, 8, ○
- 337 A multiphase contrast-enhanced CT radiomics model for prediction of human epidermal growth factor receptor 2 status in advanced gastric cancer. 13, ○
- 336 Communication between the nucleus and the mitochondria via NDUFS4 alternative splicing in gastric cancer cells. ○
- 335 Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. **2022**, 176, 13-29 ○
- 334 Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer. **2022**, 1-25 ○
- 333 Molecular Pathology of Gastric Cancer. **2022**, 22, 264 ○
- 332 Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors. **2022**, 14, 4804 ○
- 331 Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. **2022**, 13, ○
- 330 A-Kinase Anchoring Protein 9 Promotes Gastric Cancer Progression as a Downstream Effector of Cadherin 1. **2022**, 2022, 1-7 ○
- 329 PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. **2022**, 114, 352-364 1
- 328 The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression. ○
- 327 Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from 18F fluorodeoxyglucose PET/CT images in gastric cancer. 13, ○
- 326 Systems biology and OMIC data integration to understand gastrointestinal cancers. 13, 762-778 ○
- 325 A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. 12, ○
- 324 Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?. **2022**, 1

| | | |
|-----|--|---|
| 323 | EBV-associated diseases: Current therapeutics and emerging technologies. 13, | 1 |
| 322 | Case report: Significant response to PD-L1 inhibitor after resistance to PD-1 inhibitor in an advanced alpha-fetoprotein-positive gastric cancer. 12, | 0 |
| 321 | Cancer Genomics and Evolution. 1-30 | 0 |
| 320 | Dissecting the genetic and microenvironmental factors of gastric tumorigenesis in mice. 2022 , 41, 111482 | 0 |
| 319 | Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden. | 1 |
| 318 | Signaling pathways and therapeutic interventions in gastric cancer. 2022 , 7, | 0 |
| 317 | Predictive biomarkers in gastric cancer. | 1 |
| 316 | Adenocarcinoma of the stomach and esophagogastric junction with low DNA methylation show poor prognoses. | 0 |
| 315 | Extracellular vesicles from gastric epithelial GES-1 cells infected with <i>Helicobacter pylori</i> promote changes in recipient cells associated with malignancy. 12, | 0 |
| 314 | Borrmann Type Predicts Response to Preoperative Therapy in Advanced Gastric Cancer. | 0 |
| 313 | Carcinoma of the Stomach. 1-14 | 0 |
| 312 | Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. 13, | 0 |
| 311 | SH3 Domain-Binding Glumatic Acid-Rich Protein-Like 3 is closely associated with hyperglycemia and poor outcome in Epstein-Barr Virus-negative Gastric Carcinoma. | 0 |
| 310 | Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics. | 0 |
| 309 | Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. 2022 , 11, | 0 |
| 308 | The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. 2022 , 13, | 2 |
| 307 | Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. | 0 |
| 306 | Down-regulated expression of CDK5RAP3 and UFM1 suggests a poor prognosis in gastric cancer patients. 12, | 0 |

| | | |
|-----|--|---|
| 305 | Licoricidin combats gastric cancer by targeting the ICMT/Ras pathway in vitro and in vivo. 13, | 1 |
| 304 | Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives. 1-5 | 0 |
| 303 | Gene Regulatory Network Characterization of Gastric Cancer Histological Subtypes: Distinctive Biological and Clinically Relevant Master Regulators. 2022, 14, 4961 | 1 |
| 302 | Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. 12, | 0 |
| 301 | Case 31-2022: A 72-Year-Old Man with Heartburn, Nausea, and Inability to Eat. 2022, 387, 1415-1424 | 0 |
| 300 | Systems Biology and Genomics. 1-11 | 0 |
| 299 | Direct prediction of genetic aberrations from pathology images in gastric cancer with swarm learning. | 0 |
| 298 | ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer. 2022, 13, | 0 |
| 297 | Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer. 13, | 0 |
| 296 | Development of combination strategies for Focal Adhesion Kinase inhibition in Diffuse Gastric Cancer. | 0 |
| 295 | Drugging KRAS: current perspectives and state-of-art review. 2022, 15, | 2 |
| 294 | Tubulovillous adenoma with high-grade dysplasia of the vulva harboring high tumor mutational burden and cancer-associated mutations: a case report. 2022, 17, | 0 |
| 293 | Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?. 1-10 | 0 |
| 292 | Establishment of a gastric cancer cell line with high microsatellite instability, OCUM -13, derived from Borrmann type-2 primary tumor. | 0 |
| 291 | Deep learning model to predict EpsteinBarr virus associated gastric cancer in histology. 2022, 12, | 0 |
| 290 | Multi-regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. | 0 |
| 289 | A microwell platform for high-throughput longitudinal phenotyping and selective retrieval of organoids. | 0 |
| 288 | Esophageal Cancer Genetics and Clinical Translation. 2022, 32, 425-435 | 0 |

- 287 DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer. **2023**, 27, 101577 ○
- 286 The Role of DNA Methylation and DNA Methyltransferases in Cancer. **2022**, 317-348 1
- 285 Identification and validation of a new pyroptosis-associated lncRNA signature to predict survival outcomes, immunological responses and drug sensitivity in patients with gastric cancer. **2023**, 20, 1856-1881 ○
- 284 Anti-proliferating and apoptosis-inducing activity of chemical compound FTI-6D in association with p53 in human cancer cell lines. **2023**, 369, 110257 ○
- 283 Co-infection relationship with Epstein-Barr virus in gastroduodenal diseases with Helicobacter Pylori. Quantitative PCR and EBNA-1 gene-based approach. **2022**, 85, 301-308 ○
- 282 Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer. **2022**, 14, 335-345 ○
- 281 Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality. ○
- 280 The Role of Surgery in the Management of Gastric Cancer: State of the Art. **2022**, 14, 5542 ○
- 279 Mouse models of Kras activation in gastric cancer. ○
- 278 Prognostic and predictive value of a pathomics signature in gastric cancer. **2022**, 13, ○
- 277 Metabolism-associated molecular classification of gastric adenocarcinoma. 12, ○
- 276 Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer. **2022**, 14, 5615 ○
- 275 Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?. **2022**, 14, 5472 ○
- 274 Chordin-Like 2: A Possible Therapeutic Target for Gastric Cancer by Affecting Cell Cycle and Proliferation. **2022**, 2022, 1-11 ○
- 273 A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer. ○
- 272 Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction. 12, ○
- 271 A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer. **2022**, 15, 1401 ○
- 270 Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma. ○

- 269 The Versatile Role of miR-21 in Renal Homeostasis and Diseases. **2022**, 11, 3525 ○
- 268 Influence of the Microbiome Metagenomics and Epigenomics on Gastric Cancer. **2022**, 23, 13750 ○
- 267 Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancer. **2022**, ○
- 266 Repression of DERL3 via DNA methylation by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. **2022**, 166598 ○
- 265 Chromosomally Unstable Gastric Cancers Overexpressing Claudin-6 Disclose Cross-Talk between HNF1A and HNF4A, and Upregulated Cholesterol Metabolism. **2022**, 23, 13977 ○
- 264 WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function. ○
- 263 Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. **2022**, ○
- 262 Current developments in gastric cancer: from molecular profiling to treatment strategy. 2
- 261 AdBocarcinome Bogastrique Thouvelles cibles thBapeutiques. **2022**, ○
- 260 Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer. ○
- 259 Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma. **2022**, 86, 104357 ○
- 258 EBV persistence in gastric cancer cases conventionally classified as EBER-ISH negative. **2022**, 17, ○
- 257 Further prognostic stratification of intestinal type of gastric adenocarcinoma by CDX2 expression pattern. **2022**, ○
- 256 Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer. **2022**, 17, 117727192211415 ○
- 255 Artificial intelligence in gastric cancer: applications and challenges. **2022**, 10, ○
- 254 Role of Adjuvant Radiotherapy in Gastric Cancer. 23, ○
- 253 Intratumoral bacteria are an important BaccompliceBn tumor development and metastasis. **2023**, 1878, 188846 ○
- 252 FOXM1 increases hTERT protein stability and indicates poor prognosis in gastric cancer. **2023**, 36, 100863 ○

- 251 Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review. **2022**, 14, 175883592211396 ○
- 250 Kinase Inhibitor Screening Displayed ALK as a Possible Therapeutic Biomarker for Gastric Cancer. **2022**, 14, 1841 ○
- 249 Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review. 2
- 248 EpsteinBarr virus detection in endoscopic submucosal dissection-proven early gastric cancer with mixed-type histology. ○
- 247 Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target. ○
- 246 Oncolytic virus: A catalyst for the treatment of gastric cancer. 12, ○
- 245 Development of Epstein-Barr virus-associated gastric cancer: Infection, inflammation, and oncogenesis. 28, 6249-6257 ○
- 244 Gastric Cancer and the Immune System: The Key to Improving Outcomes?. **2022**, 14, 5940 ○
- 243 Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica. ○
- 242 A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy. 10, ○
- 241 PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer. 13, ○
- 240 Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies. 13, ○
- 239 Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma. 13, 1
- 238 Cross-omics integration shows cortex-wide synaptic dysfunction at later stages of Alzheimer disease. ○
- 237 ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer. ○
- 236 Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers. **2022**, 14, 5953 1
- 235 Landscape of Druggable Molecular Pathways Downstream of Genomic CDH1/Cadherin-1 Alterations in Gastric Cancer. **2022**, 12, 2006 1
- 234 Single-cell profiling uncovers aMuc4-expressing metaplastic gastric cell type sustained byHelicobacter pylori-specific inflammation. ○

- 233 Raman Spectroscopy and Imaging Studies of Human Digestive Tract Cells and Tissues Impact of Vitamin C and E Supplementation. **2023**, 28, 137 1
- 232 Identification and validation of critical genes with prognostic value in gastric cancer. 10, 0
- 231 EBV and MSI Status in Gastric Cancer: Does It Matter?. **2023**, 15, 74 0
- 230 CRAC and SK Channels: Their Molecular Mechanisms Associated with Cancer Cell Development. **2023**, 15, 101 0
- 229 IL-1 β derived from mixed-polarized macrophages activates fibroblasts and synergistically forms a cancer-promoting microenvironment. 0
- 228 A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer. **2022**, 21, 0
- 227 Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients. 13, 0
- 226 Enhancement of DNA hypomethylation alterations by gastric and bile acids promotes chromosomal instability in Barrett's epithelial cell line. **2022**, 12, 1
- 225 Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma. 13, 0
- 224 Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer. **2022**, 5, e2245836 0
- 223 Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia. 0
- 222 A Refined Molecular Classification of Gastric Cancer Associated with Distinct Clinical Outcomes and Validated by an XGBoost-Based Prediction Model. **2022**, 0
- 221 Advancing gastric cancer precision medicine with novel genomic screens. 0
- 220 Identifying the key genes of EpsteinBarr virus-regulated tumour immune microenvironment of gastric carcinomas. 0
- 219 KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis. 0
- 218 Immunohistochemical Markers of the Epithelial-to-Mesenchymal Transition (EMT) Are Related to Extensive Lymph Nodal Spread, Peritoneal Dissemination, and Poor Prognosis in the Microsatellite-Stable Diffuse Histotype of Gastric Cancer. **2022**, 14, 6023 0
- 217 A synergistic partnership between IL-33/ST2 and Wnt pathway through Bcl-xL drives gastric cancer stemness and metastasis. 0
- 216 Adversary of DNA integrity: a long non-coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells. 0

| | | |
|-----|---|---|
| 215 | Epigenetic signatures in gastric cancer: current knowledge and future perspectives. 1-13 | 0 |
| 214 | Establishment and characterization of two EpsteinBarr virus-positive gastric cancer cell lines with epitheliotropic M81 strain undergoing distinct viral and altered cellular expression profiles. 2023 , 95, | 0 |
| 213 | Confusion and prospects for carcinogenesis of gastric adenoma and dysplasia: What is the correct answer currently?. 28, 6900-6908 | 0 |
| 212 | IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. 2022 , 22, | 0 |
| 211 | Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment. 2022 , 23, | 0 |
| 210 | Bile acids and their receptors in regulation of gut health and diseases. 2022 , 101210 | 2 |
| 209 | Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review. 13, | 0 |
| 208 | EpithelialMesenchymal Transition and Cancer Stem Cells. 2022 , 1-49 | 0 |
| 207 | Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. 2023 , 15, 175883592211383 | 0 |
| 206 | Comprehensive Analysis of Clinicopathological and Molecular Features to Predict Anti-PD-1-Based Therapy Efficacy in Patients with Advanced Gastric Signet Ring Cell Carcinoma. 2023 , 13, 115 | 0 |
| 205 | RhoA G17E/Vav1 Signaling Induces Cancer Invasion via Matrix Metalloproteinase-9 in Gastric Cancer. 2023 , 22, 153303382211460 | 0 |
| 204 | Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. 2023 , 14, | 2 |
| 203 | Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion. 2023 , 15, 176 | 1 |
| 202 | Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. 2023 , 30, 875-896 | 1 |
| 201 | Regulation of EpithelialMesenchymal Transition Pathway and Artificial Intelligence-Based Modeling for Pathway Activity Prediction. 2023 , 3, 13-25 | 0 |
| 200 | LNCAROD promotes the proliferation and migration of gastric cancer: a bioinformatics analysis and experimental validation. 2023 , 23, | 0 |
| 199 | Preclinical to clinical utility of ROCK inhibitors in cancer. 2023 , | 1 |
| 198 | Management of Gastric Cancer. 000313482211483 | 0 |

| | | |
|-----|---|---|
| 197 | Clinical Relevance of Helicobacter pylori Coinfection in Epstein-Barr Virus-Associated Gastric Carcinoma. 2023 , 17, 3-5 | 0 |
| 196 | Comprehensive analysis of immune-related lncRNAs and their clinical relevance in gastric adenocarcinoma. 2023 , 23, | 0 |
| 195 | Molecular profiling of EBV associated diffuse large B-cell lymphoma. | 1 |
| 194 | Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma. 2023 , 16, 102 | 0 |
| 193 | RNA modification pattern-based subtypes reveal heterogeneous clinical outcomes and tumor immunity of clear cell renal cell carcinoma. 2023 , 2, | 0 |
| 192 | Epstein-Barr virus infection mimicking acute appendicitis: a case report. 2023 , 14, | 0 |
| 191 | A standardized pathology report for gastric cancer: 2nd edition. 2023 , 57, 1-27 | 1 |
| 190 | Epstein-Barr Virus Infection Is Associated with Elevated Hepcidin Levels. 2023 , 24, 1630 | 0 |
| 189 | Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning. 2023 , 7, | 0 |
| 188 | Identification and validation of a PD-L1-related signature from mass spectrometry in gastric cancer. | 0 |
| 187 | PDJ amplicon in triple negative breast cancer. 2023 , 13, | 0 |
| 186 | CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors. 12, | 0 |
| 185 | Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: case report and literature review. | 0 |
| 184 | Gut Microbiota Modulation: Probiotics and Prebiotics in GI Cancer. 2023 , 201-236 | 0 |
| 183 | Microbiome in Gastric Cancer. 2023 , 41-66 | 0 |
| 182 | Is there still a place for radiotherapy in gastric cancer?. 2023 , 68, 102325 | 0 |
| 181 | Non-hereditary early onset gastric cancer: An unmet medical need. 2023 , 68, 102344 | 0 |
| 180 | Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. 2023 , 8, 100762 | 0 |

- 179 The evolution of treatment for resectable gastric cancer. **2023**, 2, 100008 ○
- 178 Selective cytotoxicity of a novel mitochondrial complex I inhibitor, YK-135, against EMT-subtype gastric cancer cell lines due to impaired glycolytic capacity. **2022**, 55, 645-650 ○
- 177 DNA methylation in human gastric epithelial cells defines regional identity without restricting lineage plasticity. **2022**, 14, ○
- 176 Self-supervised learning and multi-scale ensemble for EBV prediction based on whole slide image of gastric cancer. **2022**, ○
- 175 A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. **2022**, 12, ○
- 174 Artificial intelligence applications in predicting the behavior of gastrointestinal cancers in pathology. 3, 142-162 ○
- 173 Repurposed Drugs in Gastric Cancer. **2023**, 28, 319 ○
- 172 Optimal extent of lymph node dissection in gastric cancer. 9, ○
- 171 The loss of epithelial Smad4 drives immune evasion via CXCL1 while displaying vulnerability to combinatorial immunotherapy in gastric cancer. **2022**, 41, 111878 ○
- 170 Gastric adenocarcinoma with high-level microsatellite instability: A case report. **2023**, 18, ○
- 169 Single-cell transcriptomic landscape deciphers novel olfactory neuroblastoma subtypes and intratumoral heterogeneity. ○
- 168 MicroRNA miR-1275 coordinately regulates AEA/LPA signals via targeting FAAH in lipid metabolism reprogramming of gastric cancer. **2023**, 14, ○
- 167 The clinical impact of testing for biomarkers in gastric cancer patients: a real world cohort. ○
- 166 Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. **2023**, 23, 3 2
- 165 An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis. **2023**, 15, 736 ○
- 164 Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. 13, ○
- 163 Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer. ○
- 162 The mechanisms of gastric mucosal injury: focus on initial chief cell loss as a key target. **2023**, 9, ○

- 161 Chromatin and noncoding RNA-mediated mechanisms of gastric tumorigenesis. **2023**, 55, 22-31 ○
- 160 Tumor immunology. **2023**, 245-452 ○
- 159 Hsa_circ_0000026 Sponges miR-23a-5p and Upregulates PTEN Expression to Suppress Gastric Cancer Cell Progression. ○
- 158 Current status of viral biomarkers for oncogenic viruses. **2023**, 221-252 ○
- 157 Recent Progress in Immunotherapy for Gastric Cancer. **2023**, 23, 207 ○
- 156 The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. ○
- 155 A Standardized Pathology Report for Gastric Cancer: 2nd Edition. **2023**, 23, 107 ○
- 154 Comprehensive Study of Microsatellite Instability Testing and Its Comparison With Immunohistochemistry in Gastric Cancers. 23, ○
- 153 CDK1 bridges NF- κ B and β -catenin signaling in response to H. pylori infection in gastric tumorigenesis. **2023**, 42, 112005 ○
- 152 Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. **2023**, 121459 ○
- 151 Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors. ○
- 150 Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer. **2023**, 100931 ○
- 149 Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer. **2023**, 23, 182 ○
- 148 PD-L1: expression regulation. Publish Ahead of Print, ○
- 147 Application of single-cell transcriptome sequencing in gastric cancer. **2023**, 31, 48-55 ○
- 146 A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When?. **2023**, 15, 664 ○
- 145 Epigenetic Regulation of MAP3K8 in EBV-Associated Gastric Carcinoma. **2023**, 24, 1964 ○
- 144 Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination. 23, ○

- 143 Relationships of tumor differentiation and immune infiltration in gastric cancers revealed by single-cell RNA-seq analyses. **2023**, 80, ○
- 142 Development and external validation of a non-invasive imaging biomarker to estimate the microsatellite instability status of gastric cancer and its prognostic value: The combination of clinical and quantitative CT-imaging features. **2023**, 162, 110719 ○
- 141 Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. **2023**, 14, ○
- 140 SEX DIFFERENCES IN TREATMENT ALLOCATION AND SURVIVAL OF POTENTIALLY CURABLE GASTROESOPHAGEAL CANCER: A POPULATION-BASED STUDY. **2023**, ○
- 139 Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor microenvironment in advanced gastric cancer: a phase II chemoimmunotherapy trial. ○
- 138 Lost expression of AT-rich interaction domain 1A in the gastric mucosa is a constituent of field cancerization in the stomach. ○
- 137 Updated Immunotherapy for Gastric Cancer. **2023**, 12, 2636 ○
- 136 Molecular principles of tissue invasion and metastasis. **2023**, 324, C971-C991 ○
- 135 Fundic Gland Polyps Lack DNA Content Abnormality Characteristic of Other Adenomatous Precursor Lesions in the Gastrointestinal Tract. **2023**, 36, 100117 ○
- 134 Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations. **2023**, 118, 110062 ○
- 133 Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study. **2023**, 31, 101657 ○
- 132 Ubiquitin-proteasome system reveals clinical subtypes with distinct molecular characteristics and prognoses in gastric cancer. **2023**, 32, 101660 ○
- 131 Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. **2023**, 15, 2288 ○
- 130 High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer. **2023**, 7, 100098 ○
- 129 CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer. **2023**, 247, 109238 ○
- 128 Epithelial Polyps and Neoplasms of the Stomach. **2024**, 91-118 ○
- 127 Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation. ○
- 126 The molecular biology of peritoneal metastatic disease. **2023**, 15, ○

- 125 Gastric cancer with microsatellite instability displays increased thymidylate synthase expression. **2022**, 126, 116-124 ○
- 124 High soluble OX40 levels correlate with metastatic gastric cancer. **2022**, 126, 139-143 ○
- 123 RHOA Therapeutic Targeting in Hematological Cancers. **2023**, 12, 433 ○
- 122 Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. **2023**, 15, 900 ○
- 121 Case report: Gastric adenosquamous carcinoma with EBV-positive component of squamous cell carcinoma mixed with gastric carcinoma with lymphoid stroma: A novel case report and literature review. **2023**, 29, ○
- 120 MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles. **2023**, 26, 106127 ○
- 119 Bioinformatic Analysis of PTTG Family and Prognosis and Immune Cell Infiltration in Gastric Cancer. **2023**, 2023, 1-15 ○
- 118 Cancer functional states-based molecular subtypes of gastric cancer. **2023**, 21, ○
- 117 MUC1 Expressions and Its Prognostic Values in US Gastric Cancer Patients. **2023**, 15, 998 ○
- 116 Short Telomere Lesions with Dysplastic Metaplasia Histology May Represent Precancerous Lesions of Helicobacter pylori-Positive Gastric Mucosa. **2023**, 24, 3182 ○
- 115 Developing SHP2-based combination therapy for KRAS-amplified cancer. **2023**, 8, ○
- 114 Mapping Spatiotemporal Heterogeneity in Tumor Profiles by Integrating High-Throughput Imaging and Omics Analysis. **2023**, 8, 6126-6138 ○
- 113 Overview of Chemotherapy for Gastric Cancer. **2023**, 12, 1336 1
- 112 An exploration of gastric cancer with heterogeneous mismatch repair status. **2023**, 482, 517-523 1
- 111 Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise Evidence and Implications. **2023**, 13, 538-551 ○
- 110 The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. **2023**, 42, ○
- 109 Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. **2023**, 14, 1
- 108 Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer. **2023**, 42, 1072-1087 ○

| | | |
|-----|--|---|
| 107 | Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer. 2023 , 26, 393-404 | 0 |
| 106 | Reply to: Caution Regarding the Specificities of Pan-Cancer Microbial Structure. | 0 |
| 105 | Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study. 15, 303-317 | 0 |
| 104 | Cytokine-Like Protein 1 (CYTL1) as a Key Target of M-Stage Immune Infiltration in Stomach Adenocarcinoma. 2023 , 2023, 1-12 | 0 |
| 103 | Mucins expression in gastric cancer: connection of MUC status with clinical, morphological and prognostic characteristics of the tumor. 2023 , 85, 16 | 0 |
| 102 | Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma. 2023 , 2023, 1-31 | 0 |
| 101 | Metachronous tumors of the stomach in a patient with autoimmune gastritis. 2023 , 85, 57 | 0 |
| 100 | Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. | 1 |
| 99 | Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD -1 therapy in gastric cancer. | 0 |
| 98 | Genomic landscape of virus-associated cancers. | 0 |
| 97 | Loss of viral genome with altered immune microenvironment during tumour progression of Epstein-Barr virus -associated gastric carcinoma. | 0 |
| 96 | A New Insight Into p53-Inhibiting Genes in EpsteinBarr Virus-Associated Gastric Adenocarcinoma. 2023 , 27, 34-45 | 0 |
| 95 | Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. 2023 , 14, | 0 |
| 94 | Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer. 2023 , 46, 111-119 | 0 |
| 93 | New Advances in Molecular Typing of Gastric Cancer. 2023 , 13, 2392-2396 | 0 |
| 92 | ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer. 2023 , 26, 379-392 | 0 |
| 91 | State of the Art: ctDNA in Upper Gastrointestinal Malignancies. 2023 , 15, 1379 | 0 |
| 90 | How organoids can improve personalized treatment in patients with gastro-esophageal tumors. 2023 , 69, 102348 | 1 |

- 89 Expression of AKRs superfamily and prognostic in human gastric cancer. **2023**, 102, e33041
- 88 Epigenetics in cancer development, diagnosis and therapy. **2023**,
- 87 Acquired epithelial WNT secretion drives niche independence of developing gastric cancer.
- 86 Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies. 15, 222-233
- 85 IL-8 Secreted by Gastric Epithelial Cells Infected with Helicobacter pylori CagA Positive Strains Is a Chemoattractant for EpsteinBarr Virus Infected B Lymphocytes. **2023**, 15, 651
- 84 Iroquois Family Genes in Gastric Carcinogenesis: A Comprehensive Review. **2023**, 14, 621
- 83 MiR-200/183 family-mediated module biomarker for gastric cancer progression: an AI-assisted bioinformatics method with experimental functional survey. **2023**, 21,
- 82 Splicing signature database development to delineate cancer pathways using literature mining and transcriptome machine learning. **2023**, 21, 1978-1988
- 81 System Analysis Based on Lipid-Metabolism-Related Genes Identifies AGT as a Novel Therapy Target for Gastric Cancer with Neoadjuvant Chemotherapy. **2023**, 15, 810
- 80 Comprehensive analysis of autophagy-related clusters and individual risk model for immunotherapy response prediction in gastric cancer. 13,
- 79 The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. **2023**, 15, 175883592311576
- 78 The Hippo signaling pathway in gastric cancer. **2023**,
- 77 A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma. **2023**, 15, 1628
- 76 Molecular features of malignant gastric tumors. **2023**, 4, 65-78
- 75 A noninvasive nomogram model based on CT features to predict DNA mismatch repair deficiency in gastric cancer. 13,
- 74 Multi-omics of the gut microbial ecosystem in the immunotherapy resistance in microsatellite instability-high gastrointestinal cancer patients.
- 73 Identification of GZMA as a Potential Therapeutic Target Involved in Immune Infiltration in Breast Cancer by Integrated Bioinformatical Analysis. Volume 15, 213-226
- 72 Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. 13,

- 71 Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. **2023**, 13, 508 ○
- 70 Shared features of metaplasia and the development of adenocarcinoma in the stomach and esophagus. 11, ○
- 69 Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. *gutjnl-2022-328332* ○
- 68 SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A , and microsatellite stability, and SMARCE1 / ERBB2 co-amplification. ○
- 67 Statistical Methods for Integrative Clustering of Multi-omics Data. **2023**, 73-93 ○
- 66 MOPA: An integrative multi-omics pathway analysis method for measuring omics activity. **2023**, 18, e0278272 ○
- 65 Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. **2023**, 9, ○
- 64 Proteomic profiling of gastric cancer with peritoneal metastasis identifies a protein signature associated with immune microenvironment and patient outcome. ○
- 63 HER2 Testing in Breast and Gastric Cancer with CDH1 Germline Mutations. **2023**, 149-165 ○
- 62 Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. ○
- 61 Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Volume 15, 265-275 ○
- 60 Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and EpsteinBarr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery. ○
- 59 Network-Based and Machine-Learning Approaches Identify Diagnostic and Prognostic Models for EMT-Type Gastric Tumors. **2023**, 14, 750 ○
- 58 Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. **2023**, 15, 175883592311625 ○
- 57 Definition of a Novel Immunogenic Cell Death-Relevant Gene Signature Associated with Immune Landscape in Gastric Cancer. ○
- 56 The N6-methyladenine DNA demethylase ALKBH1 promotes gastric carcinogenesis by disrupting NRF1 binding capacity. **2023**, 42, 112279 ○
- 55 Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer. **2023**, 15, 1900 1
- 54 Based on immune checkpoint inhibitor to improve cancer treatment. 36, 427-435 ○

- 53 FAK/IL-8 axis promotes the proliferation and migration of gastric cancer cells. 0
- 52 Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. 1
- 51 Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. **2023**, 7, 0
- 50 Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines. **2023**, 14, 243-257 0
- 49 Considerations in comparing intestinal- and diffuse-type gastric adenocarcinomas. 0
- 48 CDH1 loss promotes diffuse-type gastric cancer tumorigenesis via epigenetic reprogramming and immune evasion. 0
- 47 Multiancestry genomic and transcriptomic analysis of gastric cancer. **2023**, 55, 581-594 0
- 46 The Role of cMET in Gastric Cancer—A Review of the Literature. **2023**, 15, 1976 0
- 45 PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors. **2023**, 40, 0
- 44 The EBV Gastric Cancer Resource (EBV-GCR): A Suite of Tools for Investigating EBV-Associated Human Gastric Carcinogenesis. **2023**, 15, 853 0
- 43 Immunotherapy in Gastrointestinal Malignancies. **2023**, 1-23 0
- 42 Current trends in perioperative treatment of resectable gastric cancer. 15, 323-337 0
- 41 NNMT enriches for AQP5+ cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma. gutjnl-2022-328408 0
- 40 Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting. **2023**, 15, 175883592311625 0
- 39 Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. 0
- 38 Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer. **2023**, 57, 61-73 0
- 37 High-Dimensional Spectral Cytometry Reveals Therapeutically Relevant Immune Subtypes in Gastric Cancer. 0
- 36 Distinguishing Gastric/Esophageal Adenocarcinoma from Pancreatic Adenocarcinoma Using Methylation-Based Droplet Digital PCR. **2023**, 103, 100145 0

- 35 Independent Signaling of Hepatoma Derived Growth Factor and Tumor Necrosis Factor-Alpha in Human Gastric Cancer Organoids Infected by Helicobacter pylori. **2023**, 24, 6567 ○
- 34 Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification. ○
- 33 A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma. 14, ○
- 32 Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report. **2023**, 102, e33377 ○
- 31 Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients. ○
- 30 New Progress of Immunotherapy in Gastric Cancer. **2023**, 13, 4904-4911 ○
- 29 Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022. **2023**, 19, ○
- 28 Current Trends in Volume and Surgical Outcomes in Gastric Cancer. **2023**, 12, 2708 ○
- 27 Identification and verification of prognostic cancer subtype based on multi-omics analysis for kidney renal papillary cell carcinoma. 13, ○
- 26 Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. **2023**, 11, e006280 ○
- 25 The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. **2023**, 13, ○
- 24 Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial. ○
- 23 Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway. ○
- 22 Molecular profile of poorly cohesive gastric carcinoma with special reference to survival. ○
- 21 Utilizing circulating tumor DNA as a prognostic predictor of gastric cancer: A meta-analysis. 1-20 ○
- 20 The crosstalk between the RNA demethylase, non-coding RNAs, and transcription factors in gastric cancer: An ALKBH5 perspective. **2023**, 3, ○
- 19 Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats. **2023**, 616, 504-509 ○
- 18 Preliminary exploration of the effects of environmental factors on the microsatellite status of BRAF mutated colorectal cancer. ○

- 17 Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. **2023**, 15, 2273 ○
- 16 Downregulation of MUS81 expression inhibits cell migration and maintains EBV latent infection through miR-BART9-5p in EBV-associated gastric cancer. **2023**, 95, ○
- 15 Large-scale correlation network construction for unraveling the coordination of complex biological systems. ○
- 14 Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer. 14, ○
- 13 Intersections between innate immune response and gastric cancer development. 29, 2222-2240 ○
- 12 Relating mutational signature exposures to clinical data in cancers via signer 2.0. ○
- 11 Survival rate and chronic diseases of TCGA cancer and KoGES normal samples by clustering for DNA methylation. ○
- 10 Pathological Interpretation of Gastric Tumors in Endoscopic Submucosal Dissection. **2023**, 11, 15-20 ○
- 9 Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies. **2023**, 12, 2973 ○
- 8 Long Intergenic Non-Coding RNA [linc00659] Expression Changes in Gastric Cancer. ○
- 7 Gastric Cancer Epidemiology, Genetics, and Screening. **2023**, 451-459 ○
- 6 Unwelcome guests [the role of gland-associated Helicobacter pylori infection in gastric carcinogenesis. 13, ○
- 5 Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy. ○
- 4 Tumor budding in gastric cancer. 15, 578-591 ○
- 3 Circular MTHFD2L RNA-encoded CM-248aa inhibits gastric cancer progression by targeting the SET-PP2A interaction. **2023**, ○
- 2 Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology. **2023**, 93, 83-96 ○
- 1 Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study. ○